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KDM4B is a hypoxia-inducible, histone lysine demethylase responsible for primarily 
demethylating H3K9 and H3K36.  This enzyme has been implicated in the literature as a contributor to 
tumorigenesis in many solid tumor models.  Multiple factors contribute to the aggressiveness of ovarian 
cancer, including hypoxia-induced mechanisms.  Establishing the tumorigenic mechanisms regulated by 
KDM4B provide novel epigenetic links between the hypoxic tumor microenvironment and Epithelial 
Ovarian Cancer (EOC) progression.  This body of work established the in vitro and in vivo relevance of 
KDM4B in EOC, connecting expression to increased tumorigenesis.  KDM4B is expressed in patient 
primary and metastatic tumors, correlating with hypoxic regions identified by CA-IX.  Additionally, 
KDM4B is robustly induced in EOC cell lines exposed to hypoxia.  KDM4B regulates expression of 
metastatic genes in a demethylase-dependent manner, including LOXL2, LCN2, and PDGFB.  KDM4B 
expression correlates with increased ovarian cancer cell invasion, migration and attachment-free growth 
in vitro.  Intraperitoneal xenograft models demonstrated KDM4B expression corresponded with increased 
peritoneal dissemination in vivo.  Further mechanistic analysis has identified a possible link between 
KDM4B expression and another epigenetic regulator ARID5B.  Functional analysis demonstrates 
KDM4B participates in secretion of factors contributing to metastasis and tumor progression.  3-
Dimensional in vitro functional analysis suggests KDM4B contributes to increased spheroid invasion on 
Type I Collagen.  This project highlights some of the first studies demonstrating that a Jumonji-domain 
histone demethylase regulates cellular processes required for peritoneal dissemination of EOC.  The 
following observations provide additional knowledge regarding KDM4B activity and its influence in 
EOC models.  These findings provide a better understanding of KDM4B, its activity, and the role it plays 
in regulating the epigenetic landscape in tumors.  The mechanistic and functional pathways regulated by 
KDM4B may present novel opportunities to develop combinatorial therapies to improve existing 
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 Epigenetic changes are well-established contributors to cancer progression.  Aberrant epigenetic 
changes are potentially reversible and targetable for the fight against cancer progression.  In this project, 
focus is on the role of the hypoxia-inducible, histone demethylase KDM4B in ovarian cancer progression 
and peritoneal dissemination.  KDM4B provides a novel link between ovarian cancer tumorigenesis and 
the hypoxic tumor microenvironment.  Until this project, KDM4B had not been studied in ovarian cancer 
progression and explains its mechanistic role in this tumor type.  Understanding the role of KDM4B in 
ovarian cancer progression will help explain another facet of hypoxia-induced epigenetic changes. 
 
Epigenetics 
Epigenetics and Chromatin Structure 
 Epigenetics encapsulates mitotically and/or meiotically heritable changes that are reversible and 
do not alter the genetic code (Hancock, Dunne et al. 2015; Schuebel, Gitik et al. 2016).  Epigenetic 
modifications can include methylation and hydroxymethylation of cytosines and other nucleotides, the 
shortening and lengthening of telomeres, and chromatin compacting and opening through histone 
modifications (Schuebel, Gitik et al. 2016).  Chromatin is the complex of DNA and proteins that form 
chromosomes (Kouzarides 2007; Schuebel, Gitik et al. 2016).  The nucleosome is the basic unit of 
chromatin (Fig 1.1).  A single nucleosomes is composed of an octamer of the four core histone proteins 
(H3, H4, H2A, H2B) and is wrapped 1.6 times by 147 base pairs of DNA (Kouzarides 2007).  The linker 
histone, H1 is also sits on top of each nucleosome to orient and guide compaction of higher order 
chromatin structures (Schuebel, Gitik et al. 2016).  Core and linker histone proteins are globular except 
for their N-terminal tails, which have a large number of possible residue modifications (Kouzarides 2007; 
Shmakova, Batie et al. 2014; Hancock, Dunne et al. 2015).  Histone modifications influence the 
compaction state of chromatin.  The modifications are very dynamic and can change chromatin quickly 
between heterochromatin (silenced state) and euchromatin (active state) (Shmakova, Batie et al. 2014).  
The types and locations of histone modifications are numerous, each providing a different alteration to 
chromatin compaction and gene expression.  These post-translational histone modifications include: 
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acetylation, methylation, phosphorylation, ubiquitination, sumoylation, ADP ribosylation, deamination, 
and proline isomerization (Kouzarides 2007).  Methylation is of particular interest for this body of work, 







Figure 1.1 Histone Protein Structure 
Histones are proteins that organize DNA within the nucleus.  Two copies of each core histone, H2A, 
H2B, H3, and H4 form an octamer.  This octamer is wrapped 1.6 times by 146 bp of DNA (not shown), 




Histone methylation is one of many epigenetic modifications that play an important role in 
chromatin compaction and gene expression.  Numerous sites of modification are possible, each 
contributing to the expression level of marked genes.  Arginines may be modified in H3, H4, and H2A 
histone proteins (Di Lorenzo and Bedford 2011).  These modifications include monomethylarginines 
(MMA), asymmetric dimethylarginines (ADMA), and symmetric dimethylarginines (SDMA) (Di 
Lorenzo and Bedford 2011).  Arginine methylation are gene activating at the following sites: H3R17, 
H3R26, H4R3, and H2AR3 (Di Lorenzo and Bedford 2011).  Methylation modifications at the following 
arginines may repress gene expression: H3R2, H3R8, H4R3, and H2R3 (Di Lorenzo and Bedford 2011).    
Histone methylation may occur at lysine residues on histone H3, histone H4, linker histone H1, and its 
isotype H1.4 and may mark an expressed or repressed gene (Black, Van Rechem et al. 2012; Labbe, 
Holowatyj et al. 2013; Shmakova, Batie et al. 2014).  These sites may be mono- (me1), di- (me2), or 
trimethyl- (me3) marks (Labbe, Holowatyj et al. 2013).  Three lysine methylation sites on histones allow 
gene activation, that include: H3K4, H3K36, and H3K79 (Kouzarides 2007).  The lysine modification 
sites that correspond with gene repression are: H3K9, H3K27, and H4K20 (Kouzarides 2007).  Enzymes 
called methyltransferases and histone demethylases are key in regulating these marks. 
  
Histone Lysine Demethylase Families 
 Histone lysine methylation is regulated by histone methyltransferases and histone demethylases. 
Histone lysine methyltransferases, a family of enzymes that utilize S-adenosylmethionine as a methyl 
group donor, such as Disrupter of Telomeric Silencing 1-Like (DOT1L), are responsible for adding 
methyl marks to lysine (Labbe, Holowatyj et al. 2013; Hancock, Dunne et al. 2015).  Histone lysine 
demethylases are more diverse and can be classified into two enzymatic families.  The first family 
includes the flavin adenine dinucleotide (FAD)-dependent amine oxidases such as LSD1 and LSD2 
(Varier and Timmers 2011; Black, Van Rechem et al. 2012).  The second family consists of the Jumonji 
C (JmjC)-domain containing proteins, which utilize a dioxygenase reaction, requiring Fe2+, α-
ketoglutarate, and molecular oxygen (Labbe, Holowatyj et al. 2013; Hancock, Dunne et al. 2015).   
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Identification of Jumonji Proteins 
Jumonji proteins are one of the major histone demethylase families, implicated in regulating a 
variety of normal cell processes and tumorigenic pathways (Kouzarides 2007).  Jumonjis were identified 
and named in a gene trap study as an essential contributor in neural tube formation in mouse development 
(Takeuchi, Yamazaki et al. 1995).  A “cruciform” or jumonji (the Japanese translation) morphology was 
observed in the brains of mutant jumonji mice (Takeuchi, Yamazaki et al. 1995).  The normal neural 
groove and abnormal grooves on the neural plates formed a cross shape in these mutants (Takeuchi, 
Yamazaki et al. 1995).  Currently, there are 32 jumonji proteins identified by their JmjC-domain 
(Hancock, Dunne et al. 2015).  24 of these identified jumonjis act as histone demethylases (Klose, Kallin 
et al. 2006; Hancock, Dunne et al. 2015).  The KDM4 subfamily is one subset of JmjC-domain containing 
proteins. 
 
KDM4 Family of Histone Demethylases 
KDM4 Family 
 The JMJD2 (Jumonji Domain 2) or KDM4 (Lysine-specific demethylase 4) proteins are histone 
demethylases that target histone residues H3K9, H3K36, and H1.4K26 (Yang, Lin et al. 2011; Berry and 
Janknecht 2013; Labbe, Holowatyj et al. 2013).  The KDM4 family contains 4 genes (KDM4A-KDM4D) 
and 2 pseudogenes (KDM4E and KDM4F) (Fig. 1.2).  The KDM4 family is highly conserved with 
orthologs found in other vertebrates (Labbe, Holowatyj et al. 2013).  KDM4A, KDM4B, and KDM4C are 
very similar proteins, each containing a JmjN domain, JmjC domain, 2 Plant Homeodomains (PHD), and 
2 Tudor domains (Berry and Janknecht 2013; Labbe, Holowatyj et al. 2013).  KDM4D and KDM4E are 
smaller and lack the C-terminal region, which contain the PHD and Tudor domains (Katoh and Katoh 
2004; Whetstine, Nottke et al. 2006; Berry and Janknecht 2013).  Each KDM4 domain plays an important 
role in the enzymes structure and function.  JmjC domain facilitates catalytic activity for these proteins 
while the JmjN domain interacts with JmjC and provides structural integrity (Katoh and Katoh 2004; 
 8 
Whetstine, Nottke et al. 2006; Berry and Janknecht 2013).  The C-terminal PHD and Tudor domains are 
responsible for targeting and histone mark reading (Berry and Janknecht 2013).  Research has shown 
Tudor domains of KDM4A recognize H3K4me3/me2 and H4K20me3/me2 (Labbe, Holowatyj et al. 








Figure 1.2 KDM4 Family Proteins 
The KDM4/JMJD2 family is a subset of the jumonji-containing proteins.  There are 4 characterized genes 
and 2 pseudogenes.  KDM4A-KDM4C are very similar, containing a JmjN, JmjC, 2 PHD, and 2 Tudor 
domains.  KDM4D-F are smaller, lacking the C-terminal targeting end containing the PHD and Tudor 




KDM4 family proteins modify a variety of residues (Hillringhaus, Yue et al. 2011).  H3K9me3 is 
normally associated with constitutive heterochromatin, which is transcriptionally repressed (Kouzarides 
2007).  KDM4A-KDM4D have been shown to remove H3K9me3 and H3K9me2 to activate gene 
expression (Whetstine, Nottke et al. 2006).  H3K36me3 is localized within the gene body of an actively 
transcribed gene in euchromatin (Black, Van Rechem et al. 2012).  KDM4A-KDM4C has also been 
shown to remove H3K36me3 and H3K36me2 which terminates transcription (Berry and Janknecht 2013).  
Linker histone H1 is also demethylated by KDM4A-KDM4D, demethylating a tri-methylation mark from 
H1.4K26me3 to activate gene transcription (Whetstine, Nottke et al. 2006; Trojer, Zhang et al. 2009; 
Krishnan and Trievel 2013).  KDM4D is also capable of removing H1.4K26me2 (Krishnan and Trievel 
2013).  KDM4A and KDM4B have also been shown to bind and remove H4K20me2 to increase genome 
instability (Lee, Thompson et al. 2008).  In addition to demethylating histone methylation marks, 
KDM4C has also been shown to demethylate the Polycomb Repressive Complex (Pc2) to promote gene 
activation (Yang, Lin et al. 2011).  Each of these sites of methylation influence different cellular 
processes in different tissue and disease types. 
 KDM4 proteins are ubiquitously expressed in the body, at a variety of levels (Labbe, Holowatyj 
et al. 2013).  RNA Sequencing Atlas has demonstrated KDM4 family member expression in many human 
tissue types (Yang, Imoto et al. 2000).  KDM4A, B, and C are expressed in many normal human tissues 
with high expression in the spleen, ovary and colon (Yang, Imoto et al. 2000).  While KDM4D and 
KDM4E are weakly expressed in many tissue types, they are more highly expressed in the testes (Labbe, 
Holowatyj et al. 2013).  Different regulatory mechanisms control the activity, expression, and 
transcription of KDM4 family proteins.  
  
Regulators of KDM4 Family Expression 
A variety of mechanisms regulate expression, activity, and localization of KDM4 proteins.  
Transcription factors such as HIF-1α can induce KDM4B and KDM4C expression (Beyer, Kristensen et 
al. 2008; Pollard, Loenarz et al. 2008; Krieg, Rankin et al. 2010; Tausendschon, Dehne et al. 2011; Luo, 
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Chang et al. 2012).  β-catenin, a key transcription factor in developmental processes, regulates KDM4B 
(Han, Ren et al. 2016).  The tumor suppressor p53 also may regulate KDM4B (Palomera-Sanchez, Bucio-
Mendez et al. 2010; Li, Zhao et al. 2011; Zheng, Chen et al. 2014).  KDM4B can be regulated by nuclear 
hormone receptors including estrogen receptor (ER), androgen receptor (AR), and glucocorticoid 
receptors (GR) (Yang, Jubb et al. 2010; Kawazu, Saso et al. 2011; Shi, Sun et al. 2011; Coffey, Rogerson 
et al. 2013; West, Pan et al. 2016).  Ubiquitination has also been shown to regulate the protein stability of 
KDM4A (Tan, Lim et al. 2011).  KDM4A can be controlled by the SKP1-Cul1-F-box and SCFFBXO22 
ubiquitin ligase that targets it for proteasomal degradation (Tan, Lim et al. 2011; Van Rechem, Black et 
al. 2011; Johmura, Sun et al. 2016).  KDM4A and KDM4B may also be regulated by ubiquitination in 
response to DNA damage by RNF8 and RNF168 (Mallette, Mattiroli et al. 2012).  Heat Shock Protein 90 
(HSP90) has also been shown to interact with and stabilize KDM4B by blocking ubiquitin-dependent 
degradation (Ipenberg, Guttmann-Raviv et al. 2013).  KDM4B and KDM4D may also be recruited by 
PARP-1 and participate in double stranded break repair in a PARP-1 dependent manner (Young, 
McDonald et al. 2013; Khoury-Haddad, Guttmann-Raviv et al. 2014; Khoury-Haddad, Nadar-Ponniah et 
al. 2015).  MicroRNAs (miRNAs) are a class of small non-coding RNAs that repress gene expression by 
binding to 3’UTR of mRNA targets and stopping translation (Hui, Yiling et al. 2015).  miR-491-5p, a 
known tumor suppressor, has been shown to target KDM4B and slow breast cancer tumorigenesis (Hui, 
Yiling et al. 2015).  In addition to these mechanisms, protein-protein interaction can influence KDM4 
family expression and activity. 
 
Binding Partners that Influence KDM4 Family Epigenetic Regulation 
Different proteins have been shown to bind to KDM4 proteins, influencing their epigenetic and 
transcriptional activity.   Through these interactions, KDM4 demethylases regulate a variety of target 
genes involved with development, cell processes, and disease states.  At this point, KDM4 family 
members have been shown to bind to each other, transcription cofactors, nuclear hormone receptors, and 
other transcriptional regulators.  All KDM4 proteins have the capacity to form homodimers, though only 
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KDM4A, KDM4B, and KDM4C form heterodimers (Shin and Janknecht 2007).  KDM4 proteins have 
also been shown to bind to the transcription factors β-catenin, MyoD, and C/EBPβ to facilitate target gene 
expression in a demethylase-dependent manner by removing H3K9me3 and H3K9me2 repressive marks 
(Guo, Li et al. 2012; Zhao, Li et al. 2013; Berry, Kim et al. 2014; Choi, Song et al. 2015).  KDM4C has 
also been shown to bind to HIF-1α, facilitating epigenetic activation of HIF-1α downstream target genes 
(Luo, Chang et al. 2012).  NF-κβ, the major transcriptional regulator of inflammatory response, has also 
been shown to interact with KDM4B (Han, Ren et al. 2016).  p53 interacts with KDM4A to direct 
demethylase activity (Kim, Shin et al. 2012).  KDM4B also binds estrogen receptor (ER), androgen 
receptor (AR), and ecdysone receptor (EcR) to facilitate histone demethylase activity (Yang, Jubb et al. 
2010; Kawazu, Saso et al. 2011; Shi, Sun et al. 2011; Coffey, Rogerson et al. 2013; Tsurumi, Dutta et al. 
2013).  KDM4 proteins associate with Polycomb 2, the G9a methyltransferase, and chromodomain Y-like 
protein (CYDL1) (Kawazu, Saso et al. 2011; Yang, Lin et al. 2011).  KDM4A, KDM4B, and KDM4C are 
also known to complex with members of SWI/SNF chromatin-remodeling complex and may interact with 
inhibitory complexes including histone deacetylases, N-CoR, or pRB tumor suppressor (Gray, Iglesias et 
al. 2005; Zhang, Yoon et al. 2005; Klose, Kallin et al. 2006).  Inositol hexakisphosphate kinase 1 (IP6K1) 
interacts with KDM4C and regulates its demethylase function (Burton, Azevedo et al. 2013).  Each of 
these regulatory complexes provides interesting insight into the versatile nature of KDM4 family binding 
and function.  KDM4 family histone demethylases have established connections to cancer pathogenesis in 
many tumor models.  For this body of work, the focus is on the role of KDM4B.   
 
KDM4B 
KDM4B Structure and Enzymology 
 KDM4B is hypoxia-inducible, KDM4 family member that requires molecular oxygen, Fe2+, and 
α-ketoglutarate for enzymatic activity (Beyer, Kristensen et al. 2008).   KDM4B is structurally similar to 
KDM4A and KDM4C, and functions through a dioxygenase reaction (Figure 1.2 and 1.3) (Berry and 
Janknecht 2013; Langley, Brinko et al. 2016).  KDM4B localizes to the human chromosome 19p13.3 and 
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has 12 transcript variants (Berry and Janknecht 2013).  The protein KDM4B is 1096 amino acids in size 
with binding affinity for the histone residues H3K9me3, H3K9me2, H3K36me3, H3K36me2, 
H4K20me2, and H1.4K26me3 (Hillringhaus, Yue et al. 2011; Berry and Janknecht 2013).  The 
demethylation proceeds in two steps (Fig. 1.3).  For example, when KDM4B demethylates H3K9me3, 
KDM4B directly hydroxylates the methyl group on H3K9me3 (Langley, Brinko et al. 2016).  In the 
second step, which does not need dioxygenase activity, formaldehyde is released from the hydroxylated 
methyl group to generate H3K9me2 (Langley, Brinko et al. 2016).  This reaction is conserved for all sites 







Figure 1.3 KDM4B Enzymology  
KDM4B is a Fe2+ and α-ketoglutarate-dependent dioxygenase.  It demethylates histone lysine residues as 




Catalytic activity at a variety of sites suggests an important role for KDM4B in regulating the 
balance of histone methylation genome wide.  The demethylase activity of KDM4B is largely focused on 
H3K9me3 and H3K9me2, due to their highest affinity and enzymatic capabilities on these residues 
(Hillringhaus, Yue et al. 2011).  When H3K9me3 and H3K9me2 repressive marks are removed, genes are 
expressed (Kouzarides 2007).  However, KDM4B can still demethylate H3K36me3 and H3K36me2 with 
dramatically decreased specificity and catalytic ability (Hillringhaus, Yue et al. 2011).  H3K36me3 and 
H3K36me2 can mark transcriptionally active or repressed sites (Kouzarides 2007).  KDM4B also shows 
high affinity and catalytic function on H4K20me2 and H1.4K26me3 (Trojer, Zhang et al. 2009; Mallette, 
Mattiroli et al. 2012).  H1.4K26me3 indicates gene repression and genes are expressed upon 
demethylation (Trojer, Zhang et al. 2009).    Demethylation of H4K20me2 by KDM4B has been linked to 
genomic instability (Mallette, Mattiroli et al. 2012).  The expression and catalytic functions of KDM4B 
has been linked to diseases like cancer, highlighting the necessity of designing a KDM4B inhibitor.   
 
Inhibitors of KDM4B 
 High-quality and specific inhibitors are non-existent for individual KDM4 family proteins.  
KDM4 inhibitors indirectly target other KDM4 or jumonji proteins or disrupt HIF stability.  Considering 
their significant implications in diseases like cancer, it is important to identify a specific inhibitor for 
individual KDM4 family proteins like KDM4B.  At this time, KDM4 inhibitors can be divided into 3 
groups: α-ketoglutarate or 2-oxoglutarate (2-OG) cofactor mimic and disruptor, metal cofactor mimics, 
and histone substrate analogs (Labbe, Holowatyj et al. 2013).   
The vast majority of KDM4 inhibitors are α-ketoglutarate or 2-oxoglutarate (2-OG) cofactor 
competitive inhibitors that bind iron Fe2+ in the catalytic site (Rotili and Mai 2011; Labbe, Holowatyj et 
al. 2013; Maes, Carceller et al. 2015).  All JmjC containing proteins require α-ketoglutarate for activity so 
these inhibitors lack specificity, targeting multiple members of this histone demethylase family (Labbe, 
Holowatyj et al. 2013).  The α-ketoglutarate analogues N-oxalylglycine (NOG) and 
dimethyloxalylglycine (DMOG), commonly used to induce HIF signaling, also target PHD proteins, 
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affecting their role in maintaining intracellular levels of jumonji and KDM4 proteins (Rotili and Mai 
2011).  Other α-ketoglutarate analogues include 2,4-Pyridinedicarboxylic acid (PDCA) (Labbe, 
Holowatyj et al. 2013).  In addition to these inhibitors, ML324 was identified from a high throughput 
screen to bind and inhibit the catalytic site of KDM4A and KDM4E (Rai, Kawamura et al. 2010).  
However, this compound has not been explored for its efficacy on KDM4B.  At this time, α-ketoglutarate 
inhibitors are not specific for individual JmjC KDM4 proteins and other dioxygenases. 
Metal cofactor mimics and histone substrate analogs are two additional routes of KDM4 
inhibition.  Disrupting iron cofactors interferes with KDM4 catalytic activity (Sekirnik, Rose et al. 2009; 
Giri, Passantino et al. 2013).  Non-iron metals like nickel have been shown to block catalytic activities of 
KDM4A and KDM4C (Sekirnik, Rose et al. 2009; Giri, Passantino et al. 2013).  Few histone substrate 
inhibitors have been designed besides the weakly effective tudor domain inhibitors WAG-003 and the 
methyllysine cofactor mimic MS-275 (Luo, Liu et al. 2011; Wagner, Nath et al. 2012).  JIB-04 has been 
identified from cell-based screens and inhibits KDM4 family proteins (Wang, Chang et al. 2013).  JIB-04 
is not a competitive inhibitor of α-ketoglutarate (Wang, Chang et al. 2013).  Its mode of function and 
effects on additional jumonji proteins has not been delineated (Wang, Chang et al. 2013).  Despite these 
setbacks in specificity and targeting, it is important to continue developing effective inhibitors for KDM4 
family members. 
 
KDM4B and Development 
 Epigenetic modifiers are important contributors to developmental processes (Dambacher, Hahn et 
al. 2010).  KDM4B has been of particular interest in stem cell biology and development.  KDM4B 
activity has been connected to different aspects of embryonic stem cell (ESC) biology.  ESCs are 
indefinitely self-renewing and differentiating cell populations, with identities maintained or 
differentiation controlled by activation of specific genes through transcription factors or chromatin 
regulators (Dambacher, Hahn et al. 2010; Das, Shao et al. 2014; Volarevic, Bojic et al. 2014).  KDM4B is 
expressed in undifferentiated and differentiated ESCs (Katoh and Katoh 2007).  KDM4B participates in 
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embryonic stem cell self-renewal and induced pluripotent stem cell generation in mouse models by 
associating with Nanog (Das, Shao et al. 2014).  KDM4B and KDM4C work synergistically to mediate 
proper gene expression as mouse ESCs differentiate (Das, Shao et al. 2014).  KDM4B dependent 
reduction of H3K9me3 improved reprogramming of embryonic stem cells into cloned embryos (Antony, 
Oback et al. 2013).  Correct reprogramming of epigenetic modifications is important for cloning and 
repressive histone lysine methylation marks are very stable and prove problematic (Antony, Oback et al. 
2013).  This reduction of H3K9me3 levels improved in vitro development of cloned embryos (Antony, 
Oback et al. 2013). 
 KDM4B regulates mesenchymal stem cell (MSC) fate, identifying a possible control mechanism 
to exploit in directing MSC lineage (Ye, Fan et al. 2012; Qu, Liu et al. 2014).  MSCs are multipotent 
progenitor cells with multilineage differentiation potentials (Ye, Fan et al. 2012).  KDM4B controls MSC 
differentiation and fate by removing H3K9me3 and activating DLX (Ye, Fan et al. 2012; Qu, Liu et al. 
2014).  Loss of KDM4B reduced osteogenic differentiation and increased adipogenic differentiation (Ye, 
Fan et al. 2012; Qu, Liu et al. 2014).  This provides a promising therapeutic target for diseases such as 
osteoporosis, which are commonly associated with a loss of MSC commitment (Ye, Fan et al. 2012; Qu, 
Liu et al. 2014). 
 KDM4B participates in chondrogenesis and adipogenesis in MSCs (Guo, Li et al. 2012; Lee, Yu 
et al. 2016).  TGF-β dependent KDM4B expression removes the repressive H3K9me3 mark from the 
SOX9 promoter, inducing expression of one of the master regulators of chondrogenesis (Lee, Yu et al. 
2016).  In adipogenesis, KDM4B binds C/EBPβ (CCAAT/enhancer-binding protein) to promote mitotic 
clonal expansion, an important process preadipocytes enter as they differentiate (Tang, Otto et al. 2003; 
Guo, Li et al. 2012).  KDM4B binds C/EBPβ, demethylates H3K9me3 to regulate expression of cell cycle 
genes CDC45I, MCM3, and CDC25C and driving mitotic clonal expansion (Guo, Li et al. 2012). 
 In addition to stem cell maintenance and differentiation, KDM4B is involved in developmental 
biology.  KDM4B is a critical component in development of the central nervous system (CNS) (Fujiwara, 
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Fujita et al. 2016).  Neuron-specific KDM4B knockout mice displayed neurodevelopmental disorders 
including spinal malformations and hippocampal impairment (Fujiwara, Fujita et al. 2016).  The 
hippocampus exhibited hyperactive behavior, deficits in working memory, and spontaneous epileptic 
seizures (Fujiwara, Fujita et al. 2016).  This KDM4B knockout model provides a novel system for 
neurodevelopmental disorder in vivo investigations (Fujiwara, Fujita et al. 2016).   
In addition to CNS development, KDM4B regulates inner ear invagination and ear development 
(Uribe, Buzzi et al. 2015).  KDM4B is expressed during early stages of chick inner ear formation and lost 
expression results in defective otic placode invagination and morphological changes (Uribe, Buzzi et al. 
2015).  KDM4B regulates DLX3, a marker for inner ear, by demethylating H3K9me3 in its promoter 
region (Uribe, Buzzi et al. 2015).  This study provides one of the first connections between a histone 
demethylase and ear development. 
KDM4B is linked to spermatogenesis and mammary gland development (Yoshioka, McCarrey et 
al. 2009; Kawazu, Saso et al. 2011).   Increased KDM4B and decreased H3K9me3 were identified during 
prespermatogenesis (Yoshioka, McCarrey et al. 2009). This suggests a role for KDM4B in reorganization 
of constitutive heterochromatin during a period of necessary epigenetic modifications required for gamete 
function (Yoshioka, McCarrey et al. 2009).  KDM4B binds to estrogen receptor to regulate mammary 
gland development (Kawazu, Saso et al. 2011).  A mammary-epithelium specific conditional KDM4B 
knockout mouse shows defective mammary gland development, identifying KDM4B as an important 
epigenetic component (Kawazu, Saso et al. 2011).   
In addition to mammalian systems, KDM4B has been implicated in regulating Drosophila 
development (Palomera-Sanchez, Bucio-Mendez et al. 2010; Tsurumi, Dutta et al. 2013).  KDM4B is 
essential for mediating ecdysteroid hormone signaling during drosophila larval development (Tsurumi, 
Dutta et al. 2013).  KDM4A and KDM4B demethylate H3K9me3 specifically at the promoter of genes 
responsive to ecdysone signaling, such as Broad Complex (BR-C), allowing increased expression 
(Tsurumi, Dutta et al. 2013).  Double knock out of KDM4A and KDM4B results in developmental arrest 
(Tsurumi, Dutta et al. 2013).   Rescuing these double knockouts with expression of KDM4A or KDM4B, 
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demonstrates that at least one of these proteins are essential for Drosophila development and survival 
(Tsurumi, Dutta et al. 2013).  In addition to developmental processes, KDM4B has been shown to play a 
significant role in cancer progression. 
 
KDM4B and Cancer 
Tumorigenesis 
 The hallmarks of cancer are adaptations cancer cells can acquire during neoplastic transformation 
(Hanahan and Weinberg 2011).  These hallmarks are: sustained proliferative signaling, resisting cell 
death, inducing angiogenesis, enabling replicative immortality, evading immune destruction, 
reprogramming energy metabolism, evading growth suppressors, and activating invasion and migration 
(Hanahan and Weinberg 2011).  Their alterations may provide an additive effect to drive tumor 
formation.  These altered hallmarks will also promote genome instability, disrupting any remaining 
normal homeostatic cell processes and interference with the cell’s relationship with their 
microenvironment (Hanahan and Weinberg 2011).    The underlying neoplastic genome changes driving 
tumorigenesis may occur both at the genetic and epigenetic level. 
 The role of the tumor microenvironment is an essential component in driving tumor progression.  
One such environmental effector is hypoxia (Kim, Lin et al. 2009).  Considering its well-established 
connection to tumor aggressiveness, hypoxia is correlated to poor patient outcome (Welford and Giaccia 
2011).  Tumor hypoxia is a paradox.  Not only does low-oxygen drive tumorigenic changes within cells, 
it also selects for cells equipped to survive oxygen stressed conditions (Hielscher and Gerecht 2015).  
This indicates hypoxia can play a pivotal role in transformation of normal cells to neoplasms.  Hypoxia 
can occur in tissue more than 100-200 μm away from a blood supply and in various regions within the 
tumor (Helmlinger, Yuan et al. 1997).  Using HIF transcription factors to induce expression, hypoxia 
promotes cellular adaptations such as increased proliferation, increased angiogenesis, increased 
glycolysis, cellular immortality, and resistance to apoptosis (Harris 2002).  When studying the role of 
hypoxia in tumor biology, it is important to not overlook its role in inducing epigenetic changes.  
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 Aberrant genetic and epigenetic factors are key steps in driving genome instability in a tumor 
(Balch, Fang et al. 2009).  These are well-established concepts in cancer biology research (Hanahan and 
Weinberg 2011).  Understanding the function of epigenetic changes in tumorigenesis is very attractive for 
chemotherapeutic design, providing a way to target aberrant gene expression without disrupting the 
genome sequence.  Multiple studies have also shown hypoxic induced changes in chromatin marks 
(Hancock, Dunne et al. 2015).  The mechanisms for hypoxia-dependent chromatin remodeling may occur 
through different mechanisms.  HIF binding at HRE in promoters could signal recruitment of chromatin 
remodeling proteins, such as SWI/SNF or KDM3A (Perez-Perri, Acevedo et al. 2011).  The jumonji 
protein KDM4B is known to be a direct target of HIF, with increased expression under hypoxia (Beyer, 
Kristensen et al. 2008).  HIF may act as a direct binding partner of remodeling proteins to enhance their 
activity.  For example, HIF can complex with Histone Deacetylase 1 (HDAC1), bind to an HRE within a 
promoter, and facilitate HDAC1 deacetylation and repression of VEGF (Lee, Kim et al. 2010).  The 
methyltransferase G9a has been shown to increase under hypoxia, correlating with increased in H3K9me2 
(Chen, Yan et al. 2006).  Different types of epigenetic modifiers work through varying mechanisms to 
drive tumorigenesis.   
Lysine-specific methyltransferases and lysine-specific demethylases work together to maintain 
global histone modifications and are implicated in tumor progression.  When their activity and expression 
levels are disrupted, neoplasms may form (Xu, Yang et al. 2011).  Many histone demethylases are 
deregulated during pathogenesis, either activating expression of oncogenes, repressing expression of 
tumor suppressors, altering DNA repair, disrupt chromosomal stability or interact with key hormonal 
receptors that control proliferation (Varier and Timmers 2011).  The correlation between increased 
histone demethylase expression and tumor development has been established for many enzymes, such as 
LSD1 and KDM4C (Hoffmann, Roatsch et al. 2012).  Optimizing inhibitors to specifically target JmjC 
containing KDMs have become a novel facet of therapy design (Thinnes, England et al. 2014).  Recent 
bodies of work have studied the role of KDM4B and characterized its function in tumorigenesis in both 
solid and hematological tumor types (Chizuka, Suda et al. 2006).  Developing a clearer picture of the 
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activity of KDM4B in cancer models helps clarify its involvement in tumorigenesis, both dependent and 
independent of hypoxia. 
 
KDM4B in Breast Cancer 
 The involvement of KDM4B in breast cancer has a clear contribution to the aggressive nature of 
the disease in ER+ subtypes (Kawazu, Saso et al. 2011).  KDM4B is highly expressed in estrogen 
receptor (ER)-positive, aggressive subtypes (Pollard, Loenarz et al. 2008; Yang, Jubb et al. 2010; 
Kawazu, Saso et al. 2011).  Glucocorticoid receptor (GR) and ER-α may also induce KDM4B in an 
estrogen dependent manner in breast cancer (Yang, Jubb et al. 2010; Kawazu, Saso et al. 2011; West, Pan 
et al. 2016).  KDM4B is required for ERα dependent transcription, where loss of KDM4B decreases cell 
proliferation in vitro and tumor progression in vivo (Yang, Jubb et al. 2010; Shi, Sun et al. 2011) (Hui, 
Yiling et al. 2015).  KDM4B may also coordinate with additional epigenetic regulators to regulate histone 
modifications.  KDM4B can bind ER-α and MLL2 to coordinate demethylation and methylation of H3K4 
and H3K9 (Shi, Sun et al. 2011).  KDM4B and ER-α can also bind SWI-SNF-B remodeling complex to 
mediate the expression of ER responsive genes, MYB, MYC, and CCND1 (Kawazu, Saso et al. 2011).  
miR-491-5p, a tumor suppressor can bind KDM4B and slow ER-α+ breast cancer development (Hui, 
Yiling et al. 2015).  KDM4B may provide an innovative therapeutic target for ER+ breast cancer.   
 
KDM4B in Prostate Cancer 
 KDM4B expression can associate to the aggressive nature of prostate cancer (Chu, Wang et al. 
2014).  In prostate cancer cells, KDM4B expression, which correlates with the severity of tumor types, 
can cooperate with AR to induce the AR response (Coffey, Rogerson et al. 2013).  KDM4B also 
stabilizes AR through inhibiting its ubiquitination and degradation (Coffey, Rogerson et al. 2013).  
Knockdown of KDM4B results in decreased AR expression (Coffey, Rogerson et al. 2013).  The 
progression of prostate cancer from androgen-dependent to androgen-independent is one characteristic of 
this disease’s lethal progression (Heinlein and Chang 2004).  KDM4B promotes prostate cancer 
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development through an AR-independent mechanism, by activating the transcription of BMYB-target 
genes like Polo-like kinase 1 (PLK1), important for cell-cycle progression and drives tumorigenesis (Li 
and Dong 2015).  KDM4B expression interferes with HDAC inhibitor efficacy by a novel mechanism.  
When KDM4B was knocked out, HDAC inhibitor trichostatin A (TSA) treatment enhanced induction of 
apoptosis (Li and Dong 2015).  These observations lend KDM4B to be a potentially useful therapeutic 
target in prostate cancer, for both androgen-dependent and androgen-independent tumor types (Li and 
Dong 2015).  Inhibition of KMD4B in combination with other chemotherapeutic drugs may improve 
current treatment options for prostate cancer. 
 
KDM4B in Colorectal Cancer 
 KDM4B is highly expressed and is a known contributor to colorectal cancer (CRC) (Hwang, Heo 
et al. 2015).  In addition to being regulated by HIF-1α in this model, KDM4B can act as an oncogene and 
induce tumorigenesis through a variety of mechanisms (Beyer, Kristensen et al. 2008).  KDM4B, induced 
by PRL-3, a gene linked to CRC metastasis can promote CRC tumorigenesis by promoting proliferation, 
colony formation and migration of human colorectal cancer cells (Hwang, Heo et al. 2015).  KDM4B 
silencing induced DNA damage triggers senescence, apoptosis, and cell cycle arrest by the suppression of 
STAT3 signaling (Toyokawa, Cho et al. 2011).  In addition, KDM4B suppression can drive CRC 
apoptosis through mitochondria-mediated and death receptor-mediated pathways (Qiu, Fan et al. 2015). 
KDM4B, in conjunction with TC4 also binds with β-catenin to regulate expression of the oncoproteins 
JUN, MYC, and Cyclin D1 (Berry, Kim et al. 2014).  Considering the significance role of KDM4B in 
regulating many aspects of CRC, targeting this enzyme may be useful in therapeutic design.  
 
KDM4B in Gastric Cancer 
 KDM4B is connected to gastric cancer carcinogenesis, lending itself as a possible novel 
biomarker or target for inhibition.  Increased expression of KDM4B has been shown to drive gastric 
cancer proliferation, promote epithelial-mesenchymal transitions, and induce COX-2 dependent 
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inflammation (Li, Zhao et al. 2011; Agger, Miyagi et al. 2016; Han, Ren et al. 2016).  Similar to 
colorectal cancer, KDM4B functions in a complex with β-catenin and increase expression of genes 
involved in the epithelial-mesenchymal transition in a demethylase-dependent manner (Zhao, Li et al. 
2013).  KDM4B can induce Helicobacter pylori infection and resulting gastric inflammation, one of the 
strongest risk factors for gastric cancer development (Han, Ren et al. 2016).  β-catenin stimulates 
KDM4B expression that induces COX-2 expression in a histone demethylase-dependent manner (Han, 
Ren et al. 2016).  These mechanisms establish KDM4B as a significant participant in gastric cancer. 
 
KDM4B in Osteosarcoma 
 KDM4B is highly expression and has been connected to osteosarcoma tumorigenesis, a cancer 
type that effects young adults and is plagued with recurrence (Li and Dong 2015; Abarrategi, Tornin et al. 
2016).  KDM4B expression been shown to drive tumorigenesis and participate in the DNA damage 
response (Li and Dong 2015).  KDM4B can promote proliferation, migration, and invasion through 
induction of Fibroblast growth factor 2 (FGF2) (Li and Dong 2015).  Hsp90 has also been shown to 
stabilize KDM4B in osteosarcoma cell models, identifying Hsp90 inhibitors as a possible target for 
KDM4B driving tumor types (Ipenberg, Guttmann-Raviv et al. 2013).  KDM4B also participates in 
regulating the DNA damage response in osteosarcoma models (Mallette, Mattiroli et al. 2012; Young, 
McDonald et al. 2013).  After irradiation, KDM4B is recruited to DNA damage in a PARP1 dependent 
manner to remove the repressive H3K9me3 mark (Young, McDonald et al. 2013).  KDM4B activity can 
influence 53BP1 recruitment to DNA damage sites (Mallette, Mattiroli et al. 2012).  After recruitment to 
double strand breaks, KDM4B is marked by RNF8 and RNF168 and degraded in the proteasome 
(Mallette, Mattiroli et al. 2012). These findings combined suggest KDM4B expression could provide a 
novel risk factor or biomarker to consider in osteosarcoma diagnosis and treatment.   
 
KDM4B in Liver, Lung, and Bladder Cancers 
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 KDM4B activity is linked to liver, lung, and bladder cancer development (Toyokawa, Cho et al. 
2011; Hwang, Heo et al. 2015; Lu, Ho et al. 2015).  KDM4B shows increased expression correlating with 
tumor grade severity in Hepatocellular carcinoma (HCC) (Lu, Ho et al. 2015).  KDM4B is highly 
expressed in lung and bladder tissue compared to normal tissues (Toyokawa, Cho et al. 2011).  
Knockdown of KDM4B in lung and bladder cancer models showed decreased proliferation and decreased 
colony formation, through its loss of regulation of CDK6 (Toyokawa, Cho et al. 2011).  These studies 
provide relevant links between KDM4B and tumorigenesis, lending KDM4B as a feasible molecular 
target for chemotherapy. 
 
KDM4B in Neuroblastoma and Uveal Melanoma 
 KDM4B has been shown to play a role in regulating the N-Myc pathway in neuroblastoma, 
lending itself to be a useful therapeutic target in this cancer type (Yang, AlTahan et al. 2015).  KDM4B 
and N-Myc are highly expressed in neuroblastoma tumors and correlate with poor outcome (Yang, 
AlTahan et al. 2015).  Co-IP analysis showed binding between KDM4B and N-Myc (Yang, AlTahan et 
al. 2015).  When KDM4B is knocked down, there is decreased proliferation, differentiation and tumor 
growth in neuroblastoma models (Yang, AlTahan et al. 2015).  
 KDM4B expression has also been explored in uveal melanoma to investigate possible links 
between enzymatic deregulation and tumor progression (Herlihy, Dogrusoz et al. 2015).  In addition to 
aberrations of other histone modifiers, KDM4B was found to be down regulated in uveal melanoma with 
monosomy 3 (Herlihy, Dogrusoz et al. 2015).  Monosomy 3 is one of the predictive markers of poor 
prognosis in this cancer type (Sisley, Cottam et al. 1992).  These findings suggest KDM4B plays a role in 
these types of cancers. 
 
KDM4B in Hematological Tumors 
 The role of KDM4B activity in hematological cancers has been explored in acute myeloid 
leukemia (AML) and multiple myeloma (MM) (Wen, Chen et al. 2012; Agger, Miyagi et al. 2016).  AML 
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with translocations of the mixed-lineage leukemia 1 (MLL1) gene are aggressive hematopoietic 
malignancies, developing resistance to chemotherapies (Agger, Miyagi et al. 2016).  Using KDM4A, 
KDM4B, and KDM4C triple knockout mice, KDM4 demethylation of H3K9me3 was shown to be 
required for MLL-AF9 translocated AML pathogenesis in vitro and in vivo (Agger, Miyagi et al. 2016).  
A possible redundant role was identified for KDM4 family proteins in AML and non-transformed bone 
marrow (Agger, Miyagi et al. 2016).  When only KDM4C is knocked out in AML mouse models, 
leukemic cells survive (Agger, Miyagi et al. 2016).  IL3RA ectopic expression alleviated the need for 
KDM4 proteins for survival and was shown to be a critical downstream target for KDM4 proteins in 
AML (Agger, Miyagi et al. 2016).  These findings lend KDM4 family members, like KDM4B to be 
promising drug targets for consideration in AML.          
Multiple Myeloma is a plasma cell neoplasm characterized by the accumulation of terminally 
differentiated monoclonal plasma cells in the bone marrow and is one of the most diagnosed 
hematological cancer types (Wen, Chen et al. 2012).  Evidence suggests epigenetics are involved in the 
gene expression changes driving MM progression (Wen, Chen et al. 2012).  Triptolide induces apoptosis 
in AML and was explored for its effects on histone methylation and antitumor effect on MM (Wen, Chen 
et al. 2012).  Triptolide treatment induced apoptosis, and decreased KDM4B and H3K9me2 expression in 
MM (Wen, Chen et al. 2012).  These findings are consistent with previous studies that show KDM4B 
may have a protective role in apoptosis, mediating the DNA damage response (Wen, Chen et al. 2012).  
These observations suggest high KDM4B expression may drive MM progression but needs further 
exploration.  
 
Role of KDM4B in Gynecological Cancers 
 KDM4B has been poorly explored in gynecological cancers.  KDM4B has been shown to 
promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1 (Qiu, Fan et 
al. 2015).  Gynecological cancers are plagued with late diagnoses, where standard therapies will not prove 
as effective (Cho and Shih Ie 2009).  Recurrence and metastases are also problematic in these tumor types 
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due to chemotherapeutic resistance (Armstrong 2002).  A clear knowledge gap exists regarding the 
identification of the role of KDM4B and histone modifiers in other types of gynecological cancers, 
such as ovarian cancer.  Improving the understanding of KDM4B expression and function would help 
explain the enzymatic activities of KDM4B in ovarian cancer tumorigenesis and provide new biomarkers 
and targets for chemotherapeutic design.  The studies in this body of work would only improve 
interventions and resources available to fight this devastating malignancy. 
 
Ovarian Cancer 
Etiology of Epithelial Ovarian Cancer 
 The origin of EOC is subject of debate.  Three anatomical sites are the potential sites of origin for 
serous carcinoma development: the ovarian surface epithelium (OSE), the fallopian secretory fimbrial 
cells, and the mesothelium lining the peritoneal cavity (Lengyel 2010).  Currently, the fallopian tube 
fimbrae and OSE are highly debated as the precursors for tumor initiation (Auersperg 2013).  In the past, 
the idea that cells from the single layer of OSE give rise to neoplasms was widely accepted.  OSE are 
relatively isolated and quiescent cells but have considerable access to cytokines, growth factors, and 
hormones within the ovarian stroma and circulating in the peritoneal fluid (Auersperg 2013).  Ovulation 
has been pinpointed as the major contributor for OSE transformation (Lengyel 2010).  Incessant ovulation 
theory suggests that frequent cycles of ovulation and surface repair drive OSE cells towards malignancy 
(Lengyel 2010).  The OSE etiology theory is countered by evidence suggesting ovarian cancer could 
potential arise from the fallopian fimbrae. 
 In addition to OSE neoplasms forming, it is possible that secretory cells in the fallopian fimbrae 
could contain the precursors for serous carcinoma (Auersperg 2013).  The fimbrae comprise the most 
distal part of the oviduct and they sweep over the ovarian surface at ovulation to capture oocytes and 
transport them through the oviducts (Auersperg 2013).  Serous tubal intraepithelial carcinoma (STIC) are 
common malignancies with BRCA1 mutations found in the fallopian tubes (Auersperg 2013).  STICs with 
BRCA1 or BRCA2 mutations can be found within 20% to 60% of high-grade serous carcinoma in the 
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general ovarian cancer patient population (Crum, Herfs et al. 2013).  It has also been shown that fallopian 
tubes of women predisposed to developing ovarian cancer frequently show dysplasia, accompanied by 
changed in cell-cycle and apoptosis, indicating an increased risk of ovarian cancer (Piek, van Diest et al. 
2001).  This suggests that in high-risk ovarian cancer patients, bilateral salpingio-oopherectomy and 
hysterectomy would cut the risk of recurrent ovarian cancers originating from the fallopian tube (Piek, 
van Diest et al. 2001; Leeper, Garcia et al. 2002). 
 
Ovarian Cancer Epidemiology 
 Epithelial ovarian cancer (EOC) causes more deaths in the United States than any other type of 
female reproductive tract cancer (Siegel, Miller et al. 2015).  The American Cancer Society identifies a 
woman’s risk of getting ovarian cancer is roughly 1 in 75 while a woman’s risk of dying from ovarian 
cancer is 1 in 100 (Siegel, Miller et al. 2015).  The worldwide incidence of this cancer is 225,500 
diagnoses per year; in the United States in 2015 there were 21,290 new cases (Siegel, Miller et al. 2015).  
Approximately 60% of ovarian cancers are diagnosed at advanced stages and 40% of women can expect 
to survive 5 years (Siegel, Miller et al. 2015).  While fewer than 20% of ovarian cancers are localized to 
the ovaries at diagnosis, the five-year survival rate for women with tumors confined to the ovaries 
exceeds 90% for all ethnicities (Siegel, Miller et al. 2015).  The high mortality of this cancer type is 
largely explained by the fact that the majority of patients present at an advanced stage, with widely 
metastasized tumors in the peritoneal cavity (Armstrong 2002).  Global mortality of ovarian cancer 
remains high and minimal improvement in patient survival has been observed over the past decade (Liu 
and Matulonis 2014; Siegel, Miller et al. 2015). 
 
Ovarian Cancer Presentation and Diagnosis 
 Ovarian cancer is a heterogeneous disease, each patient presenting a different subtype and degree 
of metastasis (Cho and Shih Ie 2009).  Patients usually are diagnosed in later stages or more advanced 
disease states, due to symptoms being mistaken by clinicians for other ailments (Cho and Shih Ie 2009).  
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The measurement of circulating levels of ovarian tumor antigen CA-125, Cancer Antigen 125, is 
commonly used to monitor disease presence and recurrence in combination with transvaginal 
ultrasonography (Vaughan, Coward et al. 2011).  Primary tumors are localized to the ovaries while 
metastases form in the pelvic region and peritoneal cavity (Vaughan, Coward et al. 2011).  The main site 
of metastasis is the omentum, with 80% of all serous ovarian carcinoma cases showing this preferred 
localization (Nieman, Kenny et al. 2011).  Ovarian cancer progression is unique, disseminating through 
the peritoneal fluid (Cho and Shih Ie 2009).  However, hematogenous dissemination has been shown to 
be important in ovarian cancer progression but is not the main mode of metastasis (Nieman, Kenny et al. 
2011).  Ovarian cancer biomarkers such as CA-125 are debated due to their poor consistency and 
efficiency for detecting early stages of this disease (Armstrong 2002).  Even though the ovaries are one of 
the largest production sites of estrogen, it is unclear what role estrogen plays in ovarian cancer 
progression (Chan, Wei et al. 2008).  Hormonal contraceptives are linked to a decreased risk for ovarian 
cancer (Burkman, Schlesselman et al. 2004).  
 
Ovarian Cancer Staging, Types, and Treatment 
 Identifying the stage of ovarian cancer disease progression helps direct therapeutic strategies 
developed by clinicians.  Ovarian cancer stages are determined by the guidelines set in the International 
Federation of Gynecology and Obstetrics (FIGO) classifications (Mutch and Prat 2014).  Stage I is 
limited to one or both ovaries (Mutch and Prat 2014).  Stage II involves tumor placement at one or two 
ovaries and fallopian tubes with pelvic extension (Mutch and Prat 2014).  Stage III tumors are located at 
one or both ovaries with metastases spread to the peritoneum outside the pelvis (Mutch and Prat 2014).  
Stage IV includes tumor burden at the ovaries, fallopian tubes, and distant metastases (Mutch and Prat 
2014).  While other cancer types may rely on gene expression to identify stages, ovarian cancer is 
typically classified based on radiographic and surgical presentations (Armstrong 2002). 
 Several distinct tumor types or grades with unique features are classified and identified in ovarian 
cancer diagnoses.  Ovarian cancer is not a homogenous disease; each case presents different tumors and 
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displays different biological behavior (Armstrong 2002).  CA-125/MUC16 in blood serum can be used as 
a biomarker for ovarian cancer, but types are primarily diagnosed by histopathology (Jacobs and Menon 
2004).  Approximately 90% of ovarian cancer arises from the epithelium while much less frequent germ 
cell tumors and sex cord-stromal tumors may form (Mutch and Prat 2014).  Epithelial ovarian cancers are 
divided into two types, Type 1 (low-grade) and Type 2 (high-grade), based on degree of tumor 
progression and molecular profiles (Cho and Shih Ie 2009).  The 5 main histotypes of epithelial ovarian 
cancers are: low-grade serous carcinoma (5%), high-grade serous carcinoma (70%), endometriod 
carcinoma (10%), clear cell carcinoma (10%), and mucinous carcinoma (3%) (Prat 2012; Mutch and Prat 
2014).  Their respective morphological appearances are diagnosed through light microscopy (Cho and 
Shih Ie 2009).  Regardless of 60% of epithelial ovarian cancer tumors expressing ER, ER does not 
provide a reliable prognostic indicator for EOC (Cunat, Hoffmann et al. 2004; Chan, Wei et al. 2008).  
Tamoxifen, an ER antagonist, provides inconsistent efficacy in EOC patient treatments (Schwartz, 
Chambers et al. 1989; Perez-Gracia and Carrasco 2002). 
 Serous carcinomas, arising from epithelial cells on the ovary or the fallopian fimbrae, are the 
most common types of epithelial ovarian cancer (Vang, Shih Ie et al. 2009; Prat 2012; Mutch and Prat 
2014).  High-grade serous are the most common ovarian carcinomas and most patient’s present at an 
advanced, more metastasized stage at the time of diagnoses (Prat 2012).  In high-grade serous ovarian 
cancer, wild-type p53 function is lost in 96% of cases (Cole, Dwight et al. 2016).  High-grade serous 
usually display p53, WT1, p16 and Ki-67 in immunohistochemical (IHC) analysis (Bowtell 2010; Prat 
2012). Low-grade serous are much less frequent than their high-grade serous counterparts (Prat 2012).  
Their molecular profiles are similar with lower expression of Ki-67 and mutations in BRAF, KRAS, and 
ERBB2 (Prat 2012). 
 Mucinous carcinomas account for 10% of all primary ovarian tumors, however 80% are benign 
(Cho and Shih Ie 2009; Prat 2012).  The origin of these tumors is debated.  The cells in mucinous 
carcinomas may resemble the gastric pylorus, intestine, or cervix (Prat 2012).  Benign mucinous tumors 
have a low risk of recurrence and are primarily confined to the ovary (Prat 2012).  Malignant mucinous 
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tumors are often heterogeneous, displaying benign, borderline, and malignant characteristics (Hart 2005; 
Prat 2012).  The gene expression profile of mucinous carcinomas differs from serous, endometeriod, and 
clear cell (Vang, Shih Ie et al. 2009).  KRAS mutations and cytokeratin 7 (CK7) are genetic attributes of 
mucinous tumors (Prat 2012). 
 The final two histotypes are endometriod and clear cell carcinoma (Vang, Shih Ie et al. 2009).  
Endometriod and clear cell tumors closely resemble uterine cancers (Vaughan, Coward et al. 2011; Prat 
2012).  Endometriosis may be a possible precursor for endometriod tumorigenesis (Vaughan, Coward et 
al. 2011).  Endometriod tumors may have mutations in β-catenin and PTEN (Prat 2012).  These tumor 
types are immunoreactive for vimentin, cytokeratin 7, and estrogen receptor (Prat 2012).  Simultaneous 
endometriod carcinomas from the ovary and the uterus can occur (Prat 2012).  Clear cell carcinoma is 
associated with poor prognosis at later stages and has an association with endometriosis (Prat 2012).  This 
histotype has a distinct pathology among ovarian cancer types and are usually positive for HNF1-β (Prat 
2012).  
Standard treatments for ovarian cancer include tumor debulking combined with cisplatin or 
carboplatin plus taxol drugs like Paclitaxel (Weberpals, Koti et al. 2011).  Women at high risk of ovarian 
cancer often undergo risk-reducing bilateral salpingo-oophorectomy, removal of the ovaries and fallopian 
tubes (Berek, Chalas et al. 2010).  Other commonly used drugs include bevacizumab and olaparib 
(Armstrong 2002).  Bevacizumab, A VEGF inhibitor helps decrease tumor burden in ovarian cancer 
patients (Della Pepa and Banerjee 2014).  Olaparib, a PARP inhibitor, is another drug for ovarian cancer 
used in a small number of ovarian cancer patients (Ai, Lu et al. 2016).  Niraparib, another PARP 
inhibitor, was recently shown to extend survival for several months in clinical studies (Sandhu, Schelman 
et al. 2013; AlHilli, Becker et al. 2016).  Despite good initial responses to platinum drugs, resistance often 
develops (Armstrong 2002).  For patients suffering from ascites fluid buildup, therapies include: diuretics, 
radioactive isotopes, paracentesis, and shunt placement (Smolle, Taucher et al. 2014).  These approaches 
have stressful impacts and may cause toxic side effects (Smolle, Taucher et al. 2014).  Repeat 
paracentesis can also cause severe stress to the patient’s body.  Each of these factors can drive 
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chemoresistance in EOC, limiting the efficacy of the most robust therapy options.  Understanding the 
molecular and genetic mechanisms that drive the development of chemoresistance in addition to tumor 
progression will help improve current therapies for ovarian cancer treatment.  Another factor 
complicating chemoresistance are genetic and epigenetic changes driven by tumor hypoxia. 
 
HIF, KDM4B, and Epithelial Ovarian Cancer Progression 
Hypoxia, Tissue Homeostasis, and the Hypoxic Response 
 Responding to changes in environmental oxygen is critical to maintaining cellular homeostasis 
and survival.  Oxygen availability is key to energy metabolism.  Exposure to low oxygen or hypoxic 
conditions may harm tissue homeostasis.  A constant supply of O2 is required to carry out oxidative 
phosphorylation in the mitochondria to generate ATP (Harris 2002).  The series of physiological changes 
that connect environmental oxygen to cellular metabolism is termed the oxygen transport cascade (Dzal, 
Jenkin et al. 2015).  The oxygen transport cascade is composed of four steps: ventilation, diffusion of 
oxygen from the air to the blood, circulation, and diffusion of oxygen from the blood into the cells (Fisher 
and Burggren 2007; Dzal, Jenkin et al. 2015).  Physiologically normoxic conditions varies between 
human tissue types (Simon and Keith 2008).  While ambient air is 21% O2, normoxic or typical ranges in 
tissues vary between 1% O2-15% O2 (Simon and Keith 2008).  The greatest partial pressure of oxygen is 
found in the alveoli of the lungs (115 mm Hg) while the lowest partial pressures can be found in the 
thymus or kidney (7 mm Hg) (Simon and Keith 2008; Hanahan and Weinberg 2011; Welford and Giaccia 
2011).     
In addition to maintaining cell functions in normoxic conditions, organisms have developed 
physiological adaptations to survive hypoxia or low oxygen tension (Harris 2002; Dzal, Jenkin et al. 
2015).  The definition of hypoxia is an oxygen concentration of ≤ 2% (Hancock, Dunne et al. 2015).  All 
nucleated cells sense and respond to hypoxia (Semenza 2011).  Cells can initiate a variety of biological 
adaptations in response to low oxygen conditions.  The first major hypoxic response includes the shift 
from aerobic to anaerobic metabolism (Dang and Semenza 1999).  Angiogenesis, new blood vessel 
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formation and remodeling, is another of the most well studied physiological responses (Dang and 
Semenza 1999; Span and Bussink 2015).  Hypoxia also increases erythropoietin (EPO) production, a 
hormone essential in red blood cell production (Dang and Semenza 1999).  The hypoxia inducible factors 
or HIF, transcriptionally regulate the signaling pathways that mediate the cellular response to low-oxygen 
environmental stresses (Dang and Semenza 1999; Span and Bussink 2015). 
 
Hypoxia-inducible Factors Induce Transcription in Response to Low Oxygen 
 The hypoxia-inducible factors (HIF) regulate the primary transcriptional response to hypoxic 
stress in normal and transformed cells (Semenza 2011; Keith, Johnson et al. 2012).  HIFs are basic helix-
loop-helix-PER-ARNT-SIM (bHLH-PAS) proteins that form heterodimeric complexes between the 
oxygen-labile HIF-1α subunit and the oxygen-stable HIF-1β subunit or ARNT (Semenza 2011).  HIF-1α 
and HIF-1β have similarly arranged functional domains.  The N-termini of the proteins contain the DNA-
binding basic region, followed by the HLH and PAS (PER-ARNT-SIM) domains (Pawlus and Hu 2013).  
The C-terminal ends of HIF-1α contain the N-terminal activation domain (N-TAD) that overlaps with the 
oxygen-dependent degradation (ODD) domain, followed by an inhibitory domain (IH), and the C-
terminal activation domain (C-TAD) (Semenza 2011; Pawlus and Hu 2013).  The bHLH and PAS 
domains mediate dimerization between HIF-1α and HIF-1β while the basic regions from HIF-1α and 
HIF-1β direct DNA binding (Semenza 2011; Pawlus and Hu 2013).  This complex binds hypoxia-
responsive elements (HREs) that contain the conserved sequence RCGTG (Semenza 2011).  Additional 
transcriptional coactivators may bind to the C-TAD, such as CBP/p-300 and SRC-1 to initiate 
transcription (Liu and Simon 2004).  However, the oxygen tension dependent expression of HIF-1α 







Figure 1.4 HIF-1α is Regulated by Prolyl hydroxylase domain-containing protein 2 (PHD2). 
Under normoxic conditions, HIF-1α expression is labile and degraded at the proteasome.  It is designated 
for degradation by PHD2 and VHL.  PHD2 hydroxylates HIF-1α at Proline 402 and 564 by PHD2 
followed by VHL ubiquitination.  Under hypoxic conditions, this regulatory mechanism is suppressed.  
PHD2 function is inhibited, freeing HIF-1α to bind HIF-1β (ARNT) and translocate to the nucleus to 




Oxygen-Dependent HIF-1α Degradation 
 While ARNT is oxygen-stable and constitutively expressed, the HIF-1α subunit is oxygen-labile 
(Fig. 1.4).  Under tissue-specific normoxic conditions, HIF-1α is largely undetectable and is rapidly 
degraded (Liu and Simon 2004; Semenza 2011).  When oxygen levels are lower (<6%), HIF-1α is 
stabilized and translocate to the nucleus to dimerism with ARNT (Semenza 2011).  Oxygen-dependent 
degradation of HIF-1α is regulated by the hydroxylation of two key Proline residues: PRO402 and PRO564 
(Liu and Simon 2004; Semenza 2011).  Prolyl hydroxylase domain-containing protein 2 (PHD2) is the 
enzyme responsible for this reaction (Liu and Simon 2004).  These proline hydroxylations guide the 
interaction of HIF-1α with the von Hippel-Lindau (pVHL) tumor suppressor (Semenza 2011).  pVHL is 
an E3 ubiquitin-ligase complex that targets HIF-1α, ubiquitinates it, targeting it for degradation in the 
proteasome (Semenza 2011).  This oxygen-labile regulation of HIF-1α provides the main control for HIF 
complex dimerization and activity. 
 
The Role of HIF-1α in Epithelial Ovarian Cancer Progression 
 Hypoxic tumor microenvironments contribute to progression in many tumor models such as 
breast cancer, prostate cancer, brain cancer, and ovarian cancer (Harris 2002).  Nuclear expression of 
HIF-1α has been shown to be a marker of poor prognosis in ovarian carcinoma and an indicator of 
advanced stages (Osada, Horiuchi et al. 2007).  HIF-1α expression localized to necrotic regions of the 
tumor with mutated p53 (Birner, Schindl et al. 2001).  HIF-1α targets such as Carbonic Anhydrase IX 
(CAIX) and Glucose Transporter 1 (GLUT1) also show increased expression in patient tumor tissue 
(Cantuaria, Fagotti et al. 2001; Woelber, Mueller et al. 2010).  HIF-1α has not only been demonstrated to 
regulate angiogenic factors such as VEGF and PDGFB in ovarian cancer, it also drives ovarian cancer 
metastasis by promoting invasion through the downregulation of E-cadherin (CDH1) or increasing LOX 
expression (Cheng, Klausen et al. 2013; Ji, Wang et al. 2013).  Ovarian cancer spheroids develop hypoxia 
induced metabolic adaptations and become more chemoresistant (Liao, Qian et al. 2014).  Combined, 
these observations demonstrate HIF-1α plays a pivotal role in ovarian cancer oncogenesis.   
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Hypoxia increases resistance to chemotherapeutics (Agarwal and Kaye 2003; Della Pepa and 
Banerjee 2014; McEvoy, O'Toole et al. 2015).  HIF1 is an attractive target for combatting the tumor 
hypoxic response but has been challenging for drug design (Xia, Choi et al. 2012).  Most drugs are 
designed to alter direct targets of the HIF pathway, such as VEGF inhibitors (Horiuchi, Imai et al. 2002).  
In the case of patients with resistance to platinum-based treatments, Bevacizumab, a VEGF inhibitor, has 
been used (Della Pepa and Banerjee 2014).  Considering the connection between EOC tumorigenesis and 
hypoxia, it is important to explore and dissect the roles of HIF genetic and epigenetic targets such as 
KDM4B.  
 
Knowledge Gap – Identification of Roles of Epigenetic Regulators in Ovarian Cancer Progression 
 Due to the complexity of EOC, understanding the genetic and epigenetic regulatory factors is 
important.  Not only does this help design new therapeutic targets for ovarian cancer patients, it helps 
dissect the mechanisms that are driving their tumor progression.  A variety of altered epigenetic states are 
associated with ovarian tumorigenesis (Seeber and van Diest 2012).  Aberrant DNA methylation and 
histone modifications have both been demonstrated in ovarian cancer (Balch, Fang et al. 2009).  DNA 
methylation is one of the most studied epigenetic modifications in ovarian cancer, with DNA methylation 
profiles being suggested as potential biomarkers for epithelial ovarian cancer types (Gloss and Samimi 
2014).  Deregulated DNA methyl-transferase (DNMT) activity has been associated with repressing tumor 
suppressors such as BRCA1 and p16 by hypermethylation of the CpG islands in promoter regions (Balch, 
Fang et al. 2009).  At this point, DNMT inhibitors like azacitidine and decitabine have demonstrated 
limited efficacy in phase I/II trials for ovarian cancer (Weberpals, Koti et al. 2011).  However, this does 
not negate the use of DNMT inhibitors in combinatorial therapies. 
 Histone deacetylation is another transcriptional silencing mechanism studied in ovarian cancer.  
HDAC inhibitors can relieve epigenetic gene repression by inhibiting the deacetylation of histones and 
non-histone proteins (Balch, Fang et al. 2009).  Poor results have been shown in clinical trials for HDAC 
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inhibitors such as vorinostat, but may still be useful in combination with other therapies (Balch, Fang et 
al. 2009). 
 Limited research has investigated the roles of histone demethylases in ovarian cancer progression.  
At this time, only one jumonji protein, JARID1B has been investigated in ovarian cancer (Chen, Ge et al. 
2015; Wang, Mao et al. 2015).  JARID1B expression correlated with poor prognosis and chemoresistance 
in patient samples, but no molecular function was described in this model (Wang, Mao et al. 2015).  At 
this time, there is little to no knowledge existing that characterizes jumonji protein function, 
protein enzyme dynamics, downstream target genes, and connections to tumorigenic pathways such 
as invasion and migration in epithelial ovarian cancer.       
 
Project Goal - Dissecting the Role of KDM4B in Epithelial Ovarian Cancer 
Overall Purpose and Significance  
The purpose of my dissertation is to dissect and demonstrate the in vitro and in vivo roles of 
KDM4B in epithelial ovarian cancer progression.  At this time, there is no background explaining the 
enzymatic activity of KDM4B or its functional activity in ovarian cancer tumorigenesis.  Ovarian cancer 
is a disease plagued with poor outcomes, late diagnoses and recurrence.  Identifying KDM4B regulated 
genes may provide novel therapeutic targets to consider in combination with other ovarian cancer 
therapies.  Understanding the role of KDM4B may provide additional biomarkers to consider when 
staging epithelial ovarian cancer.  Most importantly, this body of work will characterize another 
mechanistic link between the hypoxic tumor microenvironment and ovarian cancer progression.  
Increasing the knowledge base on the global effects of tumor hypoxia will help clarify the entire picture 









Figure 1.5 Unknown Areas of KDM4B to be Addressed in this Project 
At this time, little is known about KDM4B expression in EOC progression.  This project will characterize 
3 main aspects: Expression levels in EOC Patient Tumors, in vitro and in vivo role of KDM4B in EOC 




Research Objective and Specific Aims 
At this time, little is known about KDM4B expression in EOC progression.  This project will 
characterize 3 main aspects: Expression levels in EOC Patient Tumors, in vitro and in vivo role of 
KDM4B in EOC Progression, and identify target genes and their mode of regulation by KDM4B in EOC 
tumorigenesis (Fig. 1.5).   
 
There are two specific aims in this research project, which are: 
1. To identify the relevance of KDM4B in vitro and in vivo using serous carcinoma models. 
2. To identify mechanisms regulated by KDM4B that drive metastasis and EOC peritoneal 
dissemination. 
 
Experimental findings relating to Specific Aim 1 are presented in and those associated with Specific Aim 
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Epithelial ovarian cancer (EOC) has poor prognosis and rapid recurrence due to widespread 
dissemination of peritoneal metastases at diagnosis. Multiple pathways contribute to the aggressiveness of 
ovarian cancer, including hypoxic signaling mechanisms. In this study, we have determined that the 
hypoxia-inducible histone demethylase KDM4B is expressed in approximately 60% of EOC tumors 
assayed, including primary and matched metastatic tumors. Expression of KDM4B in tumors is positively 
correlated with expression of the tumor hypoxia marker CA-IX, and is robustly induced in EOC cell lines 
exposed to hypoxia. KDM4B regulates expression of metastatic genes and pathways, and demethylates 
promoter regions of target genes like LOXL2, LCN2, and PDGFB. Suppressing KDM4B inhibits ovarian 
cancer cell invasion, migration and spheroid formation in vitro. KDM4B also regulates seeding and 
growth of peritoneal tumors in vivo, where its expression corresponds to hypoxic regions. This is the first 
demonstration that a Jumonji-domain histone demethylase regulates cellular processes required for 
peritoneal dissemination of cancer cells, one of the predominant factors affecting prognosis of EOC. The 
pathways regulated by KDM4B may present novel opportunities to develop combinatorial therapies to 
















Epithelial ovarian cancer (EOC) is the most deadly of gynecologic cancers, and is the fifth 
leading cause of cancer mortality in women (1). EOC is a heterogeneous disease, generally stratified by 
the aggressiveness of growth, with slower growing Type I tumors having better prognosis than more 
rapidly growing Type II tumors (Vang, Shih Ie et al. 2009).  The majority of Type II EOC patients are 
diagnosed at an advanced International Federation of Gynecology and Obstetrics stage (FIGO stage III or 
IV), with widespread dissemination of metastatic tumors throughout the peritoneal cavity (Naora and 
Montell 2005; Vang, Shih Ie et al. 2009; Lengyel 2010).  Of the 4 general pathological subtypes that 
comprise EOC (serous, endometrioid, mucinous, and clear cell), the majority of Type II EOC are high-
grade serous adenocarcinoma (HGSA), representing 70% of the total EOC cases (Vang, Shih Ie et al. 
2009; Lengyel 2010).  Front-line therapy for HGSA consists of surgical debulking followed by treatment 
with platinating agents and taxol derivatives (Lengyel 2010).  The initial response to therapy is generally 
effective; however recurrent chemo-resistant tumors reseed the peritoneal cavity within 2 to 5 years, 
causing mortality. Rapid re-establishment of tumor growth suggests that the stresses imposed by the 
metastatic process, surgery, and chemotherapy drive adaptations that facilitate epithelial ovarian cancer 
progression.  
The hypoxic tumor microenvironment is a potent contributor to malignancy in multiple cancer 
types, including EOC (Birner, Schindl et al. 2001; Chi, Wang et al. 2006; Semenza 2012). The hypoxia-
inducible factors (HIFs) are primary regulators of the hypoxic response, inducing transcription of genes 
that promote homeostasis and tumor progression via metabolic adaptation, self-renewal, angiogenesis, 
and metastasis (Semenza 2012).  HIF-1α also induces expression of several Jumonji domain histone 
demethylases (JmjC-KDMs), including KDM4B (Lysine-specific histone demethylase 4B, also called 
JMJD2B), establishing a compelling link between the hypoxic tumor microenvironment and epigenetic 
remodeling to support tumorigenesis (Beyer, Kristensen et al. 2008; Pollard, Loenarz et al. 2008; Xia, 
Lemieux et al. 2009; Krieg, Rankin et al. 2010).  KDM4B is thought to regulate gene expression by 
demethylating tri- and di-methylated histone H3 at Lysine 9 (H3K9me3/me2) and lysine 36 
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(H3K36me3/me2) (Whetstine, Nottke et al. 2006).  Despite the importance of KDM4B to general tumor 
growth, its contribution to EOC progression has not been investigated. Since HIF-1α and hypoxic 
signaling contribute to EOC (Chi, Wang et al. 2006), KDM4B may also influence EOC progression. 
Using immunohistochemical analysis of patient samples and in vitro and in vivo functional analyses of 
ovarian cancer cell lines, we have determined that KDM4B is abundantly expressed in EOC tumors, and 
contributes to multiple pathways required for peritoneal seeding. Thus KDM4B represents a novel link 
between the hypoxic tumor microenvironment and EOC, mobilizing mechanisms that facilitate the 




MATERIALS and METHODS 
Cell Lines and Culture Conditions. All OVCAR cell lines were maintained in RPMI-1640 (Invitrogen) 
supplemented with 10% heat-inactivated fetal bovine serum (HI-FBS) and 1% pen-strep (Invitrogen). 
SKOV3ip.1 cells were from Dr. Erinn Rankin (Stanford University) with permission from Dr. Gordon 
Mills (M.D. Anderson Cancer Center). OVCAR3, OVCAR4, OVCAR5, OVCAR8, and IGROV1 cells 
were from the NCI-Frederick Cancer DCTD Tumor/Cell line Repository. OVCAR10, UPN275, and 
HIO80 cells were from Dr. Andrew Godwin. Upon receipt, cells were expanded in culture to establish 
early passage stocks. After transducing with lentivirus, cells were used for experiments within 1-2 months 
to minimize cell drift or contamination, and were periodically screened for mycoplasma. For transient 
knockdown of KDM4B, SKOV3ip.1 cells were transfected with a pool of small interfering RNAs 
(siRNAs) targeting KDM4B or an irrelevant control (siK4B, Dharmacon siGenome Smartpool, Thermo 
Scientific) as previously described (Krieg, Rankin et al. 2010). For xenografts, cells were transduced with 
lentivirus to express firefly luciferase and selected in neomycin (pLenti PGK V5-LUC Neo (w623-2), 
from Eric Campeau (Addgene plasmid # 21471 (Campeau, Ruhl et al. 2009)). For stable knockdown, 
cells were transduced with pLKO.1-shRNA constructs targeting KDM4B (Open Biosystems; 
TRCN0000018014 (shK-1) and TRCN0000018016 (shK-2)) and selected in puromycin. For hypoxic 
treatment, cells were incubated for 16-24 hours in Ruskinn InVivo300 glove-box hypoxic incubators 
(Baker) set to desired oxygen tensions.  
 
Tumor Microarray Samples. Ovarian tumor microarrays (TMAs) were constructed by the University of 
Kansas Cancer Center (KUCC) Biospecimen Repository Core Facility using archival formalin fixed, 
paraffin embedded samples of primary ovarian carcinoma with matched metastatic tissue samples. 
Samples were identified from the pathology departmental archives of the University of Kansas Medical 
Center from 1998-2009. TMAs were composed of tumor samples from 48 patients with ovarian cancer: 
14 patients with primary, recurrent, and metastatic samples (including one patient with distant metastasis 
to the brain), 27 patients with primary and metastatic samples, and 7 patients with primary and recurrent 
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samples and included serous (30), mixed (14; 12 of which included a serous component), carcinosarcoma 
(1), clear cell (1), papillary carcinoma, not otherwise specified (NOS) (1) and adenocarcinoma, NOS (1) 
samples.  For every sample, hematoxylin and eosin stained slides were reviewed by a board certified 
pathologist who selected tumor rich areas.  Using the semi-automated TMArrayer (Pathology Devices, 
Inc., Westminster, MD) TMA paraffin blocks were assembled with triplicate 1.0 mm cores using the 
marked slide as a guide. 
 
Immunohistochemical Analysis (IHC). IHC was performed using standard peroxidase/DAB methods 
and hematoxylin counterstain (See Figure 2.1 for specific antibodies and conditions). Representative 
images were captured using a Nikon 80i microscope with a Photometrics CoolSNAP ES camera and NIS-
Elements AR software. Human TMA slides were scanned using an Aperio slide-scanning microscope 
(Leica) at the University of Kansas Medical Center, Department of Pathology; and the University of 
California San Francisco, Department of Radiation Oncology (Courtesy of Dr. Denise Chan). Individual 
spot images were extracted using Aperio TMALab. Slides were blinded and independently evaluated by 
at least 2 pathologists (authors GT, TK, OWT). If more than 10% of tumor epithelium in a tumor had 
nuclear staining of KDM4B, the section was classified as having high expression (Goode, Chenevix-
Trench et al. 2011).  For CA-IX staining, tumors were scored on a qualitative scale (0 = no staining, 1 = 
weak staining, 2 = moderate staining, 3 = strong staining). Scores for triplicate spots from each tumor 
sample were averaged for statistical analysis. SPSS (IBM) was used to determine significance of CA-IX 





  Assay Antigen Supplier Product NO. Description Dilution 
Western KDM4B Cell Signaling 8639 Rabbit mAb 1:1,000 
  HIF1α BD 610959 Mouse mAb 1:1,000 
  β-Actin Sigma A1978 Mouse mAb 1:2,000 
  H3K9me3 Abcam ab8898 Rabbit pAb 1 μg/ml 
  H3K9me2 Abcam ab1220 Mouse mAb 1 μg/ml 
  H3K9me Abcam ab9045 Rabbit pAb 1:500 
  H3K36me3 Abcam ab9050 Rabbit pAb 0.5 μg/ml 
  H3K36me2 Abcam ab9049 Rabbit pAb 0.5 μg/ml 
  H3K36me Abcam ab9048 Rabbit pAb 1:1,000 
  histone H3 Abcam ab1791 Rabbit pAb 1:4,000 
  α-Tubulin Thermo MS-581-PABX Mouse mAb 1:2,000 
ChIP KDM4B Cell Signaling 8639 Rabbit mAb 1:100 
  histone H3 Abcam ab1791 Rabbit pAb 2 μg per 1 million cells 
  H3K9me3 Abcam ab8898 Rabbit pAb 2-4 μg per 25 μg chromatin 
  
IgG control Cell Signaling 3900S Rabbit mAb 560 ng/ml as 
control for 
KDM4B; 2μg 
per ChIP as 
control for 
histones 
IHC KDM4B Cell Signaling 8639 Rabbit mAb 1:100 
  IgG control Cell Signaling 3900S Rabbit mAb 1:100 
  CA-IX Thermo MA5-15737 Mouse mAb 1:8000 
  PAX8 Biocare ACI438A Mouse mAb 1:100 
  Ki67 Thermo RM-9106-S0 Rabbit mAb 1:800 




Figure 2.1. List of Antibodies Used in the Study. 
  
 51 
QRT-PCR. Quantitative real-time PCR (qRT-PCR) was conducted as previously described using an ABI 
VIIA sequence detection system using 18S rRNA as an internal control (Krieg, Rankin et al. 2010). 
Primers (Figure 2.2) were designed using the Roche Universal Probe Library Design Tool 
(http://lifescience.roche.com/shop/products/universal-probelibrary-system-assay-design). Melt curve 






Assay Gene Forward (5'-3') Reverse (5'-3')
QRT-PCR hsKDM4B ggactgacggcaacctctac cgtcctcaaactccacctg
QRT-PCR hsKDM4A gccgctagaagtttcagtgag gcgtcccttggacttcttatt
QRT-PCR hsKDM4C aggcgccaagtgatgaag gagaggtttcgcccaagact
QRT-PCR hsKDM4D ggacaagcctgtaccactgag ctgcacccagaagccttg
QRT-PCR hsPDGFB ctggcatgcaagtgtgagac cgaatggtcacccgagttt
QRT-PCR hsIGFBP1 aatggattttatcacagcagacag ggtagacgcaccagcagagt
QRT-PCR hsLCN2 ctccacctcagacctgatcc acataccacttcccctggaat
QRT-PCR hsLOXL2 tgacctgctgaacctcaatg tggcacactcgtaattcttctg
QRT-PCR hsLOX ggatacggcactggctactt gacgcctggatgtagtaggg
QRT-PCR 18S rRNA gcccgaagcgtttactttga tccattattcctagctgcggtatc
QRT-PCR hsGAPDH agccacatcgctcagacac gcccaatacgaccaaatcc
Assay Gene Forward (5'-3') Reverse (5'-3') Genomic coordinates
ChIP PDGFB-1 gagccctccgccttaacc cagccaggcgcaggaa chr22:39,638,710-39,638,763
ChIP PDGFB-2 cctggcactcgggagctt tccaggttgaggctagatgga chr22:39,641,397-39,641,470
ChIP LCN2 aagtgtttccgcaggagttg gggatctagggtgggttgat chr9:130,911,623-130,911,702
ChIP LOX actgagcgcaggaacttctc cactggttccaagctggcta chr5:121,413,216-121,413,314
ChIP LOXL2-1 agcgcctgcgtaaaagttgt gctacagctgatcccaatcttga chr8:23,260,663-23,260,733
ChIP LOXL2-2 tgccttgtccacctcctatcc aacactttcattcggcagcttt chr8:23,261,969-23,262,053
ChIP DESERT-C16D8 gagcaagcagaccctaatgc ctgtccactcaggagccttc chr16:62,316,298-62,316,449
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Microarray Analysis. RNA (100 ng) was profiled using GeneChip® Human Exon 1.0 ST exonic 
transcript arrays (Affymetrix). Normalization and differential gene expression analysis was performed in 
the Partek Genomic suite (v 6.5, Partek Inc.). All experiments were performed in triplicate. The exon-
arrays were RMA-background corrected, quantile-normalized and gene-level summarized using the 
Median Polish algorithm (Irizarry, Hobbs et al. 2003).  The resulting log (base 2) transformed signal 
intensities were used in a 2-way ANOVA model to calculate differential expression. P-values were 
corrected for multiple-hypothesis testing by the Benjamini and Hochberg method (Klipper-Aurbach, 
Wasserman et al. 1995).  Genes displaying fold change of <-1.4 or lower following siK4B knockdown 
(P<0.05) compared to the siCon transfected cells were considered to be regulated by KDM4B. GeneVenn 
(http://www.bioinformatics.org/gvenn/) identified overlapping expression between different oxygen 
tensions and knockdown constructs. Specific pathways influenced by KDM4B were identified using 
Ingenuity Pathway Analysis (Ingenuity Systems). Microarray data was deposited under accession number 
GSE66894 in the NCBI Gene Expression Omnibus (Edgar, Domrachev et al. 2002).  
 
Immunoblotting. Immunoblots were performed using standard procedures as previously described 
(Krieg, Rankin et al. 2010). See Figure 2.15 for antibody dilution information. 
 
Growth Curves. Cells (50 000) were seeded in triplicate to 6 cm dishes, cultured in HeraCell 150 
incubators (ThermoFisher Scientific, Inc.) set to desired oxygen tension, counted, and reseeded every 
three days, as described by Welford, et al (Welford, Bedogni et al. 2006).  
 
Migration and Matrigel Invasion Assay. Invasion and migration assays were performed as described by 
Swenson-Fields et al. (Swenson-Fields, Vivian et al. 2013), with minor modifications. Cells (50 000) 
suspended in RPMI + 2% FBS were seeded to Boyden chambers (BD Falcon, 8 micron pore size) 
suspended in RPMI + 10% FBS. For invasion assays, chambers were coated with 100 uL 1 mg/mL 
Matrigel (BD Biosciences). After 24 hours incubation (see Cell Culture Section), cells were released by 
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trypsinization and DNA content quantified using CyQUANT Cell Proliferation Assay Kit (Life 
Technologies) according to manufacturer’s protocol. Invasion and migration were normalized to seeding 
and monolayer proliferation controls. Representative membranes were fixed and stained with Siemens 
Diff Quik Stain Set (Neobits, Inc.) and imaged using a Leitz LABORLUX12 microscope equipped with a 
Leica EC3 camera.  
 
Spheroid Formation Assay. 600 cells were seeded per well of 96-well ultra-low attachment plates 
(Corning Incorporated). After four days, spheroids were imaged by brightfield microscopy using a Leica 
DMI 4000 inverted microscope equipped with a Leica CCD camera (Courtesy of Dr. Michael J. Soares, 
KUMC). Volume (V=4/3*πr3) was calculated after measuring the diameter and radius of each spheroid 
using NIH Image J (Vinci, Gowan et al. 2012). Differences in average spheroid volume were analyzed by 
two-tail paired Student’s t-test.  Sixteen spheroids were analyzed per cell line and oxygen condition in 
each independent experiment.   
 
Intraperitoneal Tumor Xenografts. Cells (1,000,000 SKOV3ip.1-luc-neo or 5,000,000 OVCAR8-luc-
neo) were injected i.p. into NCR-nu/nu athymic mice (Taconic; 4-6 weeks old females, 10 mice per 
group, randomly assigned for injection). Study numbers allow detection of an effect size of 1.6 relative to 
control with a power of 85% (P<0.05 using Student’s T-test), assuming a tumor take rate of 80%. Tumor 
growth was monitored weekly (non-blinded) using the IVIS Spectrum in vivo imaging system (Perkin 
Elmer) in the KUMC Center for Molecular Imaging, until shGFP control mice achieved humane 
endpoints. Mice prematurely removed from the study were excluded from analysis. Mice were injected 
with 200-250 μl D-Luciferin (Gold Biotechnology, Inc.) 15 minutes prior to imaging. Pimonidazole 
(Hypoxyprobe, HPI) was injected i.p. 30 minutes before euthanasia to label hypoxic cells. Portions of the 
largest tumors (primarily omental masses) were fixed in 4% paraformaldehyde and processed for IHC. 
Frozen tumor samples were homogenized for RNA purification and analysis. Statistical significance was 
determined as described in the Statistical analysis section.  
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Chromatin Immunoprecipitation Assay (ChIP). ChIP was performed as described previously (Krieg, 
Rankin et al. 2010), with minor modifications. 8-50 µg of sonicated DNA was incubated with 1-5 µg 
antibody (Figure 2.1). Enrichment to promoters and regulatory regions was measured using QPCR 
calibrated to a dilution series of pooled input DNA and normalized to the respective input controls. For 
histone H3K9me3 analysis, input normalized signal was adjusted by subtracting IgG signal, with further 
normalization to gene desert control (C16D8). Fold changes in enrichment were calculated relative to 
shGFP control cells at 21% O2. Primers to promoters and control regions were designed using Primer 
Express software (Life Technologies) and validated for amplification efficiency and generation of a single 
amplicon (Figure 2.2).  
 
Statistics. Data represent the mean ± SEM or median ± upper and lower quartiles for at least three 
independent experiments. Human tumor data and mouse xenografts were analyzed with non-parametric 
methods such as Kruskal-Wallace, Mann-Whitney U-test and Spearman’s correlation to account for non-
normal distributions of data. Two-tailed Student’s T tests or ANOVA were used as appropriate for in 
vitro experiments. P values of 0.05 or less were considered statistically significant.  
 
Study approvals. Animal studies were approved by the KUMC Institutional Animal Care and Use 
Committee. De-identified human patient samples and any corresponding clinical data were provided by 
the KU Cancer Center’s Biospecimen Repository Core Facility (BRCF) with informed consent from 
patients.  Collection and use of de-identified human patient samples for this study was approved by the 
KUMC Human Subjects Committee.  
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KDM4B is Abundantly Expressed in Hypoxic High Grade Ovarian Serous Adenocarcinoma 
Tumors and OVCAR Cell Lines. Hypoxic regulation of KDM4B is a common mechanism in many 
different cancer cell types (Beyer, Kristensen et al. 2008; Wellmann, Bettkober et al. 2008; Xia, Lemieux 
et al. 2009; Krieg, Rankin et al. 2010), suggesting that KDM4B would also be robustly expressed in EOC. 
Expression of KDM4B was measured in ovarian cancer tissue microarrays (TMAs) (See Methods and 
Figures 2.3 and 2.4). 
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Samples   Score (% of tissue) % nuclei positive for KDM4B 









 0 9 (100) 9 0.4 0.3 0.4 0-1 
            
High Grade 
Serous 
Primary 19 (63.3) 11 (36.7) 30 22.4 20.8 18.6 0.7-61.1 
Metastases 20 (69) 9 (31) 29 19 17.6 13.6 0-54.2 
                
Totals 39 (66) 20 (33) 59 20.7 18.7 16.3 0-61.1 
           
Mixed  Primary 9 (64.3) 5 (35.7) 14 17.5 14.4 15.9 0.4-44.5 
Metastases 3 (37.5) 5 (62.5) 8 10.4 5.1 10.9 1.3-30.2 
               
Totals 12 (54.5) 10 (46.5) 22 14.9 11.4 14.4 0.5-44.5 
           
Other Primary 4 (100) 0 4 18.6 18.5 6.9 10.4-27.1 
Metastases 2 (50) 2 (50) 4 19.9 18.5 19.3 1.8-40.7 
               
Totals 6 (75) 2 (25) 8 19.3 18.5 13.4 1.8-40.7 
              
Figure 2.3. Summary of KDM4B staining in KUCC OVCAR TMAs. Nuclear staining of KDM4B was 
scored as described in Materials and Methods (represented as n (%)). Tumors with > 10% nuclei staining 
positive for KDM4B were considered "high," in a modification of a method described in (Goode, et al. 
2011). “Mixed” contain various combinations of clear cell, endometrioid, and mucinous characteristics, 
all with a serous component. “Other” contains individual tumors with diagnoses of endometrioid, clear 





Patient Grade histosubtype tumor type 





1 III serous primary 35.47 3 
2 III serous primary 2.9 2 
3 III serous primary 21.93 3 
4 III serous primary 30.1 1.67 
6 III serous primary 1.5 2.33 
7 III serous primary 20.7 2 
8 II serous primary 29.13 2.33 
9   serous primary 56.4 2.67 
12 III serous primary 23 2 
13   serous primary 34.43 2.67 
16 III serous primary 33.57 2 
17 III serous primary 6.6 3 
20 III serous primary 4.13 2 
21 III serous primary 37.9 2.67 
22 III serous primary 27.9 2 
23   serous primary 14.33 2.67 
24 III serous primary 54.35 3 
25 III serous primary 61.07 2 
26 III serous primary 4.5 2 
31 III serous primary 40.07 3 
38 III serous primary 2.73 2 
39 III serous primary 56.85 3 
40 III serous primary 0.73 2 
41 III serous primary 7.37 2 
42 III serous primary 1.53 2 
43 III serous primary 15.93 3 
45 III serous primary 15.97 3 
46 III serous primary 2.77 2.33 
47 III serous primary 6.07 2 
49 II serous primary 20.83 3 
1 III serous metastasis 24.73 2.67 
2 III serous metastasis 1.33 2 
3 III serous metastasis 38.87 3 
4 III serous metastasis 8.53 2 
6 III serous metastasis 5.6 2 
7 III serous metastasis 15.7 2.33 
8 II serous metastasis 14.97 2 
9   serous metastasis 54.2 3 
12 III serous metastasis 21.8 2 
13   serous metastasis 24.67 3 
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16 III serous metastasis 25.43 2 
17 III serous metastasis 28.2 2 
20 III serous metastasis 6.37 1.33 
21 III serous metastasis 18.7 NA 
22 III serous metastasis 39.13 2 
23   serous metastasis 16.3 2 
24 III serous metastasis 42.97 2 
25 III serous metastasis 19.87 2 
26 III serous metastasis 7 2.5 
38 III serous metastasis 10.97 2 
39 III serous metastasis 33.1 3 
40 III serous metastasis 14.83 2 
41 III serous metastasis 17.57 2.67 
42 III serous metastasis 0 NA 
43 III serous metastasis 0.87 2.33 
45 III serous metastasis 19.13 3 
46 III serous metastasis 3.1 2 
47 III serous metastasis 7.6 2 
49 II serous metastasis 28.3 3 
10 II mixed primary 1.2 1.33 
18 III mixed primary 42.2 2 
19 III mixed primary 15.43 2.33 
27 III mixed primary 44.5 2 
28 III mixed primary 24.53 2 
29 III mixed primary 7.97 3 
30 III mixed primary 13.33 2.67 
32 II mixed primary 43.1 2 
33 III mixed primary 11.6 2 
34 III mixed primary 1.23 2 
35 III mixed primary 1.23 1 
36 III mixed primary 0.47 2 
44 III mixed primary 21.43 2 
48 III mixed primary 16.1 1 
10 II mixed metastasis 30.23 2 
18 III mixed metastasis 4.5 2 
19 III mixed metastasis 24.17 3 
34 III mixed metastasis 4.13 2 
35 III mixed metastasis 1.3 1 
36 III mixed metastasis 2.13 2 
44 III mixed metastasis 11.23 2 
48 III mixed metastasis 5.7 2 
5 III other primary 27.13 3 
11 III other primary 19.27 2.67 
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14 III other primary 10.37 2 
15 III other primary 17.7 2 
5 III other metastasis 31.83 3 
11 III other metastasis 1.83 2.33 
14 III other metastasis 5.23 1.67 
15 III other metastasis 40.73 2.33 
37 III not EOC primary 10.57 3 
37 III not EOC metastasis 4.53 2 
Figure 2.4. Immunohistochemical Scoring Data for KUCC OVCAR TMAs. Tumors are listed 
by de-identified patient sample # with corresponding tumor grade (most are FIGO grade III), 
pathology histological subtype (histosubtype; serous, mixed, other, and not EOC), tumor type 
(primary, metastasis), and average scores for KDM4B nuclear staining (% nuclear staining) 
and CA9 intensity scores (0-3, in increments of 0.3). Scoring was applied as described in 
Methods. Data are ranked by histosubtype, then tumor type, then patient sample #. Sections 





Nuclear KDM4B staining was greater in tumor epithelium of HGSA tumors compared to normal ovarian 
sections (Fig. 2.5A, quantified in 2.5C).  Heterogeneous distribution of KDM4B nuclear staining was 
observed throughout primary and metastatic tumor sections (Fig. 2.5A).  Over 60% of primary and 
metastatic tumors displayed “high” expression of KDM4B (Fig. 2.5B, quantified in 2.5D, See Methods). 
Nuclear expression of KDM4B in metastatic tumors positively correlated with KDM4B expression in the 
corresponding primary tumors (Fig. 2.5E, Spearman r=0.7192, P <0.0001). Independent measurements 
using sections from nine normal ovaries showed weak KDM4B staining in normal ovarian surface 







Figure 2.5. KDM4B is robustly expressed in ovarian cancer tissue and ovarian cancer cell lines 
compared to normal ovarian surface epithelial cells. A. Representative immunohistochemical 
detection of KDM4B (top row; brown, DAB; blue, hematoxylin) in Tumor Microarray sections from 
normal ovary and high-grade ovarian serous adenocarcinoma biopsies with matched primary and 
metastatic tumor sections. IgG (middle) and H&E (hematoxylin and eosin, bottom) serve as controls for 
non-specific DAB staining and tissue structure controls, respectively. B. Representative IHC images of 
tumor sections with high (left) and low (54) KDM4B. For each image, the percentage of cancer cell 
nuclei staining positive for KDM4B is denoted in the lower left corner. For A and B, scale bar for entire 
section, 100 μm; scale bar for inset, 50 μm. C. Box-whisker plot of KDM4B nuclear staining in normal 
ovary (N, n=9), primary HGSA tumors (P, n=30) and metastases (M, n=29). Diamond, mean; 
Significance of staining differences was determined using Kruskal-Wallace, with Mann-Whitney U-test 
(*, P<0.001). D. Percentage of total patient samples in each category (normal, primary and metastasis) 
staining for high or low KDM4B (high > 10% nuclei staining positive for KDM4B, low <10%). E.  
Correlation between KDM4B staining in Metastases (n=29) compared to matched primary tumors (n=29). 
Significance determined by Spearman’s correlation. F. KDM4B expression in representative normal 




The expression of the tumor hypoxia marker Carbonic anhydrase 9 (CA-IX) was also scored in 
the TMAs (Fig. 2.6A and 2.6B, Fig. 2.4). Average intensity of CA-IX staining for triplicate tumor 
sections in the HGSA tumors (range 0-3) was positively correlated to the percentage of KDM4B-positive 
tumor nuclei (Fig. 2.6B). When the primary and metastatic tumors were analyzed separately, this 
correlation extended to each group, although significance was achieved only in the metastases (P=0.03). 
Additionally, KDM4B was robustly expressed in multiple cell lines representing a broad range of EOC 
genotypes, particularly in response to hypoxia (0.5% oxygen, Fig. 2.6C). There was weak hypoxic 
induction of KDM4B in the immortalized OSE cell line HIO80 (Fig. 2.6C). KDM4B is expressed in 








Figure 2.6. KDM4B is expressed in hypoxic ovarian cancer tumors and EOC cell lines.  A. 
Representative images of TMA sections demonstrating association between elevated KDM4B staining 
with elevated CA-IX staining. IgG and H&E serve as negative and tissue structure controls, respectively. 
Scale bar = 50 μm. B. Scatter plot of hypoxia (CA-IX staining) vs. KDM4B staining in TMA sections. 
Blue diamonds, primary tumors (n=30); red squares, metastatic tumors (n=29). Statistical significance 
determined using Spearman’s correlation. P value < 0.05, is considered significant. C. Immunoblot 
detection of KDM4B and HIF-1α in a panel of ovarian cancer cell lines in normoxia (N, 21% oxygen) and 
in hypoxia (H, 0.5% oxygen). HIO-80 cells serve as non-transformed OSE control. HIF-1α indicates 
cellular hypoxia, Beta-actin serves as loading control. 
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KDM4B Differentially Regulates Gene Expression in Atmospheric and Hypoxic Growth 
Conditions. In order to identify genes regulated by KDM4B in EOC, SKOV3ip.1 cells were transiently 
transfected with siRNA to KDM4B (siK4B) or an irrelevant control (siCon), achieving robust knockdown 
in both normoxia (21% oxygen) and hypoxia (0.5% oxygen) (Fig. 2.7A-2.7B). SKOV3ip.1 cells form 
peritoneal xenograft tumors in a manner consistent with human EOC, facilitating translation of gene 
expression data to functional analysis (Yoneda, Kuniyasu et al. 1998; Rankin, Fuh et al. 2010). Consistent 
with prior reports (Beyer, Kristensen et al. 2008), loss of KDM4B did not increase bulk H3K9 
trimethylation (H3K9me3) or dimethylation (H3K9me2) in SKOV3ip.1 or OVCAR8 cell lines (Fig. 
2.7A, Fig. 2.8A, respectively). Similar results were observed for bulk H3K36 trimethylation and 
dimethylation (Fig. 2.7A, Fig. 2.8A). These results suggest that KDM4B regulates gene expression 
through specific mechanisms rather than global shifts in chromatin modification (Beyer, Kristensen et al. 
2008). Genes dependent on KDM4B in either 21% or 0.5% oxygen were identified by expression 
microarray analysis (See Methods). KDM4B positively regulated expression of 1864 gene probes in 
normoxia, and 932 gene probes in hypoxia, with an overlap of 185 genes regulated in both conditions 
(Fig. 2.7C). The predominant pathways regulated by KDM4B in each oxygen condition were distinctly 
different (Fig. 2.9).  In normoxia, KDM4B predominantly regulated genes involved in cancer, cell cycle 
(including DNA replication, recombination, and repair), and cell death pathways. In hypoxia, KDM4B 
regulated genes associated with inflammatory response, cellular development, and cellular movement, 
implying a possible role in metastasis.  Complete microarray data was deposited under accession number 
GSE66894 in the NCBI Gene Expression Omnibus, which can be accessed to see all genes differentially 
regulated in normoxia and hypoxia with or without KDM4B (Edgar, Domrachev et al. 2002). Several 
genes were associated with metastatic pathways: Platelet derived growth factor beta (PDGFB, a potent 
angiogenic, lymphangiogenic, and transformative factor (Schito, Rey et al. 2012)); lipocalin 2 (LCN2 or 
neutrophil gelatinase, a protease associated with cell invasion and inflammatory response); and lysyl 
oxidase-like 2 (LOXL2, a collagen hydroxylase associated with metastasis (Erler, Bennewith et al. 2006; 
Barker, Chang et al. 2011; Barker and Erler 2011)) were dependent on KDM4B in both oxygen tensions 
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(Fig. 2.7D). Regulation of PDGFB, LCN2, LOXL2, and LOX (lysyl oxidase, another collagen hydroxylase 
associated with metastasis (Erler, Bennewith et al. 2006)) was further validated in SKOV3ip.1 cells stably 
transduced with two shRNA constructs specifically targeting KDM4B (shK-1 and shK-2, Fig. 2.7E, See 
Fig. 2.8 for specificity compared to other KDM4 family members). LCN2 was decreased by 
approximately 50% following KDM4B knockdown in normoxia and hypoxia, while hypoxic induction of 
PDGFB, LOX, and LOXL2 decreased by 25-30%.  Knockdown of KDM4B in OVCAR8 cells decreased 
expression of PDGFB and IGFBP1 approximately 50% in both normoxia and hypoxia (Fig. 2.8F). 
Increased expression of LOX in EOC patient tumor samples associates with poor progression-free 
survival (Gyorffy, Lanczky et al. 2012), linking a putative KDM4B target gene to disease progression 
(Fig. 2.7F). Combined, these data suggest KDM4B regulates distinct functions in different oxygen 





Figure 2.7. KDM4B regulates different pathways in normoxia and hypoxia. A. Immunoblotting of 
KDM4B expression, H3K9me3, H3K9me2, H3K9me1, H3K36me3, H3K36me2, and H3K36me1 in 
SKOV3ip.1 cells transfected with siRNA to KDM4B (4B) or control siRNA (C) in Panel A. Histone H3 
serves as control for protein loading. B, Quantitative RT-PCR of KDM4B expression in SKOV3ip.1 cells 
transfected with siRNA to KDM4B (siK4B) or control siRNA (siCon) and exposed to 21% or 0.5% 
oxygen for 16 hours. C, Venn diagram showing the overlap between genes down-regulated greater than 
1.4 fold by siK4B in normoxia (top circle) and hypoxia (bottom circle). D, Quantitative RT-PCR 
validation of selected metastasis-associated genes regulated by KDM4B. Data in B and D represent mean 
fold change ± S.E.M. normalized to 18S rRNA, calculated relative to siCon in 21% O2 (black bars). 
Results were averaged from three independent experiments, measured in triplicate. Significance of 
differences was calculated using two-tailed paired Student’s T-test (!, P<0.05 for siK4B compared to 
siCon,; #, P<0.05 for hypoxia compared to normoxia) or two-way ANOVA (*, P<0.05 for interactions 
between oxygen conditions and KDM4B expression). E.  qRT-PCR measurement of PDGFB, LCN2, and 
LOX in SKOV3ip.1 cells expressing shRNA to KDM4B (shK-1, dark grey and shK-2, light grey) cultured 
in the indicated oxygen tensions.  Data in Panels E represents mean fold change ± S.E.M, normalized to 
18S rRNA and shGFP control at 21% oxygen (n=5 measured in triplicate). *, P<0.05, determined by two-
tailed paired Student’s t-test, relative to shGFP control at the respective oxygen tension.  F.  Kaplan Meier 
progression-free survival plot of LOX expression in all stages of serous epithelial ovarian cancer from 
data set curated by Gyorffy et al. 2012  (P<0.05). 




Figure 2.8. KDM4B Regulates Expression of PDGFB and IGFBP1 in OVCAR8 expressing shRNA 
to KDM4B.  A. Immunoblotting of KDM4B, H3K9me3, H3K9me2, H3K9me1, H3K36me3, 
H3K36me2, and H3K36me1 expression in OVCAR8 cells. Histone H3 serve as control for protein 
loading. B. Quantitative RT-PCR measurement of KDM4 subfamily members in SKOV3ip.1 cells. C. 
Immunoblot of KDM4 subfamily members in SKOV3ip.1 cells. α-Tubulin serves as a loading control. D. 
Quantitative RT-PCR measurement of KDM4 subfamily members in OVCAR8 cells. Data represent 
mean ± S.E.M., normalized to 18S rRNA and shGFP control at 21% O2. Results were averaged from 
three independent experiments, measured in triplicate. *, P<0.05, determined by two-tails paired 
Student’s t-test.  E. Immunoblot of KDM4 subfamily members in OVCAR8 cells. Tubulin serves as a 
loading control. F. Quantitative RT-PCR measurement of PDGFB and IGFBP1 in OVCAR8 cells 
expressing shRNA to KDM4B (shK-1, dark grey and shK-2, light grey) in 21%, and 0.5% oxygen.  
QPCR data in panels B, D, and  F represent the mean ± S.E.M., normalized to 18S rRNA and shGFP 
control at 21% O2. Results were averaged from three independent experiments, measured in triplicate. *, 
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in 21% Oxygen 
    Top Bio Functions 
in 0.5% Oxygen 
    
Diseases and 
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Name  P-value  # 
Molecules 
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Molecules 
Cancer 6.37E-20 - 
7.63E-04  
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Genetic Disorder   2.03E-11 - 
7.94E-04 
249 Respiratory Disease  1.46E-04 - 
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Infectious Disease  9.82E-11 
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Name  P-value  # 
Molecules 
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KDM4B Binds and Demethylates Regulatory Regions of Target Genes to Promote Expression. 
KDM4B primarily regulates gene expression by demethylating H3K9me3, enhancing transcription by 
removing a modification associated with repression (Mosammaparast and Shi 2010). Stable loss of 
KDM4B did not result in any changes in bulk histone H3K9me3 in either SKOV3ip.1 or OVCAR8 cells 
under any oxygen tensions examined (Fig. 2.10A). In order to determine if KDM4B directly regulated 
putative target gene expression, SKOV3ip.1cells were exposed to 21% and 0.5% oxygen for 16 hours, 
and chromatin immunoprecipitation (ChIP) was performed using antibodies against KDM4B and 
H3K9me3. In SKOV3ip.1-shGFP cells, KDM4B was localized to regions near the transcription start sites 
of PDGFB, LCN2, LOX, and LOXL2 (Fig. 2.10B and 2.10C), with a 3-6 fold increase in association in 
0.5% oxygen. Following knockdown, association of KDM4B to regulated promoters decreased to levels 
similar to an isotype specific IgG control. Knockdown of KDM4B increased enrichment of H3K9me3 at 
the promoters of PDGFB, LCN2, LOX, and LOXL2 in 21% oxygen (Fig. 2.10D). In 0.5% oxygen, 
knockdown of KDM4B elevated H3K9me3 compared to the control. However, the overall magnitude of 
association at PDGFB, LCN2, and LOX decreased in hypoxia, making this difference less significant. 
The enrichment of H3K9me3 on a control “gene desert” region was not significantly affected by loss of 
KDM4B or by hypoxia (Fig. 2.10E). Combined, these results demonstrate that KDM4B associates with 
regulatory regions of target genes, and demethylates histones residing near transcription start sites to 





Figure 2.10. KDM4B binds regions proximal to target gene promoters and demethylates histone 
H3K9me3 to regulate expression.  A. Immunoblot measurement of KDM4B and H3K9me3 in 
SKOV3ip.1 and OVCAR8 cells expressing shRNA targeting KDM4B (shK-1 and shK-2) or GFP 
(control) in 21%, 2%, and 0.5% O2. Tubulin and histone H3 serve as loading controls. B. Map of ChIP-
qPCR primers sets used to measure KDM4B association and histone H3K9 methylation at or near target 
gene promoters. C. ChIP assay for KDM4B near promoters of PDGFB, LCN2, LOX, and LOXL2 genes in 
SKOV3ip.1 cells expressing shRNA to KDM4B (shK-2, light grey bars) compared to shGFP control 
(black bars). Cells were treated with normoxia (21%) or hypoxia (0.5%) for 16 hours. Data represent 
mean fold enrichment ± S.E.M of three independent experiments (n=3) measured in triplicate, normalized 
input and then to GFP control at 21% O2. D. ChIP qPCR analysis of H3K9me3 on indicated promoter 
regions of the PDGFB, LCN2, LOX, and LOXL2 genes following shRNA to KDM4B (shK-2, light grey 
bars) compared to shGFP control (black bars). Data represent the mean of four independent experiments ± 
S.E.M (n=4) measured in triplicate, and normalized to shGFP control following subtraction of IgG signal 
and normalization to a gene desert control region as described in Material and Methods. E. H3K9me3 
ChIP to a gene desert control region. Data represent the mean of four independent experiments ± S.E.M 
(n=4) measured in triplicate normalized to input. Significance relative to shGFP control was determined 




KDM4B Regulates Cell Invasion, Migration, and Spheroid Formation In Vitro. In order to determine 
if KDM4B mediates metastatic phenotypes, SKOV3ip.1 and OVCAR8 cells were seeded to Boyden 
chamber migration and invasion assays (Fig. 2.11A-2.11F). Following KDM4B knockdown, both cell 
lines demonstrated a significantly reduced invasion through Matrigel with up to 60% decrease in invasion 
(Fig. 2.11A, 2.11C, 2.11D, 2.11E). Migration through uncoated inserts was decreased by approximately 
25-30% in SKOV3ip.1 cells (Fig. 2.11B). In OVCAR8 cells, migration through uncoated chambers was 
severely attenuated (>80%, Fig. 2.11E), indicating that while KDM4B was universally important for 
regulating invasive behavior in both cell lines, its effects on invasion and migration may be mediated 
through distinct, but overlapping mechanisms. Stable knockdown of KDM4B had little effect on cellular 
doubling time in SKOV3ip.1 and OVCAR8 cells (Figs. 2.12A and 2.12B), nor were there significant 
differences between proliferation controls used for Boyden chamber assays (Fig. 2.12C and 2.12D).  
Another characteristic of EOC is the tendency to form clusters of cells suspended in ascites that 
seed the peritoneal compartment (Lengyel 2010). Using in vitro spheroid formation assays (Vinci, Gowan 
et al. 2012), loss of KDM4B significantly reduced the volume of spheroids by 50% in SKOV3ip.1 cells, 
with similar results in OVCAR8 cells (Fig. 2.11G and 2.11I). Decreased spheroid volume was significant 
under 21% O2 and 2% O2 treatments for SKOV3ip.1 and OVCAR8 spheroids (Fig. 2.11G and 2.11I). 
Additionally, the control spheroids were more rounded and smoother in appearance, indicating more 
robust cell-to-cell contact (Fig. 2.11H and 2.11J). Combined, these results indicate that KDM4B may 
influence ovarian cancer progression by promoting formation of ascites spheroids in the peritoneal cavity 





Figure 2.11. KDM4B supports ovarian cancer cell invasion, migration, and 3D spheroid formation. 
A.  SKOV3ip.1 Matrigel Invasion Assay. 5 × 104 SKOV3ip.1 cells expressing the indicated shRNA were 
seeded to Boyden Chambers coated with Matrigel and cultured for 24 hours in the indicated oxygen 
tensions. Cells were trypsinized and quantified as described in Methods. B. Migration Assay. 5 × 104 
SKOV3ip.1 cells were seeded to empty Boyden chambers, cultured and quantified as in Panel A. Data in 
Panel A and B represent mean ± S.E.M for five independent experiments  (n=3). C. Representative image 
of SKOV3ip.1 invasion assay. Filters treated in parallel to those in Panel A were fixed and stained, as 
described in Methods. 100X magnification, scale bar = 200 μm. D. OVCAR8 invasion assay performed 
as in panel A. E. Migration assay for OVCAR 8 cells, treated as in Panel B. Data in Panel D and E 
represent the mean ± S.E.M for four independent experiments, n=3. F. Representative images of 
OVCAR8 Matrigel invasion assay. 100X magnification, scale bar = 200 μm. G. SKOV3ip.1 spheroid 
formation assay. SKOV3ip.1 cells transduced with the indicated shRNA were cultured in ULA dishes in 
21% and 2% O2 as described in Methods. After four days, spheroid volume was calculated. Data 
represent mean volume ± S.E.M. n=16. H. Representative images (median volume) of SKOV3ip.1 
spheroids. 100X magnification, scale bar = 100 μm. I. OVCAR8 spheroid formation assay, conducted as 
described for G. J. Representative images (median volume) of OVCAR8 spheroids. 100X magnification, 
scale bar = 100 μm. For Panels A, B, D, E, G and I, significance was calculated relative to shGFP control 







Figure 2.12. Suppression of KDM4B Does Not Regulate Proliferation In SKOV3ip.1 and OVACR8 
cells. A. SKOV3ip.1 cells transduced with shRNA to KDMB (shK-1 and shK-2) were seeded for growth 
curve experiments as described in Methods, and cultured in 21% O2 and 2% O2. Data represent four 
independent experiments conducted in triplicate. B. OVCAR8 cells transduced with shRNA to KDMB 
(shK-1 and shK-2) were seeded for growth curve experiments as described in Supplemental Methods, and 
cultured in 21% O2 and 1% O2. Data represent three independent experiments, conducted in triplicate. 
Data in panels A and B represent mean ± S.E.M. #, P<0.05, comparing shK-1 to shGFP; *, P<0.05, 
comparing shK-2 to shGFP; determined by two-tailed paired Student’s t-test.  C-D, Proliferation controls 
for Boyden Chamber Migration and Matrigel Invasion Assay. 25 000 cells were seeded as monolayers in 
parallel with cells seeded for Boyden chamber assays. After 24 hours, cells were trypsinized, frozen, and 
analyzed as described in Methods. Data represent mean ± S.E.M. Results were averaged from five 
(SKOV3ip.1, C) or four (OVCAR8, D) independent experiments conducted in triplicate. * = P<0.05, 
determined by two-tailed paired Student’s t-test. 
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KDM4B Regulates Seeding and Growth of Peritoneal Tumors. The in vivo role of KDM4B in EOC 
tumor progression was determined using intraperitoneal (i.p.) tumor xenografts. Loss of KDM4B 
significantly inhibited peritoneal seeding and tumor growth for both SKOV3ip.1 and OVCAR8 cells, as 
measured by bioluminescence (Fig. 2.13). This effect was significant for both constructs in SKOV3ip.1 
cells (Fig. 2.13A-2.13C), whereas shK-2 showed the most significant effect in OVCAR8 cells, with a 
trend of reduced growth for shK-1 (Fig. 2.13D-2.13F). Total endpoint tumor weight was decreased by at 
least 50% in SKOV3ip.1 cells and OVCAR8 cells (Fig. 2.13G-2.13H). OVCAR8 cells expressing shRNA 
to KDM4B developed less ascites fluid compared to controls, consistent with the effect on tumor seeding 
and growth. (Fig. 2.13I). Terminal necropsy confirmed a general decrease in the size of metastatic 
nodules in the omentum, viscera, and peritoneal wall (Fig. 2.13J). Immunohistochemical detection of 
KMD4B in xenograft tumors confirmed the stability of knockdown throughout the study (Fig. 2.14A-
2.14D). KDM4B was expressed in hypoxic regions of tumor epithelium as determined by pimonidazole 
and PAX8 staining (Fig. 2.14E-2.14H, and 2.14I-2.14L, respectively).  There was no apparent difference 
in cell proliferation (Ki-67 staining, Fig. 2.14M-2.14P), consistent with in vitro experiments (Fig. 2.12). 
QPCR measurement of KDM4A, KDM4B, KDM4C, and KDM4D RNA in xenograft tumors (Fig. 2.14Y 
and 2.14Z, respectively) confirmed stable knockdown of KDM4B, while also identifying slight increases 
in expression of KDM4A and KDM4D. Combined, these studies demonstrate a role for hypoxic 





Figure 2.13. KDM4B regulates peritoneal seeding and growth of ovarian cancer cells. A. 
Representative ventral bioluminescent images of nude mice injected with SKOV3ip.1-luc-neo cells 
transduced with indicated shRNA constructs. Image represents the median tumor load for each group, 28 
days after injection. B. Longitudinal ventral bioluminescence measurement for all mice injected with 
SKOV3ip.1-luc-neo transduced with indicated shRNA. Data represents mean total radiance (photons/sec) 
for each group ± SEM, (n = 9 or 10 mice per group). Blue diamonds = shGFP, red squares = shK-1, 
brown triangles = shK-2. C. Dorsal bioluminescence for SKOV3ip.1 study, analyzed as in B. D. 
Representative images of mice injected with OVCAR8-luc-neo cells transduced with the indicated 
shRNA constructs. Image was captured at Week 6 of study.  E. Ventral bioluminescence measurement for 
all mice injected with OVCAR8-luc-neo transduced with indicated shRNA constructs, analyzed as in B. 
F. Dorsal bioluminescence for OVCAR8 study, analyzed as in B. Statistics for B, C, E and F were 
calculated with Kruskal Wallis and Mann Whitney U-tests (*, P<0.05; **, P<0.005). Blue asterisks, 
difference among all three groups; red asterisks, difference between shK-1 and shGFP; brown asterisks, 
difference between shK-2 and shGFP. G. Box-whisker dot plot of total tumor weight for SKOV3ip.1 
xenografts. (n = 7 per group). H. Dot plot of tumor weight for OVCAR8 xenografts (n=9 or 10). I. Dot 
plot of ascites fluid volume collected from OVCAR8 experiment. (n = 9 or 10 mice per group). For 
panels G-I, statistical significance was determined using Mann-Whitney U-test relative shGFP control (*, 
P<0.05). J. Representative end-point necropsy demonstrating differential tumor size and distribution in 
mice injected with SKOV3ip.1 or OVCAR8 cells. Scale bar = 1 cm. Visible tumors are circled in yellow. 





Figure 2.14. KDM4B is expressed in hypoxic regions of tumor xenografts. A-D. KDM4B. E-H. 
Pimonidazole. I-L. PAX8. M-P. Ki67. Q-T. IgG. U-X. H&E. Scale bar, 100 μm. N, necrosis; H, hypoxia.  
Panels A, E, I, M, Q, and U correspond to SKOV3ip.1 shGFP control tumor sections. Panels B, F, J, N, 
R, and V correspond to SKOV3ip.1 shK-2 KDM4B knockdown tumor sections. Panels C, G, K, O, S, 
and W correspond to OVCAR8 shGFP control tumors. Panels D, H, L, P, T, and X correspond to 
OVCAR8 shK-2 tumor sections. All IHC sections were counterstained with hematoxylin to visualize cell 
nuclei. Images were captured at 100X magnification. Scale bar = 200 μm. Y, QRT-PCR measurement of 
KDM4 subfamily members in SKOV3ip.1 xenograft tumors, as described in Methods. (shGFP, n=7; shK-
1, n=7; shK-2, n=7). Z, QRT-PCR measurement of KDM4 subfamily members in OVCAR8 xenograft 
tumors.  (shGFP, n=10; shK-1, n=9; shK-2, n=8). Data represents average fold change relative to shGFP 
control, after normalization to homo sapiens GAPDH. Significance was calculated by Mann Whitney U-
test relative to shGFP control (*, P < 0.05). Note co-localization of KDM4B with pimonidazole staining 





Developing more effective methods to attenuate peritoneal dissemination and tumor recurrence in 
ovarian cancer patients depends on improved understanding of the processes contributing to attachment-
free growth of cancer cells in malignant ascites, invasion of cancer cells into the mesothelium, and 
establishment of new tumors. Our data suggests that KDM4B contributes significantly to pathways that 
influence peritoneal seeding of tumors. As a hypoxia-inducible regulator of peritoneal seeding, KDM4B 






Figure 2.15. KDM4B Regulates Peritoneal Seeding of Ovarian Cancer. Hypothesized mechanism of 
KDM4B signaling to promote ovarian cancer progression. Briefly, hypoxia induces the expression of 
KDM4B, catalyzing demethylation of histone H3K9me3 at target promoters and regulating expression of 
genes that facilitate the seeding of metastases in the viscera and peritoneal wall. 
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KDM4B regulates expression of multiple genes that may contribute to ovarian cancer growth and 
metastasis (Fig. 2.7). In the case of most proliferative genes identified in the initial screen, regulation by 
KDM4B was attenuated with stable knockdown (data not shown), most likely due to compensation from 
other KDM4 family members. KDM4D is a likely candidate, since we observed increased expression of 
protein and RNA following knockdown of KDM4B in vitro and in vivo. Compensatory KDM4B 
expression has been observed in the testes of KDM4D knockout mice, suggesting that our observations 
represent an inverse effect (Iwamori, Zhao et al. 2011). Of greater interest is the regulation of genes that 
may promote tumor metastasis. PDGFB, LCN2, LOX, and LOXL2 depend on KDM4B for expression, 
corresponding to changes in histone methylation on their respective promoters. Demethylation of 
promoters in normoxia and hypoxia may facilitate expression of target genes by altering the dynamics of 
HIF binding, as in the case of KDM4C at the LDHA promoter (Luo, Chang et al. 2012).  Members of the 
KDM4 family of histone demethylases, including KDM4B, are inhibited by hypoxic conditions (Beyer, 
Kristensen et al. 2008; Sanchez-Fernandez, Tarhonskaya et al. 2013). Other KDMs, such as KDM3A, 
may compensate to demethylate promoters in hypoxia (Beyer, Kristensen et al. 2008; Krieg, Rankin et al. 
2010). Recent reports also indicate that KDM4A is stabilized in a HIF-independent manner to facilitate 
gene amplification, providing an alternate mechanism for hypoxic functions of the KDM4 family (Black, 
Atabakhsh et al. 2015). Finally, KDM4B forms a complex with MLL2 that associates with ERα to 
regulate gene expression in breast cancer (Shi, Sun et al. 2011). Future studies examining the interactions 
between KDM4B, HIF, other KDMs, and lysine methyltransferases (KMTs) will clarify the 
transcriptional mechanisms that regulate expression of KDM4B target promoters in hypoxia. 
Stable knockdown of KDM4B disrupted invasion and migration in vitro, consistent with 
diminished peritoneal tumor load in mouse xenografts. The most striking difference was in the size of 
fused omental tumors, suggesting that KDM4B may preferentially regulate metastasis to omental tissues. 
Further, the contribution of KDM4B to the formation and growth of tumor spheroids in vitro likely relates 
to in vivo function of KDM4B by facilitating peritoneal seeding (Lengyel 2010). These phenotypes 
appear to be distinct from the actions of KDM4A in EOC and other cancers, where it promotes copy 
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number gain and drug resistance (Black, Manning et al. 2013; Black, Atabakhsh et al. 2015). Considering 
the large number of genes dependent on KDM4B in SKOV3ip.1 cells, it is unclear at this time which 
specific genes or pathways are primarily responsible for these broad phenotypic effects, although LCN2, 
LOX, LOXL2, and PDGFB make particularly compelling candidates with proven abilities to influence 
either ovarian cancer growth or general metastasis (Apte, Bucana et al. 2004; Santin, Zhan et al. 2004; 
Erler, Bennewith et al. 2006; Barker and Erler 2011). Additionally, analysis of data sets curated by 
Gyorffy et al (Gyorffy, Lanczky et al. 2012) demonstrated that higher expression of LOX in tumor 
samples correlates with reduced progression-free survival in EOC (Fig. 2.7E). In an additional 
independent proof of concept, blocking PDGFB signaling in SKOV3ip.1 cells with DNA aptamers 
suppressed growth of peritoneal tumor xenografts (Lu, Shahzad et al. 2010). These results support the 
potential role of KDM4B target genes, identified in this study, in the pathogenesis of EOC. Combinatorial 
targeting of the genes regulated by KDM4B may lead to improved methods to suppress peritoneal 
engraftment of EOC tumor cells, ultimately improving the prognosis of patients with elevated levels of 
KDM4B. 
A key question rising from our study regards the utility of directly targeting KDM4B to improve 
EOC patient outcome. Although a systematic comparison has not been conducted, KDM4B appears to 
regulate pathways distinct to each cancer type. In hormone-dependent breast and prostate cancers, 
KDM4B is induced by steroid hormones, and regulates ER and AR target genes (Yang, Jubb et al. 2010; 
Coffey, Rogerson et al. 2013). In colon and gastric cancers, KDM4B regulates beta-catenin dependent 
gene expression and WNT signaling to promote attachment-free growth and metastatic behavior (Berry 
and Janknecht 2013; Zhao, Li et al. 2013). In EOC, although KDM4B regulates distinct sets of genes in 
different oxygen tensions, invasive and migratory behaviors appear to be the most robust phenotypes. 
There is the implication that disrupting KDM4B function with an inhibitor of its demethylase activity 
could attenuate tumor growth. However, there are significant barriers to creating specific inhibitors to 
individual histone demethylases (reviewed in (Hojfeldt, Agger et al. 2013; Maes, Carceller et al. 2015)). 
Despite significant effort in the design of specific inhibitors (Rai, Kawamura et al. 2010; Thalhammer, 
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Mecinovic et al. 2011), the greatest success has been restricted to inhibition of the KDM6 family 
(Kruidenier, Chung et al. 2012). A systematic analysis of KDM-inhibitor interactions reported significant 
cross-reactivity for all inhibitors tested, highlighting the difficulty of developing a specific inhibitor 
(Joberty, Boesche et al. 2016). Given the importance of KDM4A and KDM4B in regulating various 
aspects of DNA repair and cell proliferation (Mallette, Mattiroli et al. 2012; Young, McDonald et al. 
2013), directly targeting the enzymatic activity of KDM4B may lead to off-target effects in normal 
tissues. Finally, to advance KDM4B as a direct therapeutic target in EOC, it will be important to 
demonstrate the extent to which demethylase activity modulates the hypoxic response, invasive 
phenotype, and in vivo growth properties of ovarian cancer cells. Such studies would be best-
accomplished using KDM4B catalytic and targeting mutants via in situ CRISPR/Case9 gene editing. 
The importance of hypoxic signaling in EOC is highlighted by the relative success of bevacizumab 
(Avastin) in the treatment of HGSA (Bast 2011). Although only 25% of HGSA patients responded to 
bevacizumab, this effect is more robust than all other alternate chemotherapies tested to date (Bast 2011; 
Li, Zhou et al. 2015). Bevacizumab has limitations stemming from either deleterious side effects, or 
compensatory hypoxic expression (Conley and Wicha 2012; Li, Zhou et al. 2015). As a facilitator of 
multiple tumorigenic pathways in normoxia and hypoxia, KDM4B may provide unique opportunities to 
tailor combinatorial therapies for patients with hypoxic tumor signatures.  
Collectively, this study demonstrates that the hypoxia-inducible histone demethylase KDM4B is 
robustly expressed in the majority of EOC tumors assayed and supports cellular phenotypes associated 
with seeding of peritoneal tumors, the primary cause of EOC patient morbidity and mortality. To the best 
of our knowledge, this is the first functional demonstration that a Jumonji-domain histone demethylase 
contributes to EOC progression. Future studies investigating the specific transcriptional and functional 
mechanisms regulated by KDM4B and other histone demethylases may reveal novel therapeutic 





INVESTIGATING MECHANISMS REGULATED BY KDM4B IMPLICATED IN EOC 


























The hypoxia-inducible histone demethylase, KDM4B is upregulated during the progression of 
ovarian cancer, connecting the hypoxic tumor microenvironment to epigenetic activation of cancer 
promoting genes and tumor progression.  Knockdown of KDM4B with shRNA reduces tumor growth and 
peritoneal dissemination in xenograft models (Chapter 2).  Loss of KDM4B also corresponds to decreased 
invasion, migration, and attachment free growth in vitro.  These results suggest that KDM4B activity is 
involved with regulating a more invasive or metastatic tumor phenotype in EOC.  Based on these 
observations, specific mechanisms and aspects of metastasis were investigated.  RNA Sequencing 
analysis identified possible target genes involved with invasion and migration, including MUC1 and 
ARID5B.  Based on previous studies, these findings suggest a link between KDM4B and ARID5B 
through PDGF pathway activation.  In order to identify secreted factors involved with remodeling the 
tumor microenvironment, conditioned media from SKOV3ip.1 and OVCAR8 cells expressing shRNA to 
KDM4B or an irrelevant control (GFP) were used for proteome analysis on an RD angiogenesis array.  
Using these arrays with affinity for 55 proteins, 11 secreted factors from SKOV3ip.1 and 16 from 
OVCAR8 cell lines were identified.  These results suggest that these targets may be regulated in a 
KDM4B dependent manner.  In addition to identification of secreted proteins, OVCAR8 spheroids 
expressing shRNA to KDM4B or a GFP control were used to investigate spheroid invasion on Type I 
Collagen.  Preliminary results suggest KDM4B expression correlates with increased spheroid invasion.  
KDM4B expression was identified in patient ascites from EOC patients, demonstrating the clinical 
relevance of exploring KDM4B in these processes.  Future work will include HUVEC assays and 3D 





 KDM4B provides a novel epigenetic link between the hypoxic tumor microenvironment and EOC 
progression.  This enzyme plays a role in EOC invasion, migration, and attachment-free growth in vitro, 
key steps in the pathogenesis of this disease (Chapter 2).  Considering KDM4B expression is connected to 
these aspects of the metastatic cascade, it is possible it participates in other processes involved in tumor 
growth and peritoneal dissemination.  These could include angiogenesis, influencing inflammatory cell 
processes in the tumor microenvironment, and regulating specific proteins dictating the movement of the 
tumor cell in the patient (Hanahan and Weinberg 2011).  Secreted factors could also be responsible for 
driving these alterations in the tumor microenvironment. 
Secreted factors are integral components regulating inflammation and angiogenesis, promoting 
different steps in these processes.  Not only does inflammation influence initial pathogenesis of EOC, it 
may drive tumorigenesis and metastasis (Auersperg 2013).  Depending on the tumor type, inflammation 
could promote tumor regression or progression (Ness and Cottreau 1999).  Endometriosis, a contributing 
risk factor to EOC progression, involves localized inflammation in regions endometrial tissue implants 
outside the uterus (Ness and Cottreau 1999).  The inflammatory response includes interleukins like IL-8, 
growth factors like TGF-ß, and other secreted angiogenic factors like VEGF that direct vascular 
remodeling (Ness and Cottreau 1999).  This process acts as a key component in the inflammatory 
response.   
Angiogenesis, the development of new vasculature from existing vasculature, is another key in 
driving growth and metastases away from sites of primary tumor burden (Horiuchi, Imai et al. 2002).  The 
KDM4B target, PDGFB (Platelet-derived Growth Factor) is an essential component in this process 
(Chapter 2) (Lu, Shahzad et al. 2010).  KDM4B regulates PDGFB in a demethylase dependent manner 
(Chapter 2).   VEGF (Vascular Endothelial Growth Factor) is another notable participant in vascular 
remodeling (Horiuchi, Imai et al. 2002).  PDGF ligands recruit pericytes to wrap and stabilize endothelial 
cells, playing a key role in their function as blood vessels (Lu, Thaker et al. 2008).  PDGF is composed of 
4 polypeptide chains that form either the homodimers PDGF-AA, BB, CC, and DD or the heterodimer 
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PDGF-AB (Kelly, Haldeman et al. 1991; Betsholtz, Karlsson et al. 2001).  Receptor activation dictates 
the function of the bound ligand (Lu, Shahzad et al. 2010).  The ligands PDGFAA, PDGFBB, PDGFAB, 
and PDGFCC bind to the receptor PDGFRα (Lu, Shahzad et al. 2010).  PDGFBB and PDGFDD bind to 
PDGFRβ (Lu, Shahzad et al. 2010).  Even though PDGFB knockout mice show abnormal vasculature, the 
role of this ligand and pathway have not been well established in ovarian tumor vasculature (Lu, Thaker 
et al. 2008).  PDGFAA and PDGFBB have been shown to be upregulated in ovarian cancer tumors and 
patient serum, correlating with advanced FIGO stages (Madsen, Steffensen et al. 2012).  In addition to 
participating in vascular remodeling, PDGFB has established links to non-transformed and transformed 
cell motility (Aoki, Nabeshima et al. 2007).  This provides another interesting PDGFB-dependent 
mechanism regulated by KDM4B. 
KDM4B is shown to be essential in driving invasion and migration in vitro and in vivo (Chapter 
2).  In addition to these aspects, KDM4B expression plays a role in spheroid formation and maintenance 
(Chapter 2). The ability to invade as single cells or spheroids is a key driving force in EOC metastasis.  
The accumulation of ascites fluid in the peritoneal cavity is present in one third of ovarian cancer patients 
(Puiffe, Le Page et al. 2007).  The tumor cells in ascites fluid are either single cell or cell aggregates 
(Smolle, Taucher et al. 2014).  Ascites cell clusters adhere and invade at distant sites in the peritoneal 
cavity (Smolle, Taucher et al. 2014).  Despite their importance in EOC progression, no studies have 
characterized the KDM4B-dependent mechanisms regulating the invasive natures of spheroids.  The 
influence of KDM4B in regulating invasion and migration in vitro was previously analyzed using single 
cells, not spheroid aggregates (Chapter 2).  Characterizing the role of KDM4B in spheroid invasion 
provides a novel perspective on this enzyme in an innovative 3D in vitro model.  Identifying expression 
of KDM4B in patient ascites neoplastic cells may establish clinical relevance for the findings from these 
additional in vitro studies.   
In this sets of studies, the connection between KDM4B expression and secreted factors and 
spheroid invasion was explored.  RNA Sequencing identified a possible link between KDM4B, PDGF 
pathway, and ARID5B expression.  ARID5B-dependent migration is regulated by PDGF signaling in 
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mouse embryonic fibroblasts (MEFs), providing a possible link between KDM4B and a demonstrated 
target gene PDGFB (Chapter 2) (Schmahl, Raymond et al. 2007).  KDM4B expression correlated with 
differential secretion of factors involved in many aspects of metastasis, including angiogenesis and 
inflammatory responses (Chapter 3).  Data indicated increased spheroid invasion in vitro with expression 
of KDM4B and identified putative target genes regulated by KDM4B (Chapter 3). These analyses provide 
novel explanations for the role of KDM4B in EOC tumorigenesis and interesting new areas for further 
KDM4B investigations.  Establishing potential mechanistic connections between KDM4B and the PDGF 
pathway may highlight insight into KDM4B-dependent activation of angiogenesis and invasion in EOC. 
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MATERIALS AND METHODS 
Cell Lines and Culture Conditions. All OVCAR cell lines were maintained in RPMI-1640 (Invitrogen) 
supplemented with 10% heat-inactivated fetal bovine serum (HI-FBS) and 1% pen-strep (Invitrogen). 
SKOV3ip.1 cells were from Dr. Erinn Rankin (Stanford University) with permission from Dr. Gordon 
Mills (M.D. Anderson Cancer Center). OVCAR3, OVCAR4, OVCAR5, OVCAR8, and IGROV1 cells 
were from the NCI-Frederick Cancer DCTD Tumor/Cell line Repository.  HIO80 cells were from Dr. 
Andrew Godwin. Upon receipt, cells were expanded in culture to establish early passage stocks. After 
transducing with lentivirus, cells were used for experiments within 1-2 months to minimize cell drift or 
contamination, and were periodically screened for mycoplasma.  For stable knockdown, cells were 
transduced with pLKO.1-shRNA constructs targeting KDM4B (Open Biosystems; TRCN0000018014 
(shK-1) and TRCN0000018016 (shK-2)) and selected in puromycin. For hypoxic treatment, cells were 
incubated for 16-24 hours in Ruskinn InVivo300 glove-box hypoxic incubators (Baker) set to desired 
oxygen tensions. 
 
Patient Ascites Cell Culture. The KU Cancer Center’s Biospecimen Repository Core Facility (BRCF) 
provided de-identified human patient samples and any corresponding clinical data with informed consent 
from patients.  Ascites fluid was obtained during cytoreductive surgery.  Samples were spun down post-
surgery and maintained in the repository.  Ascites cell pellets were cultured and maintained in RPMI 
medium plus 30% FBS in 10-cm ultra low attachment dishes.  Protein for western blotting analysis was 
harvested using SDS lysis buffer and previously published techniques (Krieg, Rankin et al. 2010). 
 
 QRT-PCR.  RNA from cells was isolated after two PBS (1X) washes, followed by Trizol (Ambion 
15596026) or Purelink mini kit (Ambion 12183020).  Quantitative real-time PCR (qRT-PCR) was 
conducted as previously described using an ABI VIIA sequence detection system using 18S rRNA as an 
internal control (Krieg, Rankin et al. 2010). Primers (Figure 3.1) were designed using the Roche 
Universal Probe Library Design Tool (http://lifescience.roche.com/shop/products/universal-probelibrary-
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system-assay-design) and verified in silico on UCSC genome browser. Melt curve analysis confirmed 




Assay Gene Forward (5'-3') Reverse (5'-3') 
QRT-PCR hsKDM4B ggactgacggcaacctctac cgtcctcaaactccacctg 
QRT-PCR hsKDM4D ggacaagcctgtaccactgag ctgcacccagaagccttg 
QRT-PCR hsMUC1v9 cctgcctgaatctgttctgc catgaccagaacccgtaaca 
QRT-PCR hsIL-8 agacagcagagcacacaagc atggttccttccggtggt 
QRT-PCR hsPDGFB ctggcatgcaagtgtgagac cgaatggtcacccgagttt 
QRT-PCR hsIGFBP1 aatggattttatcacagcagacag ggtagacgcaccagcagagt 
QRT-PCR hsG0S2 ggaggagaacgctgaggtc tttccatctcggctctgg 
QRT-PCR hsRNF144B cctgacatggtgtgcctaaa cacaggtaccaaacaggcaat 
QRT-PCR hsMYO1D agaaaagtctcgagtgattgtgc ttctgaacctccttggagtagc 
QRT-PCR hsARID5B tggactcaacttcaaagacgttc acgttcgtttcttcctcgtc 
QRT-PCR hsCMPK1 tcaaggatggaacaagacca caagacatcgttcaatacaaatctc 
QRT-PCR hsSNN ctggcctcctgctcagacta tttttagaagaggcttgggtga 
QRT-PCR hsBPNT1 atgctgtgctgcgagtagg gaggctttgccttcaatcag 
QRT-PCR hsPPAP2B gctcatctgcctcgacct tggtgcttgtctcgatgatg 
QRT-PCR hsCOPS2v1 gtgcgatgatgaggaggact cacatttggctcggagttacta 
QRT-PCR hsPDGFRβ catctgcaaaaccaccattg gagacgttgatggatgacacc 
QRT-PCR hsCDH1 tggaggaattcttgctttgc cgctctcctccgaagaaac 
QRT-PCR hsCDH3 agggaggctgaagtgacctt gggcagcccatgaatactt 
QRT-PCR hsICAM6 cactgtgggcgtggaatac tcaacgtgaagtttcctcctg 
QRT-PCR hsNCAM2 gagcctcctcctctccttct ctccaacactaagctctactttgct 
QRT-PCR hsITGA6 tttgaagatgggccttatgaa ccctgagtccaaagaaaaacc 
QRT-PCR hsITGA7 ccctgatagccactacctcct caatgttggtcacaaaaagca 
QRT-PCR hsMMP15  acggtcgttttgtctttttca  gtcagcggctgtgggtag 
QRT-PCR hsITGA2 tcgtgcacagttttgaagatg  tggaacacttcctgttgttacc  
QRT-PCR hsITGA4 gatgaaaatgagcctgaaacg  gccatactattgccagtgttga  
QRT-PCR hsMMP1 gctaacctttgatgctataactacga tttgtgcgcatgtagaatctg 








RNA Sequencing.  Total RNA was isolated as previously described.  Prior to creating Ilumina Tru-Seq 
mRNA libraries, RNA integrity was verified via Agilent Bioanalyzer 2100 analysis in the KUMC 
Genome Sequencing Facility.  Stranded mRNA libraries were completed following kit protocol.  Library 
DNA quality and size was verified using Agilent Bioanalyzer 2100.  Ilumina Tru-Seq 100 cycle Paired-
End (PE) sequencing was completed on an Ilumina Hi-Seq 2500 sequencer.  Read alignment and 
quantification was performed with Qiagen CLC Bio software.  Additional statistical edgeR analysis was 
completed using Qiagen CLC Bio software.  
 
Immunoblotting. Immunoblots were performed using standard procedures as previously described 




Assay Antigen Supplier Product NO. Description Dilution 
Western KDM4B Cell Signaling 8639 Rabbit mAb 1:1,000 
  HIF1α BD 610959 Mouse mAb 1:1,000 
  ARID5B Bethyl A302-235A-M Rabbit pAb 1:1,000 
  EPCAM Thermo MA5-13917 Mouse mAb 1:500 
  β-Actin Sigma A1978 Mouse mAb 1:2,000 









Spheroid Formation Assay. 600 cells were seeded per well of 96-well ultra-low attachment plates 
(Corning Incorporated). After four days, spheroids were imaged by bright field microscopy using a Leica 
DMI 4000 inverted microscope equipped with a Leica CCD camera (Courtesy of Dr. Michael J. Soares, 
KUMC). Volume (V=4/3*πr3) was calculated after measuring the diameter and radius of each spheroid 
using NIH Image J (Vinci, Gowan et al. 2012).  Sixteen spheroids were analyzed per cell line and oxygen 
condition in each independent experiment.  Differences in average spheroid volume were analyzed by 
two-tail paired Student’s t-test.  These results are found in Chapter 2 of this work. 
 
Spheroid Invasion Assay.  Spheroids formed as indicated in the spheroid formation assay were removed 
from their 96-well ultra low attachment plate via pipetting and placed upon polymerized Type I Collagen 
(BD Catalogue Number 354249) in a 48-well culture plates.  Individual spheroid and ECM invasion 
assays were exposed to either 16 hours normoxic (21% O2) or hypoxic (2% O2) treatment for the 
remainder of the study.  1 ml of normal RPMI cell culture maintenance media was added to the top of 
these and replaced every 3 days to prevent evaporation of media from the well.  Spheroid invasion was 
imaged as indicated on an Olympus IX71 inverted microscope.  Measurements were done using NIJ 
ImageJ program and calculated as shown in the diagram in Figure 3.7.  Differences in average invasion 
area were analyzed by two-tail paired Student’s t-test.  Results represent one independent experiment with 
eight technical replicates per cell line and oxygen tension condition. 
 
Angiogenesis Array.   OVCAR8 and SKOV3ip.1 cells containing stable knockdown of KDM4B were 
plated in RPMI + 2% FBS at 1.5 x 105 in a 6-well plate for 24 hour.  These plates were either placed at 
21% or 1% O2 for 16 hours at 37 C in either tri-gas incubators (Fisher) at 21% or Ruskinn InVivo300 
hypoxia chambers (Baker) set to 1% O2 and 5% CO2.  Conditioned media was collected from both 
OVCAR8 and SKOV3ip.1 cell lines and cell debris was pelleted and removed.  The angiogenesis array 




TCGA Data Statistics.  cBIO Genome Portal was used to generate a Kaplan-Meier Disease Free 
Survival Curve for high-grade serous patients with expression of ARID5B (Z score <1) (Cerami, Gao et 
al. 2012; Gao, Aksoy et al. 2013). 
  
 Statistics.  Data represent the mean ± SEM or median ± upper and lower quartiles for at least three 
independent experiments.  Two-tailed Student’s T tests or ANOVA were used as appropriate for in vitro 
experiments.  P values of 0.05 or less were considered statistically significant.  
Study approvals.  The KU Cancer Center’s Biospecimen Repository Core Facility (BRCF) provided de-
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Loss of KDM4B Expression Corresponds with Decreased MUC1 and ARID5B Expression.  In order 
to identify genes regulated by KDM4B in EOC, SKOV3ip.1 and OVCAR8 cells were transiently 
transduced with shRNA targeting KDM4B (shK-1 and shK-2) or GFP (control) in 21% and 0.5% O2.  
(Fig. 3.3).  Genes dependent on KDM4B in either 21% or 0.5% oxygen were identified by CLC Bio 
edgeR statistical analysis (See Methods).  RNA Sequencing identified 73 genes down-regulated in 
SKOV3ip.1 cells and 495 genes in OVCAR8 cells with loss of KDM4B and hypoxia treatment (Fig 3.3B-
Fig 3.3C).  A subset of 14 genes, including KDM4B, was commonly down regulated in both SKOV3ip.1 
and OVCAR8 (Fig 3.3C).  The commonly regulated 14 gene names, descriptions, and basic functions are 
explained in Fig 3.3C.  qPCR validation of these 14 target genes in replicate experiments is also shown in 
Fig 3.4.  These commonly regulated targets are implicated in various cellular processes, including cell 
cycle control and transcriptional regulation (Heckmann, Zhang et al. 2013; Zhang, Ni et al. 2016).  
However, MUC1 provides a connection between KDM4B and tumorigenic invasion.   
RNA Sequencing has identified a possible connection between KDM4B and Mucin 1 (MUC1) 
expression (Fig 3.3C).  MUC1 encodes an O-glycosylated membrane-bound protein, with links to 
increased invasion (Wang, Ma et al. 2007).  MUC1 has also displayed high expression in both primary 
epithelial ovarian cancers and matched metastatic ovarian cancer tissue and patient ascites (Wang, Ma et 
al. 2007; Miyamoto, Ruhaak et al. 2016).  Inhibition of MUC1 decreased cellular adhesion and survival 
on fibronectin in representative EOC models (Yin, Fang et al. 2016).  Regulation of MUC1 by KDM4B 
may facilitate invasion, migration, and attachment-free growth.     
Based on these expression results, a link was identified between KDM4B and ARID5B.  ARID5B, 
provides a potential connection to EOC development and progression.  ARID5B functions as a histone 
demethylase in combination with PHF2 to remove di-methyl marks from H3K9 (Baba, Ohtake et al. 
2011).  Increased ARID5B expression corresponds with decreased survival in high-grade serous patients, 
demonstrating a strong clinical connection for this presumed KDM4B target gene (Cancer Genome Atlas 
Research 2011). Identification of these novel connections between KDM4B, MUC1, and ARID5B 
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provides another clinically relevant mechanism for exploration in epithelial ovarian cancer progression, in 












Figure 3.3.  RNA Sequencing identifies 14 genes commonly down regulated under hypoxia and with 
shKDM4B knockdown in OVCAR8 and SKOV3ip.1 cell lines.  A.  Steps in RNA isolation and library 
preparation processes are explained in this flowchart.  Libraries were prepared for both SKOV3ip.1 and 
OVCAR8 cell lines expressing shRNA targeting KDM4B (shK-2) or GFP (control) in 21% and 0.5% O2 
(n=3).  RNA Sequencing was completed and preliminary gene identification performed using edgeR 
analysis with CLC BIO; FDR P<0.05. B. Venn diagram showing 73 genes are down regulated after 
hypoxic treatment and KDM4B knockdown in SKOV3ip.1 and 495 genes respectively in OVCAR8.  14 
genes, including KDM4B are commonly down regulated in both SKOV3ip.1 and OVCAR8.  Identities 







Figure 3.4.  qPCR validation of 14 genes commonly down regulated under hypoxia and with 
shKDM4B knockdown in SKOV3ip.1 and OVCAR8 cell lines.  A. qPCR validation of 14 commonly 
down regulated target genes; KDM4B, KDM4D, G0S2, MYO1D, ARID5Bv1, BPNT1, RNF144B, SNN, 




KDM4B May Regulate ARID5B Through PDGF Pathway Activation in Epithelial Ovarian Cancer.  
ARID5B-dependent migration is regulated by PDGF signaling, providing a novel link between KDM4B 
and its target gene PDGFB (Chapter 2) (Schmahl, Raymond et al. 2007).  KDM4B was shown to regulate 
PDGFB expression in a demethylase dependent manner in previous studies (Chapter 2).  KDM4B may 
activate expression of PDGFB, providing the appropriate ligand for PDGF Receptor Beta pathway 
activation (Fig 3.5A).  ARID5B may be induced through different downstream signaling cascades 
activated by the PDGF receptor, including the PI3K/AKT pathway and MAPK (Mitogen activated protein 
kinase) pathway (Fig 3.5A).  Relevant pathway components including KDM4B, PDGFB, PDGFRβ, and 
ARID5B showed down regulation of expression with loss of KDM4B in OVCAR8 cells in qPCR analysis 
(Fig 3.5B).  The downstream target, ARID5B was also suppressed in a KDM4B dependent manner in 
OVCAR8 (Fig 3.5C). KDM4B expression dependent down regulation of ARID5B was conserved in 
SKOV3ip.1, a second representative cell line (Fig 3.5D).  ARID5B was expressed in additional cell lines 
representing a range of EOC genotypic backgrounds (Fig 3.5E).  HIO80, a non-transformed ovarian 
epithelial line, also displayed ARID5B expression suggesting a relevant normal cell function for this 
protein (Fig 3.5E).  Increased ARID5B expression correlates with decreased survival in high-grade serous 
patients, demonstrating a strong clinical connection for this presumed KDM4B target gene (Fig 3.6; 
p=0.0017) (Cancer Genome Atlas Research 2011).  This connection between PDGF signaling and 
ARID5B may explain invasive and migratory defects highlighted in loss of KDM4B studies in vitro and 
in vivo described in Chapter 2.  Currently, ARID5B has not been investigated in the context of ovarian 







Figure 3.5.  KDM4B may regulate ARID5B expression through activation of the PDGF pathway.  
A.  Diagram demonstrating the possible connection between KDM4B expression and ARID5B 
expression.  This may occur through demethylation of H3K9, subsequent activation of the PDGF 
pathway, and activation of the PI3K cascade or MAPK/ERK cascade.  B.  Immunoblot measurement of 
ARID5B expression in OVCAR8 cells expressing shRNA targeting KDM4B (shK-1 and shK-2) or GFP 
(control) in 21% and 0.5% O2.  β-actin serves as a loading control.  C.  Immunoblot measurement of 
ARID5B expression in SKOV3ip.1 cells expressing shRNA targeting KDM4B (shK-1 and shK-2) or GFP 
(control) in 21% and 0.5% O2.  α-tubulin serves as a loading control.  D. Immunoblot detection of 
ARID5B in a panel of ovarian cancer cell lines in normoxia (N, 21% oxygen) and in hypoxia (H, 0.5% 
oxygen). HIO-80 cells serve as non-transformed OSE control.  β-actin serves as loading control. E. qPCR 









Figure 3.6. Increased expression of ARID5B corresponds with decreased survival in high-grade 
serous patient tumors.  TCGA analysis of high-grade serous tumors using CBIO showed decreased 


















KDM4B Expression Associates with Differential Secretion of Factors Involved in Tumorigenesis in 
EOC Cell Lines.  Angiogenesis and inflammation are key processes promoting tumor progression and 
invasiveness in EOC (Bast, Hennessy et al. 2009).  Tumor cells communicate with the local 
microenvironment by secreting angiogenic factors to remodel the surrounding microenvironment and 
form new blood vessels (Matei, Kelich et al. 2007).  KDM4B was shown to regulate PDGFB in Chapter 
2, providing evidence that this enzyme plays a role in regulating this physiological process.  In order to 
investigate the role of KDM4B in vascular and lymphatic remodeling, angiogenesis arrays were employed 
to identify key secreted factors in these processes.  Using conditioned media collected from normoxia 
(21% O2) and hypoxia (1% O2) treated SKOV3ip.1 cells transduced with shGFP or shK-2, 11 secreted 
angiogenesis related proteins were identified on a set of angiogenesis arrays (Fig 3.7A and Fig 3.7B).  
KDM4B expression corresponds with secretion level changes for both pro angiogenic, anti angiogenic 
and other inflammatory factors (Fig 3.7A and Fig 3.7B).  Identified pro-angiogenic proteins included: 
SERPINE1 (Serpin Family E Member 1), IGFBP1 (Insulin Growth Factor Binding Protein 1), uPA 
(Urinary-type Plasminogen Activator), ET-1 (Endothelin-1), IL-8 (Interleukin 8), and VEGF (Vascular 
Endothelial Growth Factor) (Fig 3.7A and Fig 3.7B).  Identified anti-angiogenic secreted factors included: 
TIMP1 (Tissue Inhibitor of Metalloproteinase-1), TSP1 (Thrombospondin 1), IGFBP3 (Insulin Growth 
Factor Binding Protein 3), Activin A, and COL18A1 (Endostatin) (Fig 3.7A and Fig 3.7B).  Secretion of 
both pro-angiogenic and anti-angiogenic factors was observed; however, results did not identify a 
relationship between KDM4B expression and a distinct angiogenic or inflammatory phenotype in 
SKOV3ip.1. 
 To verify if secreted factors were conserved between EOC cell lines, this set of experiments was 
replicated in a second model line, OVCAR8.  Using conditioned media collected from normoxia (21% 
O2) and hypoxia (1% O2) treated OVCAR8 cells, 14 secreted angiogenesis related proteins were identified 
(Fig 3.8A and Fig 3.8B).  Consistent with SKOV3ip.1, OVCAR8 cells displayed secretion level changes 
for both pro and anti angiogenic factors in a KDM4B-dependent manner (Fig 3.8A and Fig 3.8B).  
Among those identified were 8 proteins that overlapped between cell lines.  Identified pro-angiogenic 
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proteins also secreted by SKOV3ip.1 included: SERPINE1, IGFBP1, uPA, ET-1, EG-VEGF (Fig 3.8A 
and Fig 3.8B).  In addition to these, ANGTP2 (Angiopoetin-2), ARTM (Artemin), CD142 (Coagulation 
Factor III), and PDGF-AA were also identified (Fig 3.8A and Fig 3.8B).  Identified overlapping anti-
angiogenic secreted factors between SKOV3ip.1 and OVCAR8 included: TIMP1, TSP1, IGFBP3, and 
Activin A (Fig 3.8A and Fig 3.8B).  Additionally, OVCAR8 cells secreted PTX3 (Pentraxin 3) and TSP2 
(Thrombospondin 2) (Fig 3.8A and Fig 3.8B).  KDM4B expression does not correspond with a specific 
type of angiogenic or inflammatory profile in OVCAR8 cell lines.  However, the array results identify 
novel changes in many tumorigenic secreted factors including PDGF-AA and IGFBP1.  Relevant protein 
secretions may be regulated by KDM4B via an upstream target or be indicative of a transcriptional 






Figure 3.7.  Loss of KDM4B influences differential secretion of factors in the epithelial ovarian 
cancer line SKOV3ip.1.  A.  Conditioned media from SKOV3ip.1 cells expressing shRNA targeting 
KDM4B (shK-2) or GFP (control) in 21% and 1% O2 showed differential expression of pro-angiogenic 
and anti-angiogenic factors on angiogenesis array blots (R and D) (n=1).  Layout from top to bottom is as 
follows: 21% O2 SKOV3ip.1-shGFP array, 21% O2 SKOV3ip.1-shK-2 array, 1% O2 SKOV3ip.1-shGFP 
array, and 1% O2 SKOV3ip.1-shK-2 array.  Differentially expressed proteins are labeled in the top array 
for reference.  RS refers to built-in reference spots.  B.  Quantitation of protein expression changes is 







Figure 3.8.  Loss of KDM4B influences differential secretion of pro-angiogenic and anti-angiogenic 
factors in the epithelial ovarian cancer line OVCAR8.  A.  Conditioned media from OVCAR8 cells 
expressing shRNA targeting KDM4B (shK-2) or GFP (control) in 21% and 1% O2 showed differential 
expression of pro-angiogenic and anti-angiogenic factors on angiogenesis array blots (R and D) (n=1).  
Layout from top to bottom is as follows: 21% O2 OVCAR8-shGFP array, 21% O2 OVCAR8-shK-2 array, 
1% O2 OVCAR8-shGFP array, and 1% O2 OVCAR8-shK-2 array.  Differentially expressed proteins are 
labeled in the top array for reference.  RS refers to built-in reference spots.  B.  Quantitation of protein 
expression changes are shown (n=1).  Expression has been normalized to reference spots on arrays. 
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Loss of KDM4B Expression Corresponds to Expression Changes in IL-8 and IGFBP-1. IL-8 and 
IGFBP-1 have established connections to epithelial ovarian cancer progression (Dal Maso, Augustin et al. 
2004; Baxter 2014; Stronach, Cunnea et al. 2015).  Secretion of these factors was identified using 
angiogenesis arrays (Fig 3.7 and Fig 3.8).  SKOV3ip.1 showed decrease of IL-8 and IGFBP-1 secretion 
with loss of KDM4B (Fig 3.7A and Fig 3.8B).  These changes corresponded to increased IL-8 and no 
significant changes in IGFBP-1 expression in SKOV3ip.1 cells (Fig 3.9A).  Even though IGFBP-1 and 
IL-8 showed no notable changes upon OVCAR8 angiogenesis array analysis, IL-8 increased while 
IGFBP-1 expression decreased (Fig 3.9B).  Considering the importance of angiogenesis and secreted 
factors in EOC metastasis, continued expression analysis of array targets will help establish functional 







Figure 3.9. IL-8 and IGFBP-1 show differential regulation in the context of KDM4B expression 
between SKOV3ip.1 and OVCAR8 cell lines.  A.  qPCR validation of IL-8 and IGFBP-1 expression in 
SKOV3ip.1 with shRNA targeting KDM4B (shK-1 and shK-2) or GFP (control) in 21% and 0.5% O2 
(n=3) (p<0.05).  B.  qPCR validation of IL-8 and IGFBP-1 expression in OVCAR8 with shRNA targeting 







































Expression of KDM4B Increases Spheroid Invasion in vitro.  Dissemination and metastasis of ovarian 
tumors involves the formation, invasion, and adhesion of cancer cell clusters called spheroids (Puiffe, Le 
Page et al. 2007).  In patients, spheroids detach from the primary tumor and attach and invade at distant 
areas within the peritoneal cavity (Davidowitz, Selfors et al. 2014).  Previous studies have shown 
KDM4B expression increases spheroid formation and maintenance in vitro and peritoneal dissemination 
in vivo (Chapter 2).  Boyden chamber invasion through Matrigel and migration assays connect KDM4B 
to increased invasion (Chapter 2).  These findings suggest increased KDM4B expression could drive 
spheroid invasion.  In order to test this hypothesis, a novel 3D spheroid invasion assay was utilized.  
OVCAR8 spheroids were formed as indicated in previous studies (Chapter 2) and placed upon a 
polymerized ECM component, Type I collagen (Fig 3.10A and Fig 3.10B).  Images were taken 7 and 14 
days post spheroid addition to quantify invasive spheroid potential (Fig 3.10A).  In order to quantify 
invasion distance, basic measurements were taken using ImageJ as indicated (Fig 3.10C).  A central 
spheroid area and area of invasion were measured for all spheroid replicates in each condition at day 10 
and day 17 as indicated (Fig 3.10A and Fig 3.10C).  Representative images of OVCAR8 spheroid 
invasion assays from day 10 of this assay are shown (Fig 3.11A).  OVCAR8 spheroids with loss of 
KDM4B show decreased invasion on this substrate at both 21% O2 and 2% O2 (Fig 3.11A).  OVCAR8-
shGFP control spheroids display increased disaggregation or budding from the main spheroid area (Fig 
3.11A).  The budding phenotype is not present in knockdown spheroids (Fig 3.11A).  Invasion area 
quantification for 7 days of Type I Collagen invasion is included (Fig 3.11B).  Even though these findings 
are not significant, they show a decreased quantification of invasion area (Fig 3.11B).  In addition to 
MUC1, ARID5B, and MYO1D (Fig 3.4), additional target gene expression involved with invasion, 
migration, and epithelial-to-mesenchymal transitions were validated (Fig 3.11C).  CDH1 (E-cadherin), 
CDH3 (P-cadherin), ICAM6 (Intracellular Adhesion Molecule 6), NCAM2 (Neural Cell Adhesion 
Molecule 2), ITGA6 (Integrin Subunit Alpha 6), ITGA7 (Integrin Subunit Alpha 7), MMP15 (Matrix 
Metalloprotease 15), ITGA2 (Integrin Subunit Alpha 2), ITGA4 (Integrin Subunit Alpha 4), and MMP1 
(Matrix Metalloprotease 1) show KDM4B dependent decreases in expression in OVCAR8 (Fig 3.11C).  
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These target genes may be regulated downstream of KDM4B and influence spheroid invasion and 





Figure 3.10.  Development of 3-D spheroid invasion model for epithelial ovarian cancer.  A.  
Timeline describes the process for spheroid invasion experiment.  Spheroids were formed and the 
invasion assay set up as described in Materials and Methods and placed upon polymerized Type I 
Collagen.  Images were taken after 7 and 10 days.  B.  Diagram shows representation of spheroid in 
relation to the polymerized Type I Collagen.  C.  Invasion distance was calculated as shown in the figure.  








Figure 3.11.  KDM4B expression increased invasion of OVCAR8 spheroids on Type I Collagen in 
vitro and differential gene expression of putative target genes involved with invasion and epithelial 
to mesenchymal transition.  A.  Images are from representative replicates from the invasion assay at the 
normoxic (21% O2) and hypoxic treatment (1% O2) following 7 days of specified oxygen tension 
treatment.  (N=1; n=8)   B.  Quantification of OVCAR8 spheroid invasion area from experiment imaged 
in A is shown here.  Error bars indicate standard deviation within technical replicates.  C.  qPCR 
validation of putative target genes with connections to regulation of invasion and EMT, including: 
KDM4B, CDH1, CDH3, ICAM5, NCAM2, ITGA6, ITGA7, MMP15, ITGA2, ITGA4, and MMP1.  
Expression analysis from OVCAR8 cells with shRNA targeting KDM4B (shK-1 and shK-2) or GFP 




KDM4B Expression is Present in Patient Ascites Cells.  In order to establish the clinical relevance of 
KDM4B in spheroid invasion and migration, patient ascites expression was explored.  Patient ascites 
contains spheroids and other relevant factors secreted in the peritoneal fluid during metastasis (Puiffe, Le 
Page et al. 2007).  Ascites cells were obtained from frozen stock cultures and maintained in ultra-low 
attachment cell culture dishes.  Representative images of 4 separate patient samples are shown (Fig 
3.12A-Fig 3.12B).  Even though these were obtained from patients in different stages, there is no 
significant difference in appearance in culture conditions.  KDM4B expression was present in various 
levels, not dependent on oxygen tension (Fig 3.12C).  Loading control expression may very between 
epithelial ovarian cancer cell lines.  This validated including both β-catenin and α-tubulin expression (Fig 
3.12C).  Since ascites contains a heterogeneous mix of cell types, EPCAM (Epithelial Cell Adhesion 
Molecule) was included to confirm the presence of epithelial cells (Fig 3.12C).  The distinctive variation 
in expression of all proteins between the 4 patient lines may indicate a viability issue at protein lysis.  
However, the presence of KDM4B in patient ascites cells may identify a novel role for this protein in 






Figure 3.12.  KDM4B is expressed in patient ascites maintained in ultra-low attachment conditions 
in vitro.  A and B.  Images of patient ascites maintained in ultra-low attachment cell culture plates are 
shown.  De-identified patient codes are used to label ascites cell lines and FIGO staging for cell line is 
included.  C.  Immunoblot measurement of KDM4B expression in patient ascites lines maintained in 
ultra-low attachment cell culture at normoxic (N) condition or 21% O2 and hypoxic (H) condition or 0.5% 
O2.  α-tubulin and β-actin serve as loading controls.  EPCAM is included as a marker to identify tumor 







 Identifying the role of KDM4B in processes driving peritoneal dissemination and metastasis may 
provide novel therapeutic targets for consideration in EOC.  Our previous experiments in Chapter 2 
demonstrate a correlation between KDM4B expression and increased invasion, migration, and spheroid 
formation in vitro and in vivo.   These findings suggest KDM4B influences vascular remodeling via 
differential secretion of factors and could affect inflammatory responses in the tumor microenvironment.  
The spheroid invasion assays also identifies a connection between KDM4B expression and EOC spheroid 
invasion, a detrimental component of advanced EOC progression (Chapter 3).  RNA Sequencing 
identified a putative link between KDM4B, the KDM4B target gene PDGFB, and ARID5B expression.  
These proteins are established contributors to aspects driving metastasis including angiogenesis, 
inflammatory response, invasion, and cell motility and may impact the observations in these functional 
assays (Dong, Grunstein et al. 2004; Baba, Ohtake et al. 2011; Hata, Takashima et al. 2013; Emerenciano, 
Barbosa et al. 2014).  Identifying how KDM4B regulates these aspects of tumorigenesis will explain 
another connection between this histone demethylase and EOC progression. 
RNA Sequencing analysis between two representative cell models identified 14 commonly 
regulated target genes, including MUC1.  This putative target gene provides compelling rationale for 
continued investigation and dissection in KDM4B-dependent EOC experimentation.  MUC1 encodes an 
O-glycosylated membrane-bound protein that plays an essential role in forming protective mucous 
barriers on epithelial surfaces and lines mucosal surfaces of many different tissues (Budiu, Elishaev et al. 
2013).  Putative target genes, such as PDGFB, do not regulate MUC1 but previous studies indicate the 
utility in exploring the potential relationship between KDM4B and MUC1 in tumorigenic function.  A 
previous EOC tumor microarray study by Wang, et al. identified high MUC1 expression in both primary 
epithelial ovarian cancers and in matched metastatic ovarian cancer tissue (> 90%), with MUC1 
cytoplasmic expression correlating with poor overall survival and invasive capacity (P<0.05) (Wang, Ma 
et al. 2007).  During tumor progression, MUC1 can become overexpressed and differentially glycosylate 
highlighting a role for MUC1 expression as a tumor associated antigen (Chauhan, Vannatta et al. 2009).  
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The extracellular domain of MUC1 may be cleaved and found in patient serum, suggesting its use as a 
prognostic biomarker (Engelstaedter, Heublein et al. 2012).  These possible established links between 
MUC1 and EOC progression may implicate KDM4B in regulating invasion, migration, and attachment-
free growth.  However, MUC1 is a complex protein.  Currently, there are 78 identified isoforms and 
numerous protein modifications possible on MUC1, potentially complicating the ability to effectively 
manipulate this gene in vitro and in vivo (Zhang, Vlad et al. 2013).  ARID5B not only provides a potential 
link to the KDM4B target gene PDGFB, but a less complex target for mechanistic dissection.       
The potential connection between KDM4B-dependent PDGFB expression and ARID5B provide 
provocative reasons to investigate their mechanistic relationship in regulating invasion and migration.  
ARID5B functions as a histone demethylase in combination with PHF2 to remove di-methyl marks from 
H3K9 (Baba, Ohtake et al. 2011).  The PDGF pathway may also activate ARID5B expression (Schmahl, 
Raymond et al. 2007).  Increased ARID5B expression correlates with decreased survival in high-grade 
serous patients, demonstrating a strong clinical connection for this presumed KDM4B target gene (Cancer 
Genome Atlas Research 2011).  Mutations in ARID5B have been implicated in endometrial cancer and 
ALL, acute lymphoblastic leukemia (Cancer Genome Atlas Research, Kandoth et al. 2013; Emerenciano, 
Barbosa et al. 2014).  Loss of ARID5B also decreases lipid metabolism, providing a potential link to 
ovarian cancer preferential omental targeting (Baba, Ohtake et al. 2011; Nieman, Kenny et al. 2011). 
Investigating the connection between KDM4B and ARID5B may provide another interesting link 
between KDM4B, another epigenetic modulator, and EOC progression.   
 In order to establish the tumorigenic functional role of the putative KDM4B target ARID5B, 
in vitro analysis to investigate proliferation, invasion, and migration and in vivo xenograft models would 
be pragmatic approaches.  To demonstrate the effect of the loss of ARID5B on proliferation, a standard 
counting assay to estimate rate of proliferation could be performed. SKOV3ip.1 and OVCAR8 cells 
expressing shRNA to ARID5B or a GFP control would be seeded and treated with separate O2 
concentrations, 21% and 0.5% O2.  2D scratch-wound assays would estimate the role of ARID5B in 
migration. Cells will be manipulated as indicated for the proliferation assay and seeded in scratch-would 
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assays at both 21% and 0.5% O2.  To estimate cell motility rate, imaging of the scratch would be 
performed every 4 hours until wound closure.  NIH ImageJ measurements of the wound could be used to 
calculate rate of motility using the formula Rate=Distance/Time (R=D/T).  In addition to 2D motility, 
defects on invasion and migration could be characterized using shRNA cell lines in 3D transwell Boyden 
Chamber Matrigel Assays at either 21% O2 or 0.5% O2.  The ability of cells to invade through a Matrigel 
barrier could be estimated using CyQUANT® blue and correlated to the expression level of ARID5B and 
respective oxygen concentration. The in vitro contribution of ARID5B could be established using 
intraperitoneal xenograft models in nude mice using SKOV3ip.1 cells transduced with GFP or shARID5B 
constructs. Cells can be transduced with pLenti PGK V5-Luciferase Neo to allow for weekly 
bioluminescence imaging using the IVIS Spectrum in vivo imaging system.  Post mortem analysis would 
determine: 1) overall tumor mass, 2) tumor nodule localization, and 3) ascites formation.  Representative 
tumors will be harvested from each subject for RNA and protein analysis to verify ARID5B and KDM4B 
expression.  To dissect the possible PDGFB dependent activation of ARID5B and invasion, the proposed 
2D scratch and 3D transwell Boyden Chamber Assays could be completed using OVCAR8 and 
SKOV3ip.1 cell lines treated with PDGFB ligand.  The findings from these proposed experiments would 
establish the functional and mechanistic roles of ARID5B in EOC tumorigenesis and establish a potential 
connection to PDGF pathway, a definite knowledge gap in this field.    
The secreted proteome analyzed via the antibody arrays suggest KDM4B plays a role in secreting 
a myriad of factors involved with angiogenesis and inflammatory responses.  KDM4B regulates secretion 
and expression of multiple factors, including IL-8 and IGFBP1 (Fig 3.7-3.9).  IL-8 is a proinflammatory 
cytokine that promotes angiogenic and other tumorigenic effects (Stronach, Cunnea et al. 2015).  IL-8 in 
EOC tumors corresponds with poor prognosis and advanced FIGO staging (Merritt, Lin et al. 2008).  
Overexpression of IL-8 in EOC has been shown to increase attachment-free growth, invasion, and 
vascular remodeling (Wang, Xu et al. 2012).  IL-8 could provide a KDM4B target responsible for 
remodeling the tumor microenvironment in metastatic processes.   
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IGFBP1 was also identified as a differentially secreted protein in antibody array profiling (Fig 
3.7-3.9).  IGFBP1 is a protein secreted by the liver during inflammation to regulate IGF1(Rutkute and 
Nikolova-Karakashian 2007).  IGFBP1 also has been shown to promote a pro angiogenic effect in tumor 
cell models (Rutkute and Nikolova-Karakashian 2007).  IGFBP1 is a mitogen that has a demonstrated 
role in increasing cell proliferation and suppressing apoptosis (Terry, Tworoger et al. 2009).  IGFBP1 has 
also been linked to increased ovarian cancer cell proliferation and invasion in vitro, suggesting a key role 
for this protein in these processes (Resnicoff, Ambrose et al. 1993).  This connection between IGFBP1 
and ovarian cancer tumorigenesis may indicate another tumorigenic pathway influenced by KDM4B 
activity. 
Antibody array analysis used in these studies does not identify a particular KDM4B-dependent 
relationship between pro-angiogenic or anti-angiogenic factors.  Secretion of different pro-angiogenic and 
anti-angiogenic factors varies between the cell lines used in proteome analysis (Fig. 3.7-3.9).  Without 
further experimentation, these results can only suggest that loss of KDM4B effects protein secretion 
differently between cell lines.  These unclear and complicated findings demonstrate the complexity of 
mechanisms regulating EOC angiogenesis.  To further establish the role of KDM4B in angiogenesis, 
HUVEC (Human Umbilical Vein Endothelial Cell) in vitro assays using EOC cell lines containing an 
shRNA to KDM4B or a GFP control could be completed.  This assay could pinpoint if KDM4B-
dependent secretion of angiogenesis factors had a more pro-angiogenic or anti-angiogenic effect.  
Although chemotherapeutics targeting angiogenic factors show limited efficacy in EOC treatment, these 
types of experiments would identify additional tumorigenic pathways influenced by KDM4B expression 
(Della Pepa and Banerjee 2014; Li, Zhou et al. 2015; Petrillo, Nero et al. 2016).    
Loss of KDM4B expression associated with decreased spheroid invasion (Fig 3.8-3.9).  Spheroid 
formation and migration are indispensible factors driving the EOC metastatic cascade.  The contribution 
of KDM4B in spheroid invasion assays matched earlier observations implicating KDM4B in increased 
invasion and migration in Boyden chamber assays (Chapter 2).  In order to dissect how KDM4B 
influences spheroid invasion, this assay should be repeated using other components of the extracellular 
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matrix.  Ovarian cancer cells can attach and spread on multiple ECM components, including: Type I 
Collagen, Type IV Collagen, Laminin, Vitronectin, and Fibronectin (Davidowitz, Selfors et al. 2014).  
Ovarian cancer cell lines also adhere and spread on mesothelial cells lining the peritoneal cavity. 
Complimenting additional ECM spheroid invasion assays with Mesothelial Clearance Assays would 
provide powerful insight into how KDM4B regulates the embedding and reattachments of invasive 
spheroids (Davidowitz, Selfors et al. 2014).  At this time, the cellular mechanisms regulating mesothelial 
cell displacement by EOC spheroids are not well defined in previous research.  KDM4B expression is 
associated with changes in numerous genes that regulate invasion, migration, and the epithelial to 
mesenchymal transition, including ITGA6, IL-8, IGFBP1, and CDH1 (Fig. 3.11).  Further dissection 
using shRNA stable knockdown of these genes individually in spheroid invasion assays would identify 
their contribution to this spheroid property.  Spheroid invasion assays should be completed using different 
extra cellular matrix components to identify their exact functional contribution to cellular movement.  
ChIP analysis of KDM4B binding would identify if these putative target genes are regulated directly or 
indirectly by this protein. Further investigation into this area may provide important insight into the 
KDM4B regulated mechanisms association with these cellular movement processes. 
Presentation of ascites in advanced stages of EOC is a common finding at patient diagnoses (Cho 
and Shih Ie 2009).  Ascites formation relies upon increased migratory and invasive potentials of spheroids 
(Davidowitz, Selfors et al. 2014).  Utilizing ascites for experimentation is novel and highly relevant to 
EOC progression.  KDM4B was differentially expressed in patient ascites cell lysates (Fig 3.10).  
However, ascites contains a myriad of cell types both neoplastic and normal from the surrounding tumor 
microenvironment (Smolle, Taucher et al. 2014).  Further studies should be completed to appropriately 
sort cell types before immunoblotting or qPCR analysis.  Follow-up assays using patient derived ascites 
cell lines would demonstrate the relevance of KDM4B activity in a representative ex vivo model.  
This study demonstrates that the hypoxia-inducible histone demethylase KDM4B supports 
cellular adaptations influencing factors of the metastatic cascade, including invasion, migration, 
angiogenesis, and inflammation.  Each aspect of metastasis drives disease pathogenesis and patient 
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mortality.  The novel connection between KDM4B expression and the PDGF pathway may influence 
mechanistic or transcriptional regulation of these phenotypes.  Future studies based on these observations 
would provide more extensive analysis into how KDM4B enzymatically regulates these pathways.  














































Importance of this Project 
Characterizing the roles of KDM4B in EOC provides novel epigenetic links between the hypoxic 
tumor microenvironment and histone methylation.  Epigenetics and genetic aberrations work 
simultaneously in promoting tumorigenesis (Lund and van Lohuizen 2004).  Delineating epigenetic and 
genetic changes establishes how they separately and synergistically drive tumorigenesis in EOC.  This 
body of work is novel because it includes the first studies to investigate the role of KDM4B in EOC.  
Although not every aspect of KDM4B activity was explored, the data in this project connects KDM4B 
expression to aspects of the metastatic cascade, including: invasion, migration, and attachment-free 
growth in vitro (Chapter 2 and 3) (Naora and Montell 2005).  In addition to in vitro observations, 
KDM4B expression corresponded to increased peritoneal dissemination and tumorigenesis in 
intraperitoneal xenograft models (Chapter 2).  Identifying the functions regulated by KDM4B activity in 
EOC increases the understanding of the enzyme’s activity and clarifies cell processes it may regulate.  
These observations establish KDM4B as an essential component influencing EOC progression, 
warranting further consideration and exploration by the field.  At this time, no conserved KDM4B 
mechanisms and functions have been identified that are consistent between cell type and model system.  
Lack of a conserved mechanism dictates the necessity for continued KDM4B analysis.  
Not only is KDM4B induced by HIF-1α, this project suggests another possible transcriptional 
link between HIF-1α and KDM4B activity (Beyer, Kristensen et al. 2008).  These studies demonstrated 
possible interplay between KDM4B and HIF-1α activity.  Commonly regulated targets, including PDGFB 
and LOXL2 were identified in expression and ChIP analysis in SKOV3ip.1 and OVCAR8 (Chapter 2 and 
3).  This type of connection between KDM4B and HIF-1α has not been explored in the literature.  HIF-1α 
recruits KDM3A to specific target genes, including ADM and SERPINE1 (Krieg, Rankin et al. 2010; 
Perez-Perri, Acevedo et al. 2011).  Considering the overlap between KDM4B and HIF-1α targets, it is 
possible this type of recruitment mechanism influences gene expression regulation in KDM4B EOC 
studies.  This mechanism could only be established with further experimentation.     
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KDM4B expression is increased in EOC patient tumors and influences progression, presenting 
itself as a unique and novel target for therapeutic consideration and design (Chapter 2 and 3).  Innovative 
therapeutic design will assist in combatting recurrent tumor formation and the late diagnoses plaguing 
effective EOC treatments (Giornelli 2016).  Genomic expression and epigenetic abnormalities alter the 
background of each ovarian cancer cell and complicate the efficacy of standard therapies (Cho and Shih 
Ie 2009).  .  These contributing factors have slowed progress in improving therapeutics and increased 
tumor relapse in EOC (Mei, Chen et al. 2013).  Ingenuity Pathway Analysis (IPA) identified KDM4B-
dependent regulation of cell processes involved in EOC tumorigenesis, including cell death, cell 
movement, and DNA repair (Chapter 2).  KDM4B dependent regulation of tumorigenic genes, including 
PDGFB, LCN2, and LOXL2 was demonstrated using EOC models (Chapter 2 and 3).  Targeting the 
enzymatic activity of KDM4B could provide genomic regulation of specific tumorigenic genes and cell 
processes regulating EOC.  Positive outcomes from targeting KDM4B may establish KDM4B inhibition 
as a useful and progressive therapeutic option for treating other types of solid tumor cancers. 
KDM4B expression may also be utilized as a novel EOC biomarker.  At this time, biomarkers 
such as CA-125 are inconsistent and unreliable for adequate and early EOC diagnoses (Ueda, Enomoto et 
al. 2010).  CA-125 expression varies between EOC stages and fluctuates during periods of tumor 
recurrence (Jacobs and Bast 1989).  The unreliability of CA-125 justifies the exploration of using new 
biomarkers.  KDM4B Tumor Microarray Analysis identified increased expression in primary, metastatic, 
and recurrent patient tumors (Chapter 2).  KDM4B could also be used as an indicator of drug response.  
Given the relationship between KDM4B and PARP, PARP inhibitors like Niraparib may useful in EOC 
patients expressing KDM4B (Khoury-Haddad, Guttmann-Raviv et al. 2014; Hwang, Heo et al. 2015).  
Further pathological analysis of KDM4B expression in EOC could justify its utility as an EOC biomarker, 
prognostic indicator, or indicator of therapeutic efficacy. 
 
KDM4B in Cancer 
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 KDM4B expression has increased expression and established functional links to progression in 
numerous solid tumor cancers, including prostate, renal cell, breast, and gastric cancer (Kawazu, Saso et 
al. 2011; Coffey, Rogerson et al. 2013; Young, McDonald et al. 2013; Zhao, Li et al. 2013).  In different 
cancer models, KDM4B expression has been linked to several aspects of tumorigenesis in vitro and in 
vivo including epithelial-to-mesenchymal transition, cell proliferation, apoptosis, DNA damage response, 
colony formation, cell survival, and metastasis (Kawazu, Saso et al. 2011; Tsai and Wu 2012; Young, 
McDonald et al. 2013; Berry, Kim et al. 2014; Hui, Yiling et al. 2015; Li, Wu et al. 2015).  KDM4B 
activity has previously established connections to invasion, migration, and attachment-free growth in vitro 
and metastases in vivo (Kawazu, Saso et al. 2011; Li, Wu et al. 2015; Qiu, Fan et al. 2015).  However, 
this body of work was the first to connect KDM4B expression on invasion, migration, and attachment-
free growth in vitro using an EOC models. 
 Regulation of KDM4B expression and activity are important factors to consider while 
investigating KDM4B in cancer models.  These control mechanisms are continuously being established in 
the literature.  KDM4B may be regulated by a number of mechanisms in tumor models including, 
transcription factors, nuclear hormone receptors, tumor suppressors, or ubiquitin-dependent degradation 
(Palomera-Sanchez, Bucio-Mendez et al. 2010; Li, Zhao et al. 2011; Tsai and Wu 2012; Coffey, 
Rogerson et al. 2013; Ipenberg, Guttmann-Raviv et al. 2013; Zheng, Chen et al. 2014).  KDM4B may be 
transcriptionally regulated by HIF-1α, β-catenin, and p53 (Beyer, Kristensen et al. 2008; Berry, Kim et al. 
2014; Zheng, Chen et al. 2014).  Nuclear hormone receptors such as Androgen Receptor (AR), 
Progesterone Receptor (PR), and Estrogen Receptor (ER) also influence expression of KDM4B (Yang, 
Jubb et al. 2010; Coffey, Rogerson et al. 2013).  KDM4B can also be regulated by ubiquitination in 
response to DNA damage by RNF8 and RNF168 (Mallette, Mattiroli et al. 2012).  Potential control 
mechanisms such as these are important to consider in future KDM4B studies.  They could be directly 
regulating KDM4B or other targets, driving additional effects in different model systems.  The 
significance of their role in disease pathogenesis will depend upon the model type and genetic 
background. 
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 KDM4B regulates expression of many relevant cancer related targets across different tumor 
models, including MYB, C-MYC, and CCND1 (Kawazu, Saso et al. 2011; Qiu, Fan et al. 2015).  Proteins 
complexed with KDM4B, such as other transcription factors and nuclear hormone receptors help dictate 
and regulate these genetic changes.  For instance, in gastric cancer models KDM4B binds the 
transcription activator β-catenin to induce expression of JUN, MYC, and CCND1 (Zhao, Li et al. 2013).  
KDM4B activity has been connected to expression and activity of histone lysine methyltransferases.  
KDM4B works in concert with the methyltransferase MLL2 to regulate expression of ER+ target genes in 
breast cancer models, including TFF1 (Trefoil Factor 1) and EBAG9 (Estrogen Receptor Binding Site 
Associated, Antigen, 9) (Shi, Sun et al. 2011).  Additional breast cancer studies have demonstrated 
KDM4B binds with ER and the SWI/SNF-B chromatin-remodeling complex to facilitate expression of 
MYC and MYB (Kawazu, Saso et al. 2011).  Targets may be regulated through different mechanisms by 
the activity of KDM4B with different proteins.   
The mechanisms driving KDM4B gene activation are not clearly characterized or conserved 
between cancer models.  Some studies have shown KDM4B drives gene expression in a demethylation-
dependent manner while others have not demonstrated this relationship (Kawazu, Saso et al. 2011; 
Coffey, Rogerson et al. 2013; Berry, Kim et al. 2014).  This does not indicate genes in those studies were 
not expressed in a demethylation dependent manner.  It is likely genomic variability influences KDM4B 
binding sites.  Other proteins complexed with KDM4B may also dictate genomic targeting.  KDM4B 
activity has also been linked to a variety of transcription factors, including HIF-1α and β-catenin (Berry 
and Janknecht 2013).  Even though these are two demonstrated binding partners of KDM4B, it is likely 
other transcription factors or epigenetic remodelers could associate with KDM4B to influence activity and 
gene expression changes.  These could include NF-kappa B (NF-kB) or STAT proteins, often implicated 
in the progression of tumorigenesis (Ling and Kumar 2012).  KDM4B has also been shown to bind with 
the chromatin remodeling complex SWI/SNF-B to transition heterochromatic regions to a more 
euchromatic state, allowing accessibility to transcription factors to drive gene expression (Kawazu, Saso 
et al. 2011).  A connection has been established between the methyltransferase MLL2 and KDM4B in 
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ER+ breast cancer models that effect chromatin compaction and subsequent gene expression (Kawazu, 
Saso et al. 2011).  Combined, these mechanisms indicate the versatile nature of KDM4B in regulating 
tumorigenic gene expression in cancer models.   
 
Relevance 
KDM4B in Epithelial Ovarian Cancer 
Demonstrating the role of KDM4B in ovarian cancer established a novel epigenetic link between 
the hypoxic tumor microenvironment and ovarian cancer progression.  Epigenetic activity in ovarian 
cancer tumorigenesis remains an understudied aspect of EOC research (Marsh, Shah et al. 2014).  Few 
studies have addressed identification of histone demethylase activity in gynecological cancers, let alone 
characterizing contributions from jumonji-domain containing proteins (Qiu, Fan et al. 2015; Wang, Mao 
et al. 2015).  Hypoxia and HIF-1α activity are established contributors influencing tumor pathology and 
ovarian cancer progression (Osada, Horiuchi et al. 2007).  However, little explanation for all HIF-1α 
regulated genetic and epigenetic changes within ovarian cancer tumor cells have been delineated.   
KDM4B has well-established links to progression in many tumor models in the literature, except 
EOC.  These sets of studies are highly unique, identifying the first connections between KDM4B 
expression and EOC tumorigenesis and peritoneal dissemination (Chapter 2 and 3) (Berry and Janknecht 
2013).  This project was the first to demonstrate the presence of KDM4B in epithelial ovarian cancer and 
pursue the purpose for its expression.  The relevance of KDM4B was evident in patient samples and 
translated to significant effects in functional assays and expression analysis (Chapter 2 and 3).  KDM4B 
expression was increased in primary, metastatic, and recurrent tumor sections (Chapter 2).  KDM4B 
expression and activity was linked to tumorigenic gene expression and pathway changes, increased 
invasion, migration, attachment-free growth, and secreted factors in vitro (Chapter 2 and 3).  The degree 
of KDM4B-dependent peritoneal dissemination was also increased using in vitro intraperitoneal xenograft 
models (Chapter 2).  The data shows KDM4B is an essential enzyme for EOC progression and worthy of 
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consideration between other cancer models.  Not every mechanistic question could be addressed in this 
body of work, leaving many areas for pursuit. 
This body of work identified novel connections between KDM4B expression and invasion and 
migration in vitro and peritoneal dissemination in vivo (Chapter 2 and 3).  The influence of KDM4B in 
regulating invasion and migration was shown using single cell Boyden chamber assays and multicellular 
spheroids (Chapter 2 and 3).  These observations suggest KDM4B plays a conserved role in regulating 
SKOV3ip.1 and OVCAR8 single-cell and multi-cell motility, both problematic contributors to EOC 
progression and dissemination (Cho and Shih Ie 2009).  Invasion and migration studies were conducted 
using matrigel, which contains multiple components of ECM, and Type 1 Collagen individually (Chapter 
2 and 3).  With this in mind, it is likely KDM4B regulates expression of cell adhesion factors or proteases 
responsible for invasion and migration through these types of substrates.  MUC1, LCN2, and LOXL2 were 
identified as possible contributors in these studies (Chapter 2 and 3).   
MUC1 was identified through RNA Sequencing as a putative KDM4B target gene and may 
influence the results in invasion and migration experimentation (Chapter 3).  MUC1 expression is linked 
to poor prognosis and highly metastatic EOC (Dong, Walsh et al. 1997; Horm and Schroeder 2013).  
Invasion through Matrigel is also increased by expression of this glycoprotein (Horn, Gaziel et al. 2009).  
Blocking MUC1 with the antibody C595 decreased tumor invasion and dissemination in EOC xenograft 
models (Wang, Chen et al. 2011).  This possible connection between KDM4B and MUC1 may explain 
one aspect of how KDM4B regulates attachment-free growth, invasion, and migration.   
LCN2, which processes MMP9 (Matrix Metallopeptidase 9), was also identified as a putative 
target gene regulated in these studies that influences tumor cell adhesion and invasion (Koh and Lee 
2015).  MMP9 has been established as a regulator of invasion and metastasis in ovarian cancer models 
(Kwon, Lee et al. 2014).  LCN2 was shown to be upregulated in EOC tumors and correlated with tumor 
differentiation (Cho and Kim 2009).  Targeting LCN2 has shown decreased angiogenesis and metastasis 
in breast cancer models, demonstrating its possible utility as an EOC target (Guo, Yang et al. 2016).   
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LCN2 provides a novel target for consideration in identification of KDM4B-dependent invasion and 
migration changes. 
LOXL2 (Lysl Oxidase-like Protein-2) was also identified as a KDM4B target, regulated in a 
histone-demethylation dependent manner (Chapter 2 and 3).  LOXL2, responsible for crosslinking 
Collagen Type IV, increases invasion and metastasis in a number of tumor models including breast and 
gastric cancers (Peng, Ran et al. 2009; Barker, Chang et al. 2011; Kim, Dong et al. 2014).  The qPCR, 
ChIP analysis, and invasion and migration findings lend LOXL2 as an interesting possible link between 
KDM4B and increased invasion.  Further pathological investigation may identify KDM4B as a useful 
biomarker for identifying more metastatic and invasion EOC diseases. 
Shifting between an epithelial and mesenchymal state influences invasive and metastatic 
potentials of ovarian cancer cells as well as the ability of tumors to maintain attachment-free growth in 
spheroids (Deng, Wang et al. 2016).  Some targets identified in this study could influence invasion and 
attachment-free growth like CDH1 (E-cadherin).  CDH1 (E-cadherin) was shown to be downregulated 
with the loss of KDM4B expression (Chapter 3).  Loss of E-cadherin shifts the tumor cell towards a more 
mesenchymal type, increasing its motility and ability to survive attachment free (Du and Shim 2016).  
KDM4B may be driving invasive potentials of tumor cells by influencing the transition from epithelial to 
mesenchymal type.  A link between KDM4B and EMT has been shown in gastric and pancreatic cancers, 
indicating the possibility of this mechanism in EOC (Zhao, Li et al. 2013; Li, Wu et al. 2015).   
Although increased angiogenesis was not indicated in a KDM4B dependent manner in patient or 
xenograft tumors (data not shown), a direct link between KDM4B and PDGFB was identified (Chapter 2 
and 3).  PDGFB is an established factor involved with angiogenesis and lymphangiogenesis, key aspects 
driving ovarian cancer metastasis and dissemination (Dong, Grunstein et al. 2004; Tejada, Yu et al. 2006).  
PDGFB may still influence increased invasion and peritoneal dissemination through other avenues 
besides vascular remodeling.  PDGFB acts as a recruitment signal, initiating pericyte invasion and 
migration (Kelly, Haldeman et al. 1991).  PDGFB was identified as a direct KDM4B target, regulated in a 
histone-demethylation dependent manner (Chapter 2 and 3).   Aptamer targeting of PDGFB shows 
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reasonable efficacy in slowing angiogenesis in EOC (Lu, Shahzad et al. 2010).  This connection between 
KDM4B and PDGFB is new to the KDM4B cancer field, potentially linking KDM4B to multiple aspects 
driving tumorigenesis. 
This body of work showed KDM4B activates expression of PDGFB, LOX, LOXL2, and LCN2 in 
a demethylation dependent manner on their respective promoters (Chapter 2).  KDM4B does not regulate 
a genome wide effect on histone methylation.  Loss of KDM4B did not increase global methylation of 
H3K9me3, H3K9me2, H3K9me, H3K36me3, H3K36me2 and H3K36me in EOC models (Chapter 2).  
This indicates that the demethylase activity of KDM4B at specific promoters may be the most important 
regulatory aspect of this enzyme at least for these genes.  
 Considering the functional importance of KDM4B and identified target genes, this protein is 
worth considering in therapeutic or combinatory treatment plans for EOC patients.  At this time, 
inhibitors struggle with specificity of KDM4B.  KDM4B is a member of a family of proteins sharing 
conserved domains, demethylase mechanism, and substrates for activity (Berry and Janknecht 2013).  
Targeting KDM4B may also cause secondary effects by disrupting functions that require its activity, such 
as ESC differentiation, driving other cell processes towards tumorigenic phenotypes (Das, Shao et al. 
2014).  Targeting of KDM4B regulated genes implicated in EOC tumorigenesis may provide another 
mode of EOC inhibition.  Therapeutics are available that target PDGFB, LOX, LOXL2, and LCN2 are 
available and should be tested in appropriate EOC in vitro and in vivo models in the context of KDM4B 
dependent expression. 
 Expression of KDM4B was also identified for the first time in this study in EOC patient ascites 
lysates.  Ascites spheroids provide a useful patient-derived model to test the contribution of KDM4B to 
these tumorigenic functions.  Ascites fluid contains spheroids or multicellular groupings that are 
metastatic tumors formed during EOC progression (Puiffe, Le Page et al. 2007).  This result suggests 
KDM4B is active and regulating gene expression in patient spheroids (Chapter 3).  However, without 
further dissection its difficult to identify the mode of ascites spheroid formation KDM4B is regulating.  
Analysis of spheroid lysates provided a novel look into KDM4B dependent disease progression.  Even 
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though this project addressed unknowns regarding KDM4B in EOC, many gaps still exist in the KDM4B 
field. 
 
Knowledge Gaps in the KDM4B Field 
  This project answers questions regarding the previously unaddressed question of the role of 
KDM4B in EOC progression.  These findings are innovative, but certain questions remain untouched by 
this body of work and available publications. 
 Several essential questions regarding histone demethylase transcriptional regulation and activity 
remain entirely unaddressed in regard to KDM4B function in any experimental model.  The protein or 
signals responsible for recruiting KDM4B to specific sites for demethylation or transcriptional activation 
have not been clearly delineated in many models.  Double strand breaks after γ-irradiation have been 
shown to recruit KDM4B to sites of DNA damage, supporting a role for the protein in the early DNA 
damage response in osteosarcoma models (Young, McDonald et al. 2013).  Demethylation of H3K9me3 
by KDM4B follows recruitment to these heterochromatic regions (Young, McDonald et al. 2013).  
However, this does not explain a conserved mode of recruitment for KDM4B in other cancer models.   
There are likely additional signaling mechanisms directing KDM4B to bind and function at 
specific genomic loci.  Not only is KDM4B induced by HIF-1α, it is possible this protein regulates its 
presence and activity within the cell (Beyer, Kristensen et al. 2008).  HIF-1α is shown to recruit KDM3A 
to specific target genes (Krieg, Rankin et al. 2010; Perez-Perri, Acevedo et al. 2011).  Considering the 
similar relationship between HIF-1α and KDM3A/KDM4B, it is a possible this recruitment mechanism 
also functions in KDM4B models.  This potential HIF-1α/KDM4B connection could be addressed in 
future studies.  This could be approached utilizing siRNA/shRNA for in vitro expression analysis, with 
binding profiled using ChIP assays.  A conserved mode of recruitment by HIF-1α would be an innovative 
finding for the KDM4 research field. 
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KDM4B lysine residue and DNA targeting is not well characterized. KDM4B sequence-specific 
binding motifs have also not been identified.  Loss of the Tudor and PHD domains has been shown to 
disrupt localization of KDM4B to heterochromatin during the DNA damage response (Young, McDonald 
et al. 2013).  KDM4C also depends upon its Tudor domains for targeting to mitotic chromatin during 
mitosis (Kupershmit, Khoury-Haddad et al. 2014).  There is also no identified KDM4B Response 
Element or conserved binding motif.  Mutagenesis studies in EOC establishing the contributions of the 
Tudor and PHD domains in KDM4B binding would provide novel insight into targeting capacity of 
KDM4B.     
The external (i.e.-ligand/receptor) and internal (i.e.-cellular cascade) signaling mechanisms that 
may contribute to KDM4B expression and activity should be identified and characterized.  Transcription 
factors such as HIF-1α and β-catenin have been shown to regulate KDM4B expression (Beyer, Kristensen 
et al. 2008; Berry, Kim et al. 2014).  The tumor suppressor p53 and nuclear hormone receptors such as 
AR and ER are also implicated in driving KDM4B expression (Palomera-Sanchez, Bucio-Mendez et al. 
2010; Kawazu, Saso et al. 2011; Coffey, Rogerson et al. 2013).  Because these signaling mechanisms are 
not universally conserved between cancer models, it is likely other factors are influencing induction of 
KDM4B expression and activity. 
Specific relationships between certain histone methyltransferases and histone demethylases that 
regulate modification dynamics have not been identified.  Dozens of histone lysine demethylases and 
histone lysine methyltransferases contribute to the regulation of histone methyl modifications at residues 
on H3K9 and H3K36 (Whetstine, Nottke et al. 2006; Kouzarides 2007).  All histone lysine demethylases 
and methyltransferases as well as other epigenetic modifiers function in a genome-wide balance of 
chromatin modification writers and erasers.  Establishing the connection between KDM4B and an H3K9 
or H3K36 methyltransferase such as G9A, SUV39H1, or SET2 could explain KDM4B recruitment 
signals and epigenetic contributors regulation expression dynamics at specific genes (Fritsch, Robin et al. 
2010; Jha and Strahl 2014).  
 156 
Exploring possible compensatory relationships between KDM4 proteins would finer points of 
KDM4 activity regulation.  This project suggested a compensatory role for KDM4A and KDM4D in lieu 
of silenced KDM4B expression in EOC (Chapter 2).  This suggests that when the cancer cell lacks 
appropriate levels of KDM4B to maintain functions, KDM4A and KDM4D are increased to maintain 
gene activation or repression at H3K9 and H3K36 (Chapter 2) (Kouzarides 2007).   Complete knockout 
of all KDM4 family proteins in vitro or in vivo may prove difficult because KDM4A and KDM4B are 
required for cell survival or apoptotic regulation in some models (Tsurumi, Dutta et al. 2013; Li and Dong 
2015).  It is also possible the cell may be programed to compensate for the loss of one KDM4 protein by 
increasing expression of another KDM4 or another jumonji protein.  At this time, exploration of KDM4 
compensation needs to be addressed. 
Another innovative set of studies could identify non-histone substrates that may be modified by 
KDM4B.  These types of questions may identify new roles for KDM4 histone demethylases and highlight 
new mechanisms for controlling chromatin condensation and gene transcription.  Few studies have 
addressed KDM4 activity on non-histone substrates.  At this point, KDM4C has been shown to modify 
Pc2 (Polycomb Repressive Complex 2) (Yang, Lin et al. 2011).  KDM4B also has binding affinity for 
WIZ (Widely Interspaced Zinc Finger Motifs), CDYL1 (Chromodomain Protein Y-Like), CSB (DNA 
Excision Repair) and G9a (Euchromatic histone-lysine N-methyltransferase 2) (Ponnaluri, Vavilala et al. 
2009).  Investigating possible connections between KDM4B and these non-histone substrates could 
identify new enzymatic roles for this protein in transcription and DNA repair, and explain possible 
cooperation with histone methyltransferases like G9a.  G9a expression is induced by hypoxia and is 
oncogenic in cancer, providing another interesting link to KDM4B (Chen, Yan et al. 2006; Lee, Kim et al. 
2009; Chen, Hua et al. 2010).  Establishing new connections to non-histone substrates could translate into 
relevant modes of gene expression regulation in other models.   
Another area of KDM4B research with little success is drug targeting and development.  At this 
point, specific inhibitors for this single enzyme are not available and advertised inhibitors should be 
considered with great scrutiny.  Current available therapeutic inhibitors like ML324 and JIB-04, have 
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been marketed to target a specific class of enzymes but have broader effects (Rai, Kawamura et al. 2010; 
Chu, Wang et al. 2014).  Developing specific inhibitors for individual jumonji proteins is difficult due to 
similarities between the structures of all members of the jumonji family (Whetstine, Nottke et al. 2006).  
These proteins contain JmjN and JmjC domains, use common cofactors for activity (Fe2+, α-ketoglutarate, 
and oxygen), and bind similar histone and non-histone substrates (Whetstine, Nottke et al. 2006).  These 
overlapping factors often prohibit specific inhibition and drives broad targeting of many jumonji family 
proteins.  Investigations to conclusively identify specific diseases that would benefit from KDM4B 
targeting have also not been completed at this time.  Unspecific inhibitors such as JIB-04 have shown an 
ability to decrease cell proliferation, cell viability in vitro and reduce tumor burden in xenograft models, 
but nothing has translated to usable patient therapies that specifically targets sole KDM4 family proteins 
(Wang, Chang et al. 2013; Chu, Wang et al. 2014).   
Development and analysis of KDM4B knockout mice has been neglected in the KDM4B research 
field.  At this time, there are few characterized transgenic KDM4B mouse models (Fujiwara, Fujita et al. 
2016).  Homozygous deletion of KDM4C results in embryonic lethality (Dambacher, Hahn et al. 2010; 
Pedersen and Helin 2010; Wang, Zhang et al. 2010).  Incorporating loss of KDM4B models should be 
considered in other mutagenic mouse models.  Even though heterozygous knockout mice lines have been 
developed and maintained, they have not been characterized.  Conditional knockout or knock in mice 
could also answer tissue-specific questions regarding KDM4B in developmental and cancer promoting 
processes.  Developing Tet-inducible models may also answer specific questions regarding timing of loss 
or gain of KDM4B expression in various cell processes or diseases.   
The development of a tissue-specific KDM4B conditional knockout mouse would help answer 
relevant biological questions about the in vivo role of KDM4B in EOC tumorigenesis or other cancer 
models.  At this time, these types of KDM4B models have not been developed and characterized.  The 
only studied and published conditional KDM4B knockout mouse is a neuron-specific knockout, which 
may act as an in vivo model for neural development disorders (Fujiwara, Fujita et al. 2016).  Parallel to 
KDM4B conditional knockout mice, it would be useful to incorporate the study of this gene into relevant 
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tumor models.  Combining a KDM4B tissue specific knock in or knockout model with a spontaneous 
tumor-forming model may help answer some deeper questions regarding KDM4B dependent in vivo 
tumorigenesis.  An example of a useful cross for EOC studies may be to combine a KDM4B knockin 
mouse with a spontaneous tumor-forming model like the p53/Rb1 ovarian surface epithelium knockout 
(Flesken-Nikitin, Choi et al. 2003).  This type of transgenic model may give further insight into KDM4B-
dependent EOC tumor formation from the ovarian surface epithelium. 
Given the current depth of KDM4B research in cancer models, exploring its activity in other 
systems would be novel.  The role of KDM4B in reproductive biology remains largely unstudied.  Mining 
the RNA Sequencing Atlas, KDM4B displayed high expression in the ovary and the testes of normal 
human tissues (Yang, Imoto et al. 2000; Krupp, Marquardt et al. 2012; Labbe, Holowatyj et al. 2013).  
Little is known about the role of epigenetic regulators, including histone demethylases in ovarian biology.  
Another jumonji containing protein, KDM3B has recently been characterized in a knockout mouse model 
(Liu, Oyola et al. 2015).  KDM3B is highly expressed in female reproductive organs including ovary, 
oviduct and uterus (Liu, Oyola et al. 2015).  Knockout of KDM3B correlated with irregular estrous 
cycles, decreased ovulation capability, and fertilization rate (Liu, Oyola et al. 2015).  These findings show 
the jumonji protein KDM3B plays an essential role in regulating gene expression during developmental 
processes (Liu, Chen et al. 2015).  Considering the high expression of KDM4B in the ovary and testes, 
this enzyme may also contribute to reproductive processes (Labbe, Holowatyj et al. 2013).  Each of these 
proteins may become induced and regulate different genes at separate times.  Exploring the role of 
KDM4B in reproductive biology would provide answers to the uncharacterized role of epigenetics and 
histone demethylases in reproductive biology.   
 
 
Future Directions for KDM4B Studies in Ovarian Cancer 
 Considering the observations from this project, further studies should start by addressing these 
main areas in the ovarian cancer model: hypoxic connection to KDM4B activity, identification of a 
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functional target gene, transcriptional mechanisms of KDM4B activity, contribution of specific domains 
to activity, and connections between KDM4B and EOC tumorigenesis from fallopian fimbrae.  While 
there are other topics to address, these studies would provide the most powerful and applicable knowledge 
to the KDM4B field in the context of ovarian cancer.  These follow-up studies would expand upon what 
we already know, without spending time revalidating previous research.  As useful as it would be to 
revalidate known ideas, it may not drive novel discoveries.  
 
Establish Function and Connections between Hypoxia and KDM4B in EOC Pathogenesis       
 KDM4B is a hypoxia-inducible enzyme; however, this project did not characterize the 
contribution of KDM4B to ovarian cancer progression in a hypoxia-dependent context (Beyer, Kristensen 
et al. 2008).  Ovarian cancer has an established connection to a hypoxic tumor microenvironment and is 
an important component not to overlook in the study of a hypoxia-inducible enzyme (Osada, Horiuchi et 
al. 2007).  KDM4B dependent target gene expression and in vitro assays were investigated using a 
hypoxic (0.5% O2 – 2% O2) and normoxic (21% O2) treatment (Chapter 2 and 3).  The role of hypoxia in 
driving KDM4B activity was not independently addressed in these experiments.  Although loss of 
KDM4B decreases invasion, migration, proliferation, and spheroid formation in vitro, the lack of hypoxia 
driving these phenotypes in a KDM4B dependent manner was not explored (Chapter 2 and 3).  This may 
be due to a variety of reasons, including enzyme dynamics or other internal cellular control mechanisms 
regulating KDM4B.  It is possible under hypoxia during presumed maximum induction of KDM4B, this 
protein’s binding may saturate its substrate binding sites and plateau.  A substrate availability 
phenomenon could explain why KDM4B does not induce phenotypes further under hypoxia.  It is also 
possible that too much expression of KDM4B is not healthy for the cell, offsetting the interdependent 
balance of other epigenetic regulators functioning to maintain cell processes.  Internal cellular signaling 
mechanisms may also be controlling the expression and activity levels of KDM4B.  KDM4B activity may 
be limited by necessary and available transcriptional cofactors for enzyme activity, such as c-Myc or 
Nanog (Yang, Jubb et al. 2010; Das, Shao et al. 2014).   
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In addition to the lack of exploration of hypoxia-driven, KDM4B-dependent functional assays, 
the sets of downstream suspected targets mined for expression and downstream target studies should also 
be reconsidered.  KDM4B-dependent normoxic and hypoxic gene expression changes were identified 
(Chapter 2 and Chapter 3).  This project focused on the commonly overlapping changes between the 
hypoxic and normoxic data sets.  Overlapping target genes between oxygen tensions are likely the most 
robust and replicable targets.  However, only considering the commonly regulated targets does not 
explain the role of hypoxia driven KDM4B activity in ovarian cancer.  Additional ChIP and 
transcriptional analysis would clarify the contribution of hypoxia in this cancer model. 
 
Identification of Functionally Relevant KDM4B Target Gene 
Identification of a novel, functionally relevant KDM4B regulated target gene in the ovarian 
cancer model is another essential question that remains unanswered.  In order to increase the power of 
KDM4B in ovarian cancer progression, it is essential to explain how it genetically regulates ovarian 
cancer tumorigenesis and demonstrate this in vitro and in vivo.  This is one of the most important 
lingering questions but may not be the easiest aspect of KDM4B activity to answer.  KDM4B research is 
complicated by the lack of conserved functions between cancer and developmental models.  Identifying a 
functionally relevant downstream target gene may not be a simple question to answer because of the 
endless possibilities of KDM4B activity and interference from compensating proteins (Chapter 2).  At this 
point, numerous putative target genes have been investigated in this research group’s hands in ovarian 
cancer functional assays.  These targets include LOX, LCN2, and PDGFB (Chapter 2 and 3).  KDM4B-
dependent expression and promoter binding can be shown using qPCR and in some cases ChIP, but the 
functional importance of the downstream target genes has not been demonstrated.  ChIP of these 
commonly regulated target genes has also been difficult to replicate between ovarian cancer cell lines, 
only confounding the identification of putative downstream genes.  
Investigation of putative target genes that are upregulated with loss of KDM4B expression may 
also help identify functionally relevant KDM4B target genes.  Upregulated genes could be mined from 
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the microarray and RNA Sequencing analysis completed in this project.  At this time, only downregulated 
genes with the loss of KDM4B expression have been explored.  KDM4B could be controlled with indirect 
regulation of tumorigenic genes.  Genes may be repressed upstream by another gene regulated by 
KDM4B expression and activity.  Further in silico analysis of completed RNA Sequencing and 
microarray analysis would help develop the network of regulation regarding KDM4B.  Connecting these 
molecular links will help explain the broad network of targets regulated by KDM4B. 
 In light of these issues, it seems necessary to rethink the philosophy and approaches used to 
address this lingering target gene question.  Instead of “fishing” for specific target genes, it would be 
beneficial to start broad or genome wide with next-generation sequencing techniques.  ChIP-Sequencing 
analysis of KDM4B binding and histone methylation profiles of 2-3 ovarian cancer cell models could 
pinpoint the most relevant and conserved KDM4B demethylase-dependent target genes.  KDM4B ChIP-
Sequencing has not been published for this cancer model type and would provide a useful resource for the 
field.   Upon identification of the most conserved target genes, appropriate tumorigenic functional assays 
could be employed.  Antibody specificity may also be an issue to consider when performing ChIP.  
Suspected target genes have not replicated well in ChIP experiments between the SKOV3ip.1 and 
OVCAR8 cell lines.  This may be due to experimental conditions, including antibody specificity.  In 
previous target gene identification attempts, it is also possible genetic manipulations of these genes using 
shRNA or siRNA were not completed appropriately and dampened experimental results.  PDGFB 
remains one of the most consistent targets between ovarian cancer cell lines expressed in a KDM4B-
dependent manner.  In other experiments conducted by previous Krieg lab members, it is possible 
shPDGFB plasmid constructs were not titrated appropriately in preliminary experiments, effecting results 
in attachment-free growth assays.  LOX, given its established connection to invasion, was investigated 
using Boyden Chambers and pooled siRNA.  Experimental results were inconclusive and it is possible 
these were confounded by the use of siRNA instead of shRNA.  Considering the rapid development of in 
vitro assays for invasion and migration in cancer research, it is realistic to consider that analysis of 
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invasion, migration, proliferation, or attachment-free growth may be better quantified using a different 
experimental technique. 
 Even though some of the major pathways of tumorigenesis were explored, it is possible that 
another important aspect regulating ovarian cancer tumorigenesis in a KDM4B-dependent manner was 
overlooked.  Given the genome wide activity of KDM4B, it is likely that KDM4B regulates multiple 
tumorigenic pathways.  The xenograft studies from Chapter 3 are the pinnacle and keystone experiments 
that demonstrate KDM4B expression is essential for ovarian cancer progression.  It is obvious from these 
studies that KDM4B effects some tumor cell functions encompassed in the regarded “Hallmarks of 
Cancer” (Hanahan and Weinberg 2011).  Invasion, migration, attachment-free growth, and proliferation 
have all been addressed and demonstrate KDM4B dependent roles in ovarian tumor progression.  
Resistance to apoptosis and increased angiogenesis should be investigated in vitro.  Results from the 
proliferation counting assays showed loss of KDM4B decreased proliferation (Chapter 3). The 
proliferative defects could be due to a loss of the balance between proliferation and apoptosis, suggesting 
a role for KDM4B in regulating the activation of these processes (Hanahan and Weinberg 2011).  It is 
possible that proliferation decreases while apoptosis is actually increasing.  Breaking down the connection 
between KDM4B expression and cell cycle regulation could also clarifying the observation of decreased 
proliferation in the ovarian cancer model. 
 
Clarification of KDM4B-dependent Transcriptional Mechanisms  
 Identification and clarification of KDM4B-dependent transcriptional mechanisms is the third 
component to address in future work.  Current research shows KDM4B regulates gene expression in a 
demethylase dependent manner in many models, while working with a variety of transcriptional co-
activators, including c-Myc, p300, and β-catenin (Berry and Janknecht 2013; Yang, AlTahan et al. 2015; 
Lee, Yu et al. 2016).  Interaction between KDM4B and the methyltransferase MLL2 has also been 
established in ER+ breast cancer types (Coffey, Rogerson et al. 2013).  The proteins involved with 
KDM4B in the transcriptional coactivation complex have not been investigated in ovarian cancer models.  
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Conversely, it is worth investigating if KDM4B activity has connection to transcriptional repressors.  
Given this topic is a virtual unknown; these questions could be approached with Co-IP and mass 
spectrometry.  Understanding the complex KDM4B would answer questions not only on transcription and 
demethylase activity, but identify unknown binding partners for this protein.  These types of experiments 
would help explain the behavior of KDM4B in ovarian cancer and possibly play a role in other models. 
 The transcriptional interplay between HIF-1α and KDM4B should also be explored.    Hypoxia is 
one contributing factor in EOC tumorigenesis, driving invasion and metabolic adaptations (Osada, 
Horiuchi et al. 2007).  HIF-1α nuclear expression has also been shown to promote tumorigenesis and 
correlates to poor prognosis in EOC (Osada, Horiuchi et al. 2007).  HIF-1α also induces KDM4B 
expression, identifying an epigenetic link between tumor progression and a hypoxic tumor 
microenvironment (Beyer, Kristensen et al. 2008; Pollard, Loenarz et al. 2008; Yang, Jubb et al. 2010).  
This project demonstrates that KDM4B expression influences EOC progression.  However, putative target 
genes regulated by KDM4B, including PDGFB and MUC1, are also induced by HIF-1α.  This suggests a 
connection between KDM4B and HIF-1α targets.  KDM4B could act as a recruitment signal for HIF-1α 
to a particular HRE.    This recruitment hypothesis has been demonstrated in another jumonji protein, 
KDM3A (Pollard, Loenarz et al. 2008).  Determining if KDM4B regulates gene expression in this model 
in a demethylase-dependent or independent manner becomes a fundamental question to answer.  Genome-
wide dissection of the connection between HIF-1α, KDM4B activity, and tumorigenic gene expression 
would further explain the connection between KDM4B and HIF-1α driven EOC progression. 
 
Establishing the Contributions of KDM4B Domains to Enzymatic Targeting and Activity  
 Further investigation exploring the contribution of specific KDM4B domains to demethylase 
activity should be completed.  At this time, this project does not adequately demonstrate if there are key 
roles of H3K9 demethylase activity through jmjC domains or histone binding activities through 
Tudor/PHD domain of KDM4B in the pathogenesis of epithelial ovarian cancer.  H3K9me3 
demethylation by KDM4B is dependent upon the jmjC domain in other models (Fodor, Kubicek et al. 
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2006).  However, the role of the targeting Tudor/PHD domains has not been demonstrated well between 
many models (Coffey, Rogerson et al. 2013).  Further studies on domain contribution would help 
understand how KDM4B binds and functions at certain genomic sites.  Understanding the activity of the 
domains could provide useful knowledge for developing targeting therapies in ovarian cancer models.  
  
Investigating the Connection between KDM4B and Fallopian EOC Tumorigenesis 
In addition to further dissection of transcriptional and hypoxic mechanisms, KDM4B expression 
should be investigated in the fallopian tube fimbriae.  The debate in the ovarian cancer field regarding the 
precursor tissue for ovarian cancer tumorigenesis is important and would be useful to explore (Auersperg 
2013).  Currently, this has not been addressed.  KDM4B will likely be expressed in the fallopian tube, 
given its ubiquitous presence and activity in many normal tissues (Labbe, Holowatyj et al. 2013).   If 
KDM4B were expressed in the fallopian fimbriae, this would not necessarily indicate that tumor 
progression always begins at this site.  Increased KDM4B expression in the fimbrae would suggest that it 
might begin at this site.  In the context of ovarian surface epithelium as site of origin, lack of KDM4B 
expression in normal ovarian surface epithelium suggests a transformative event may possibly induce this 
gene during cancer progression (Chapter 2) (Auersperg 2013).  Further studies answering this question 
would help piece together different aspects influencing the “site of origin” debate.  
 
Significance 
 This project is one of the first to demonstrate the relevant role of KDM4B in epithelial ovarian 
cancer progression.  Demonstrating any connection between KDM4B and EOC progression is pioneering 
for the KDM4 and ovarian cancer fields.  This project has provided clarity on many key aspects of 
KDM4B enzymatic activity and function in ovarian cancer tumorigenesis.  In addition to showing that 
KDM4B expression is increased in primary and metastatic high-grade EOC patient tumors, this project 
has also completed novel dissection of the functional contribution and genetic activities dependent on 
KDM4B in ovarian cancer (Chapter 2 and 3).  The manuscript in chapter 2 provides the first 
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demonstration of KDM4B’s importance in facilitating invasion, migration, spheroid formation, and 
peritoneal dissemination in vitro and in vivo in EOC and shown these roles are conserved between two 
relevant EOC models.  This work has established the first connections between KDM4B and any known 
genes contributing to ovarian cancer progression, including PDGFB and LOX.  This project has also 
shown that KDM4B regulates these genes in a promoter specific, demethylase-dependent manner.  These 
findings delineate clear and biologically relevant genetic and functional roles for KDM4B in EOC.  Not 
only does this project fill a knowledge-gap on the functional contributions of jumonji domain-containing 
proteins in EOC progression, it also adds to the breadth of KDM4B mechanisms previously published in 
other cancer types.  
 
Overall Conclusion 
 These novel investigations established the first mechanisms regarding KDM4B activity in 
epithelial ovarian cancer models.  Most importantly, this project helped establish new links between the 
hypoxic tumor microenvironment and molecular changes in EOC tumorigenesis.     The relevance of 
pursuing KDM4B was solidified by this work’s analyzed patient tumor microarray study and observation 
of KDM4B expression in patient ascites lysates (Chapter 2 and 3).  Staining analysis showed increased 
protein expression in primary, metastatic, and recurrent EOC patient tumors (Chapter 2).  KDM4B 
expression corresponded to increased invasion, migration, and attachment-free growth in vitro (Chapter 2 
and 3).  KDM4B was shown to regulate tumorigenic gene expression in a promoter-specific, 
demethylase-dependent manner.  These efforts help improve the understanding of KDM4B activity and 
establish portions of its mechanistic role in regulating EOC progression.  Considering KDM4B is likely 
regulating expression genome-wide, future investigations will continue to characterize additional faucets 
of KDM4B activity and build upon these observations.  Future studies will continue to unravel and 
establish the biological importance of this histone demethylase in driving EOC tumorigenesis and other 
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